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ABSTRACT
Arenaviruses and hantaviruses are human pathogens that cause significant
morbidity and mortality. The current lack of vaccines and treatment options for these
viruses is a global concern. Despite producing only 4 proteins, these viruses are able to
maintain a persistent and asymptomatic infection in wild rodents while being continuously
shed into the environment. In humans, these viruses cause a spectrum of diseases ranging
from aseptic meningitis to severe hemorrhagic fever syndromes. Little is known about how
arenavirus and hantavirus proteins engage and interact with the human proteome during
the complex process of viral biogenesis, or how the interactions with human proteins
contribute to viral propagation as well as the onset and progression of disease. This
dissertation provides a road map of the protein interactions formed between a prototypic
envelope glycoprotein encoded by either an arenavirus or hantavirus, and the human
proteome.
The viral envelope glycoprotein (GP) decorates the surface of the virion. The
primary function of the GP is to mediate attachment of the virus to specific cellular
receptors, and after internalization of the virion, fuse the viral membrane with an internal
endosomal membrane. In order to carry out these specific tasks, the viral GPs must first
co-opt the extensive machinery found within the cellular secretory pathway to coordinate
the proper glycosylation, folding, proteolytic maturation, and targeting of the GP during its
biosynthesis. We identified a human protein with a conserved interaction amongst these
two groups of viral GPs termed the Endoplasmic Reticulum (ER)-Golgi Intermediate
Compartment Protein of 53 kiloDaltons (ERGIC-53). ERGIC-53 is an intracellular cargo
receptor that normally cycles within the early secretory pathway of cells, where it is
responsible for ferrying a small subset of cellular glycoproteins, most notably the
coagulation factors FV and FVIII, from the ER to the Golgi apparatus.
Herein we describe a novel role for ERGIC-53 in the propagation of not only
arenaviruses, but also coronaviruses and filoviruses. Following infection with an
arenavirus, ERGIC-53 leaves the early secretory pathway and becomes incorporated into
the virus as it pinches off from the cell surface. Newly formed viruses lacking ERGIC-53
are no longer infectious due, in part, to a defect in their ability to attach to host cells. We
suggest that ERGIC-53 represents a promising broad-spectrum antiviral target because of
its association with the GPs from many families of pathogenic viruses, as well as its ability
to exert control over their infectivity; and finally, because ERGIC-53 itself is not required
for human health. The discovery of ERGIC-53 outside of its normal location inside of cells
suggests that it may have additional unknown functions. Lastly, by revealing the
importance of the cellular protein in controlling viral infectivity, we provide insight into
the ongoing co-evolution of virus and host.
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COMPREHENSIVE LITERATURE REVIEW
Overview of aims and significance

Arenaviruses are enveloped, negative sense, RNA viruses harbored in wild
rodents in a variety of locales globally. Their natural history, genetic strategy, and
cellular biology have provided a wealth of knowledge to researchers for nearly a century.
In addition to providing scientists with an elaborate model to study virus-host
interactions, these viruses are first and foremost, human pathogens that cause significant
morbidity and mortality annually. Arenaviruses are known to cause a spectrum of disease
ranging from aseptic meningitis to a severe hemorrhagic fever syndrome. The outcome of
infection varies based on the route and amount of inoculation, as well as the genetics of
the incoming virus. Additional clinical variation arises from differences in the age and
immunological status of the infected person. With high mortality rates and a lack of
preventative or therapeutic options available, arenaviruses represent an emerging and reemerging zoonotic group of pathogens with a clear need of targeted antiviral
development strategies. Herein, this dissertation presents the first systematic and
comprehensive documentation of the interactome of the prototypic arenavirus
glycoprotein (herein revised as GP) derived from lymphocytic choriomeningitis virus
(LCMV), in addition to the interactome of the prototypic New World (NW) hantavirus
glycoprotein derived from Andes virus (ANDV). The inclusion of a hantavirus
glycoprotein is that of a natural control and companion to the arenavirus GP.
Hantaviruses, similarly, are rodent-borne, negative sense, enveloped RNA viruses lacking
1

in not only vaccines, but treatment options. Hantaviruses, however, are genetically
distinct and share few pathophysiological features. As members of the bunyavirus family,
they are thus grouped alongside arenaviruses, filoviruses, and flaviviruses as agents
causing viral hemorrhagic fevers.
The process of identifying and characterizing the interactome of the arenavirus
and hantavirus GPs provided a platform for four distinct goals. First, by identifying the
proteins in complex with these viral glycoproteins, a more detailed understanding of the
basic cellular biology governing biogenesis and pathogenesis could be established at the
resolution of protein-protein interactions. Secondly, by revealing which individual
proteins, as well as protein networks, involved in biogenesis are biologically relevant to
propagation and pathogenesis, a strategic approach to targeting crucial stages of the viral
lifecycle could be implemented. Following bioinformatics comparisons, biochemical
verification, and functional validation studies, characterization of a core suite of
conserved cellular proteins that will serve as potential broad spectrum antiviral targets
can occur. Next, mechanistic insight can be gained into the stage specific role of the
virus-host interaction, through analyzing the organization and interaction of the protein or
protein complexes, and their respective contributions to GP form and function. Lastly, by
uncovering the protein determinants responsible for mediating the interaction, future
studies can utilize this information to selectively disrupt the interactions therapeutically.
The detailed investigation of the consequence and molecular mechanisms governing the
arenavirus GP interactome revealed an interesting and unlikely candidate that coincided
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with the four goals of this investigation; Endoplasmic Reticulum – Golgi intermediate
compartment protein of 53 kilodaltons (kDa), hereafter referred to as ERGIC-53.
We demonstrate that ERGIC-53, a previously assumed intracellular cargo
receptor required for trafficking of coagulation factors V and VIII (FV & FVIII), is part
of a receptor complex with multiple coagulation factor deficiency protein 2 (MCFD2)
that interacts with arenavirus and hantavirus glycoproteins. This interaction is shared,
minimally, amongst coronavirus, filovirus, and orthomyxovirus envelope glycoproteins,
and is required for the production of infectious viral particles. These dissertation studies
revealed that during infection with an arenavirus, ERGIC-53 will traffic to the plasma
membrane, and be incorporated into newly formed arenavirus particles. Depletion of
ERGIC-53, or genetic ablation of its anterograde trafficking potential, severely impairs
viral propagation. Depletion of MCFD2, inversely, bolsters viral replication. ERGIC-53
and MCFD2, despite representing halves of a single molecular complex, propagate
opposing forces on the viral lifecycle. Interrogating the ERGIC-53:MCFD2 complex has
revealed a rich and interesting molecular insight to the history of virus and host, and
represents a novel molecular machine to interfere with therapeutically.

1.1. The Arenaviridae
Arenaviruses are zoonotic, enveloped, RNA viruses commonly associated with
the Muridae family of rodents (Childs & Peters, 1993), with exceptions being Tacaribe
virus (TACRV; Artibeus, fruit bat,) (Downs, Anderson, Spence, Aitken, & Greenhall,
3

1963), California academy of science virus (CASV, Corallus annulatus, the annulated
tree boa), and, finally, Golden Gate virus and Collierville virus (GGV and CCV, Boa
constrictor) (Stenglein et al., 2012). The majority of known arenavirus species are not
associated with human disease and are thought to have co-evolved with their rodent hosts
to cause little to no pathology. Lassa virus (LASV), Lujo virus (LUJV), and Lymphocytic
choriomeningitis virus (LCMV) constitute the most widely recognized human pathogens
in the Old World (Emonet, Lemasson, Gonzalez, de Lamballerie, & Charrel, 2006). Junín
virus (JUNV), Machupo virus (MACV), Guanarito virus (GTOV), Sabia virus (SABV),
Chapare virus (CHAPV), and White Water Arroyo virus (WWAV) are the predominant
human pathogens in the NW grouping (Bowen, Peters, & Nichol, 1996).
The Arenaviridae consists of a single genus with approximately 25 species currently
recognized by the international committee on the taxonomy of viruses (ICTV), and
several new species are pending approval. The virus family is subdivided into Old and
New world groups based on antigenic reactivity (serology) (Casals, Buckley, & Cedeno,
1975), geographic location, and genome similarity (Emonet et al., 2006). Old World
(OW) viruses are predominantly found in Africa, as well as Asia and Europe. New World
(NW) viruses are distributed in North and South America. The prototype of the Old
World viruses, LCMV, is globally distributed and maintains a great deal of diversity with
~20 known strains (Albarino, 2010). Phylogenetic analyses of the OW grouping suggest
up to four lineages of LCMV globally (Albarino, 2010), as well as four lineages of LASV
within Western African countries (Bowen et al., 2000). Inter-species diversity is common
among pathogenic New World arenaviruses (Bowen et al., 2000) and “non”-pathogenic
4

arenaviruses (Michael D. Bowen, Clarence J. Peters, & Stuart T. Nichol, 1997). The
heterogeneity that is prevalent amongst both pathogenic and non-pathogenic
arenaviruses, as well as intra-species genetic variation, may provide clues to mechanisms
of pathogenesis. The New World arenavirus group is further subdivided into clades A, B,
C, and more recently the Rec A/B sub-grouping (Charrel et al., 2003). Currently,
pathogenic NW viruses all group into clade B (Charrel, de Lamballerie, & Emonet, 2008)
with the exception being WWAV, which is found in the Rec A/B. The NW arenavirus
group Rec A/B is posited to be the result of a recombination event from an ancestral
North American arenavirus species (Charrel et al., 2002). As new arenaviruses are being
identified and characterized, additional phylogenetic and evolutionary groupings may
begin to appear. The current phylogenetic organization and diversity of the Arenaviridae
is thought to have arisen from extensive co-evolution of viruses with their rodent hosts
(Emonet, de la Torre, Domingo, & Sevilla, 2009). Accordingly, closely related arenavirus
species (i.e. JUNV and MACV) are harbored in closely related rodent species (C.
musculinus and C. callosus) (Michael D. Bowen et al., 1997), and WWAV and Catarina
virus (CTNV) (N. albigula and N. micropus) (Cajimat et al., 2008; Cajimat, Milazzo,
Bradley, & Fulhorst, 2007).
1.2. Arenavirus epidemiology: pathogenic Old World arenaviruses

1.2.1. Lassa virus

5

The predominant African arenavirus is LASV, the etiologic agent of Lassa Fever
(LF) (Buckley & Casals, 1970; Frame, Baldwin, Gocke, & Troup, 1970; Leifer, Gocke,
& Bourne, 1970; Speir, Wood, Liebhaber, & Buckley, 1970), and is endemic in countries
along the Western coast of Africa (Sierra Leone, Nigeria, Liberia, and Guinea). It is
estimated that 100,000 – 300,000 cases of LF occur annually (McCormick, Webb, Krebs,
Johnson, & Smith, 1987; Monath, Maher, Casals, Kissling, & Cacciapuoti, 1974).
Epidemiological studies suggest overall mortality rates of 1-2% (McCormick et al.,
1987), however, fatalities in hospitalized patients are substantially higher (~15-20%)
(Bausch et al., 2001) and can reach upwards of 80% during outbreaks (Günther & Lenz,
2004). LASV is particularly dangerous to both pregnant women (Monson, Frame,
Jahrling, & Alexander, 1984; Price, Fisher-Hoch, Craven, & McCormick, 1988) and
developing fetuses with mortality rates of 30-50% and 70-90%, respectively (Günther &
Lenz, 2004). However, these numbers vary depending on the age of the mother and fetus
(Monson et al., 1987; Webb et al., 1986). In endemic regions, upwards of 50% of the
human population are seropositive for LASV antibodies, and the Mastomys natalensis
reservoir seropositivity ranges from 8-80% demonstrating a large potential for continued
transmission events (Frame et al., 1970; McCormick et al., 1987; Monath, Newhouse,
Kemp, Setzer, & Cacciapuoti, 1974). Re-infection rates and underreporting may change
the complete picture of the disease burden. Also, given the antigenic similarities of the
African arenaviruses, the human seropositivity rates in the LASV endemic region may
also represent pre-exposure to non-pathogenic species as well as exposure to strains of
LASV that cause less severe disease (Günther & Lenz, 2004; McCormick et al., 1987;
Thomas P. Monath et al., 1974).
6

The LASV rodent reservoir population covers a widespread geographic area that
extends beyond the LASV endemic zone (Lalis et al., 2012). The rodents are commonly
found amongst dwellings and are consumed as bushmeat, both of which contribute to the
common occurrence and spread of LASV in the region (Keenlyside et al., 1983; Meulen
et al., 1996). Multiple Mastomys species may be involved in the transmission of LASV,
however, the exact phylogeny is still unclear for these rodents (Salazar-Bravo, Ruedas, &
Yates, 2002). LASV also poses a new found risk as an imported pathogen, as several
cases of imported LF have been documented globally (Amorosa et al., 2010; Haas et al.,
2003; Hirabayashi et al., 1989).
1.2.2. Lujo virus
An unusually fatal outbreak of hemorrhagic fever in 2008 resulted in the
identification of the most recent pathogenic Old World arenavirus, referred to as Lujo
virus (LUJV) (Briese et al., 2009). Lujo virus was isolated and identified following the
air-transfer of a patient from Zambia to South Africa. The nosocomial spread resulted in
an 80% mortality rate and highlights the risk involved in hospital settings dealing with
emergence/re-emergence of arenaviruses in a naïve community (Paweska et al., 2009).
Lujo represents the first pathogenic arenavirus isolated in Africa in approximately four
decades, and suggests a wider distribution of pathogenic species than has been previously
documented. However, during the intervening years, a number of non-pathogenic viruses
have been identified including: Ippy, Mobala, Mopia, and Luna viruses which overlap or
are adjacent to LASV endemic areas. The vector responsible for transmitting LUJV has
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yet to be identified. The index patient was reported to be near rodents in the week prior to
the onset of symptoms, which is in accordance with most arenaviral transmission events.
1.2.3. Lymphocytic choriomeningitis virus
Lymphocytic choriomeningitis virus, the prototype virus of the family, has a
global distribution which coincides with that of its reservoir, the common house mouse
(Mus musculus or Mus domesticus) (Traub, 1936). The wide distribution of infected mice
has been confirmed in several surveys within the United States and European countries
which have demonstrated reservoir seroprevalence ranges of ~ 3-14% in urban settings
(Childs, Glass, Korch, Ksiazek, & Leduc, 1992; Childs et al., 1991; Ledesma et al.,
2009). The mortality rate for LCMV infection in an immunocompetent human host is <
1%. However, in the setting of solid organ transplantation, LCMV, or Dandenong virus
(DANV), an LCMV-like virus (Palacios et al., 2008b), has recently been shown to be
extraordinarily lethal (Staci A. Fischer et al., 2006; Macneil, Ströher, et al., 2012;
Macneil, Stroher, et al., 2012; Palacios et al., 2008b). In addition to immunosuppressed
transplant recipients, developing fetuses are also highly susceptible to disease (Daniel J.
Bonthius, 2012; Bonthius et al., 2007). Congenital LCMV infections are thought be an
underdiagnosed phenomena (D. J. Bonthius, 2012; Enders, Varho-Gobel, Lohler,
Terletskaia-Ladwig, & Eggers, 1999). A number of outbreaks have also occurred in
rodent breeding facilities (Centers for Disease & Prevention, 2012; Knust et al., 2014), as
well as in research laboratories (Baum, Lewis, Rowe, & Huebner, 1966; Dykewicz, Dato,
Fisher-Hoch, & et al., 1992; Knust et al., 2014), and from exposure to infected pet
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rodents (Amman et al., 2007; Gregg, 1975; Rousseau, Saron, Brouqui, & Bourgeade,
1997), suggesting multiple routes and opportunities for human exposure to virus.
1.3. Arenavirus epidemiology: pathogenic New World arenaviruses
1.3.1. Junín virus
Junín virus, the etiological cause of Argentine hemorrhagic fever (AHF), was first
reported in 1955 (Arribalzaga, 1955) as a febrile hemorrhagic disease of unknown origin,
and was soon after isolated by Parodi et al. (Parodi et al., 1958). The virus is endemic
amongst the rich agricultural land found in the pampas region and is responsible for
approximately 100-3,000 cases annually in an area encompassing 150,000 km2
(Maiztegui, 1975). The area of endemicity has increased from ~15,000 km since
surveillance began, and now covers an area inhabited by ~ 1-5,000,000 people (Gómez et
al., 2011). The principle host of JUNV is the vesper mouse (Callomus musculinus),
however, some degree of spillover may be present in other closely related species (Mills
et al., 1994; Salazar-Bravo et al., 2002). Approximately 10% of the vesper mice trapped
in longitudinal studies have been reported as being seropositive (Mills et al., 1994; Mills
et al., 1992), suggesting potential for widespread exposure.
The case fatality rate for Junín virus is approximately 20-30% when untreated,
however administration of immune sera from convalescent patients reduces this to ~ 1%,
albeit with a modest risk of late neurological complications (Maiztegui, Fernandez, & de
Damilano, 1979; Ruggiero et al., 1986). The virus predominantly affects male
agricultural workers in the endemic region (Maiztegui, 1975). Amongst the South
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American arenaviruses, Junín is thought to be responsible for the majority of human
arenavirus disease; however recent vaccination coverage with a live-attenuated vaccine
(Candid1) has substantially reduced annual cases of severe human disease, and has been
delivered to several hundred thousand people in at risk populations within Argentina
(Enria, Ambrosio, Briggiler, Feuillade, & Crivelli, 2010; Maiztegui et al., 1998). The
attenuated vaccine varies from the parental strain (XJ) by 13 amino acids (Goni et al.,
2006), and has been given an investigational new drug status by the FDA. Concerns
about the genetic stability of the vaccine, as well its passage history, have hampered its
use outside of the endemic zone (Contigiani, Medeot, & Diaz, 1993). Despite the
concerns, Candid1 has thus far provided roughly 90% protection against severe disease,
and provides researchers a safe alternative (biosafety level 2 virus) to the BSL4 parental
strain.
1.3.2.

Machupo virus and Chapare virus
Machupo virus, the pathogen responsible for Bolivian hemorrhagic fever (BHF),

carries with it a similar disease course and mortality rate as JUNV, but is more sporadic
in incidence (Patterson, Grant, & Paessler, 2014). The virus became known to the
western world in 1963 following a series of HF outbreaks in the village of San Joaquin
(Johnson, 1965; Mackenzie, 1965). The virus reservoir, Calomys callosus, is commonly
found amongst houses, unless preventative measures are set in place (Kuns, 1965;
Salazar-Bravo et al., 2002). In addition to MACV, Chapare virus (CHAPV) was
identified as an additional pathogenic arenavirus present in Bolivia. In December of 2003
and January 2004, Chapare virus was identified in an area outside of the MACV endemic
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zone, following reports of several VHF cases. Sera was recovered and made available
from the only known fatal case of which Chapare virus was later isolated and
characterized (Delgado et al., 2008).
1.3.3. Guanarito virus and Sabia virus
Guanarito virus (GTOV), the agent responsible for Venezuelan hemorrhagic fever
(VHF), was identified in the rural area of Portuguesa State in central Venezuela (Salas et
al., 1991). Epidemiological studies suggest that the number of infected animal reservoirs
(Zygodontomys brevicuda) (Fulhorst et al., 1999)) in the endemic area to range from 515% up to 48% and the human seroprevalence rates are approximated at 2.5% based on
the limited serological surveillance to date (Milazzo, Cajimat, et al., 2011; Tesh et al.,
1993). Sabia virus (SABV) was isolated from a fatal case of VHF in Sao Paolo, Brazil
(Lisieux et al., 1994). During characterization and isolation of the virus, a laboratory
worker became ill with the newly identified virus, but recovered successfully
(Vasconcelos et al., 1993). The natural host of this virus has yet to be determined,
however, given the history of rodents in arenavirus transmission, it is assumed to be an
indigenous rodent species. These viruses (JUNV, MACV, GTOV, SABV, and CHAPV)
constitute the known human pathogenic arenaviruses in South America able to cause viral
hemorrhagic fever.
1.3.4. White water arroyo virus
White Water Arroyo virus (WWAV), identified in 2001, is associated with a brief
outbreak of severe disease in California (Byrd et al., 2000), and is the only NW
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pathogenic arenavirus currently recognized in North America. Its Neotomys sp., host
covers a large area in the southwestern United States (Milazzo et al., 2010). In addition to
WWAV, the other North American arenavirus suspected of being involved in human
infection is Tamiami virus (TAMV). TAMV seropositivity exists minimally amongst a
group of Seminole Indians, as well as the Sigmodon hispidus (TAMV) reservoir, which is
geographically distinct from Neotoma albigula (WWAV) rodents (Fulhorst et al., 1996;
Milazzo, Campbell, & Fulhorst, 2011). Despite the widespread prevalence of antibodies
in North American rodents to arenaviruses, a limited number of bona-fide human
pathogens have emerged (Milazzo et al., 2010; Salazar-Bravo et al., 2002). Additional
epidemiological surveys and studies to identify molecular determinants of pathogenesis
are required to ascertain the full risk involved with endogenous North American
arenaviruses.
1.4. Reservoir biology
Arenaviruses, with the exception of tacaribe virus, and the newly identified grouping
causing inclusion body disease (IBD) in related snake species, are each found within a
discreet rodent species with minimal overlap and/or spillover. As such, their geographic
distribution is restricted to the ecological range of the rodent hosts (Salazar-Bravo et al.,
2002). Maintenance of arenaviruses within these reservoir species is more than simple
tolerance, rather it is likely an intricate co-evolution of virus and host (M. D. Bowen, C.
J. Peters, & S. T. Nichol, 1997; Charrel et al., 2003; Emonet et al., 2006; Hugot,
Gonzalez, & Denys, 2001). A record of this is maintained not only in the arenavirus
genome, but also in the rodent genomes (Choe, Jemielity, Abraham, Radoshitzky, &
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Farzan, 2011; Demogines, Abraham, Choe, Farzan, & Sawyer, 2013; Tayeh, Tatard,
Kako-Ouraga, Duplantier, & Dobigny, 2010; Zapata & Salvato, 2013). Along these lines,
the most similarly related arenaviruses (e.g. JUNV and MACV, or LASV and MOBV)
can be found in closely related rodents (e.g. Calomus musculinus and Calomus callosus
or Mastomys sp). These relationships are not always obvious, however, as substantial
heterogeneity also exists within the family and sub-species.
One of the distinguishing features of arenaviruses is the ability to establish a chronic
infection in a host/cell whilst leaving the host/cell largely unharmed. This has been
demonstrated both in vivo (Traub, 1936) in various rodent hosts, as well as in-vitro
(Lehmann-Grube, Slenczka, & Tees, 1969) in laboratory settings. Rodent reservoirs,
despite typically showing no overt signs of disease, are able to shed infectious virus into
the environment via urine, saliva, and fecal leavings. The infectious fomites are thought
to be the principal source for transmission of infectious matter into humans either through
inhalation of aerosols, contaminated food sources, or through skin abrasions.
Consumption of infected rodent meat may also play a role in rodent to human
transmission. More recently, organ transplantations have produced a unique avenue for
human to human transmission with exceptionally fatal outcomes (Botten, King, Klaus, &
Zeigler, 2013).
The mechanisms of viral persistence have been examined from a molecular
perspective (e.g. viral gene regulation and D.I. particle production) (Oldstone &
Buchmeier, 1982; Rawls, Chan, & Gee, 1981; Welsh & Buchmeier, 1979), as well as
from a systems - immunological perspective (Teijaro et al., 2013). Close examination of
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both virus and host has provided ongoing clues to the amalgam of mechanisms at play in
maintaining a persistent infection (Oldstone & Buchmeier, 1982; Valsamakis et al.,
1986). Common themes include down-regulation of co-stimulatory molecules (e.g.
MHC), avoiding and dampening type I interferon (IFN-I) production (Borrow, MartínezSobrido, & De la Torre, 2010; Teijaro et al., 2013), and promotion of T cell exhaustion
(e.g. PD-1) (Wherry et al., 2007; Zajac et al., 1998; Zinselmeyer et al., 2013).
1.4.1. Arenavirus transmission: rodent-rodent and rodent-human
The principal route of maintenance for the prototype arenavirus, LCMV, relies upon
transmission from infected mother to her dams. This LCMV-mouse model has been
widely used as a surrogate to study arenavirus transmission amongst rodent reservoirs,
due in part to the biosafety concerns with more pathogenic species, as well as the
difficulties found in studying transmission in the endemic areas. These developing
rodents are qualified as carriers and harbor virus systemically. As such, they can shed the
virus via urine, feces, blood, and saliva. Evidence for horizontal transmission amongst
some NW and OW rodents, particularly during aggressive encounters, suggests it may
also play a substantial role. This is in contrast to LCMV in-uetero vertical models, as
experimentally infected C. musculinus are reported to have reproductive consequences
(Vitullo, Hodara, & Merani, 1987). However, this topic remains an issue of debate as
additional studies suggest a prominent role also for vertical transmission (Vitullo &
Merani, 1990).
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The horizontal mechanism of transfer, though not key to maintenance is critical for
zoonosis, and represents an additional ecological layer of complexity. Viral mutations
acquired randomly can be selected via tissue-specific pressures which may assist in
successful spillover into a naïve species (e.g. humans), as well as other closely related
rodents depending on the fluctuations in rodent population numbers and behaviors (Gire
et al., 2012; McCormick et al., 1987).
1.5. Pathophysiology of arenaviruses in humans and animal models.
Despite genetic dissimilarities, disparate vectors, and geographical separations,
arenaviruses when transmitted to humans elicit some common symptoms. The common
and unique aspects of arenavirus induced pathophysiology offers a challenge to both
clinicians and researchers as they seek to understand the etiology of disease and to
intervene in its progress. The onset of an infection by an arenavirus is widely considered
insidious. Fever ensues, and is often relentless. The prevalence of the viruses
geographically with other agents known to cause debilitating febrile illnesses often leads
to complications in recognition and treatment (Daniel J. Bonthius, 2012; McLay, Liang,
& Ly, 2014; Peters, 2002).
The prototype of the family, LCMV, generally, causes a subclinical disease that is
self-limiting and often goes unreported (Buchmeier & Zajac, 1999). The primary LCMV
case, reported in 1934 by Lillie and Armstrong, briefly described a middle aged woman
complaining of general malaise, severe headache, and of being “very hot” (Armstrong &
Lillie, 1934). The initial discovery was made during an outbreak of Saint Louis
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encephalitis, and was typical of the disease occurring at the time, until passaging of the
infectious agent through rhesus monkeys and white mice revealed the unique, and never
before seen characteristics of the virus including its presence in the choroid plexus and
meninges, of which it’s named was garnered.
In certain conditions, LCMV, can cause a variety of severe diseases in humans
including, but not limited to, aseptic meningitis and encephalitis (Buchmeier & Zajac,
1999). Sporadic reports of other manifestations (i.e. orchitis) in non-meningeal cases
have also been documented (Baum et al., 1966). LCMV, though not frequently associated
with hemorrhagic fevers, has also been documented as causing notable coagulopathy
(Staci A. Fischer et al., 2006; Scott & Rivers, 1936). The disease in humans can manifest
either systemically and/or neurologically and follows a biphasic course of development
characterized by a febrile and late neurological episode that usually begins within 1-2
weeks after exposure (Botten et al., 2013; Lehmann-Grube, 1989). Non-meningeal forms
that have been documented have similar general symptoms including a febrile illness
with fever, loss of appetite, low back pain, general malaise, nausea, vomiting, retroorbital headache, photophobia, maculopapular rash, occasional alopecia, with common
lab findings leucopenia and occasional thrombocytopenia (Baum et al., 1966; Lewis &
Utz, 1961; Strausbaugh, Barton, & Mets, 2001). LCMV acquired in-utero has been
demonstrated to be highly teratogenic, can result in abortion of the fetus, and can cause
severe developmental defects. Common signs in the fetus and surviving children are:
hydrocephalus, microcephalus, chorioretinitis and retinal scarring, mental and
psychomotor retardation, and cerebral palsy (Barton & Hyndman, 2000; Bonthius et al.,
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2007; Enders et al., 1999; Wright et al., 1997). Prenatal LCMV infections are thought to
be an underdiagnosed disease due to similar and overlapping symptoms of TORCH
(toxoplasmosis, rubella, cytomegaoviurs, and herpes virus) (Daniel J. Bonthius, 2012;
Bonthius, Mahoney, Buchmeier, Karacay, & Taggard, 2002; Bonthius et al., 2007;
Wright et al., 1997).
African arenaviruses, in particular LASV, cause symptoms within 7-12 days postexposure (Yun & Walker, 2012). Common symptoms include fever, severe headache,
sore-throat, retro-sternal pain, myalgia, facial and neck swelling, and pharyngitis (Bausch
et al., 2001; Buckley & Casals, 1970). An early leucopenia is often observed, followed by
a late leukocytosis. LF, if fatal, occurs usually within 12 days, and follows a hypotensive,
hypovolemic, and/or hypoxic shock syndrome (Edington & White, 1972; Fisher-Hoch,
McCormick, Sasso, & Craven, 1988). Hemorrhaging, often gingival or more rarely
gastrointestinal, is less common during LF and is an indicator of poor prognosis, along
with neurological involvement (Bausch et al., 2001; Günther & Lenz, 2004; Gunther et
al., 2001). An unusual sequala of LF is sensorineural hearing deficit, which is estimated
to occur in up to 30% of LF patients. The etiology of the hearing loss is not well
understood, and has been suggested to be an immunopathological development, as
opposed to a direct result of virus infecting the cells involved (Cummins, McCormick,
Bennett, & et al., 1990; Okokhere, Ibekwe, & Akpede, 2009).

A more thorough

description of the cellular and systemic features of this fatal disease course is lacking due
to insufficient and infrequent post-mortem examinations.
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An interesting feature of severe LASV disease is the insufficient immunological
response early during infection (Mahanty et al., 2003). Antigen presenting cells (APCs)
are thought to be a crucial early cell type infected with virus (macrophages and dendritic
cells). Secondary dissemination occurs in most visceral tissue and virus can be found in
hepatocytes, endothelial cells, epithelial cells, and fibroblasts. Immunosuppression is
hypothesized to result from multiple dysfunctions within infected APCs, which could
lead to a general repression of a functional antiviral CTL response thus facilitating
uncontrolled viral replication (Günther & Lenz, 2004). Accordingly, uncontrolled viral
replication and high titer are one of the few indicators of disease severity (Edington &
White, 1972; Johnson et al., 1987). Several mechanisms have been proposed explaining,
in part, how LASV deters activation of an immune response via nucleoprotein (NP) and
matrix protein (Z) interactions involving cytosolic pattern sensors –RIG I and MDA5 and
Caspase inhibition. These will be discussed below in the arenavirus protein sections.
Also, the glycoprotein (GP) mediated tropism of the virus allows for direct infection of
professional antigen presenting cells and is thought to interfere with sufficient antigen
presentation and support the immunosuppressive state during the disease course
(reviewed in (Russier, Pannetier, & Baize, 2012)).
The lack of extensive cytopathology by the virus has been a conundrum for
clinicians and scientists. Disruption of the vascular endothelium, and its barrier function,
is a feature thought to contribute to pathogenesis (Kunz, 2009; Peters & Zaki, 2002). The
immunosuppressive phenotype observed during OW arenavirus infection, seems at odds
with the disease course for NW arenaviruses, as will be discussed in the following
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section. The paucity of neutralizing antibodies seen following infection, contrasts with
NW arenavirus convalescence, where high nAbs are a common feature that protect
against re-infection (Bausch et al., 2000; Bond, Schieffelin, Moses, Bennett, & Bausch,
2012).
South American pathogenic arenaviruses all generate a very similar clinical
picture (Schattner, Rivadeneyra, Pozner, & Gómez, 2013). The clinical descriptions and
pathophysiology of Junín virus are the most well-documented. Symptoms begin within 710 days post-infection and are highlighted by fever, malaise, macular popular rash, severe
headache, photophobia, and petechial hemorrhaging (Grant et al., 2012; Molinas, Bracco,
& Maiztegui, 1981). Neurological complications are common and include tongue tremor,
hyporeflexia, confusion, ataxia, seizures, and coma in severe cases (Marta et al., 1999).
As in severe LF, AHF cases have a terminal shock of unknown etiology. Autopsies from
fatal cases report the involvement of lymphatic tissue as sites of replication with
macrophages, dendritic cells, and monocytes being primary targets of replication (Pozner
et al., 2010), as well as focal necrotic hepatic lesions (Gonzalez, Cossio, Arana,
Maiztegui, & Laguens, 1980). In contrast to LASV infections, the South American
arenaviruses elicit a potent inflammatory response in correlation with viral titer and
disease severity, demonstrate high levels of proinflammatory cytokines -TNF alpha, IL-6,
and have greater incidence of hemorrhaging (Heller, Saavedra, Falcoff, Maiztegui, &
Molinas, 1992; Marta et al., 1999). Hemorrhaging caused by SA arenaviruses, in contrast
to OW, does not correlate with disease severity or outcome (Heller et al., 1995; Molinas,
de Bracco, & Maiztegui, 1981). In both OW and NW human disease, a consistent lack of
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cytopathology exists which is insufficient to explain the severe disease and shock
manifestations that people succumb to (Elsner, Schwarz, Mando, Maiztegui, & Vilches,
1973; Walker et al., 1982).
The exact alterations in the hematological system during arenavirus infections
across New and Old World viruses that lead to bleeding abnormalities have been elusive,
and multiple explanations have been proposed. Many explanations, however, are based
on studies in animal models or tissue culture systems, such as the role of nitric oxide in
endothelial cell permeability following PICV infection (Brocato & Voss, 2009). NO
production during AHF has been noted in patients, confirmed in an endothelial cell
culture systems, and is suggested to promote hemorrhage through barrier disruption
(Gomez et al., 2003). Platelet dysfunction via IFN over-stimulation is another hypothesis,
and accordingly, JUNV virus has been found to infect megakaryocytes, which can lead to
deficits in pro-platelet production (Pozner et al., 2010). Specific deficiencies and
alterations have also been observed in clotting factors, and their regulatory cofactors in
animal models, and in patient serological examinations (Felisa C. Molinas et al., 1981;
Molinas, Paz, Rimoldi, & de Bracco, 1978; Schwarz et al., 1972). Given the observation
of infection of hepatocytes and megakaryocytes, and the synthesis of clotting factors
within these sites (Lenting PJ, 1998), this hypothesis has gained interest. An additional
possible contributor is an inhibitor of platelet aggregation, which has been suggested, but
not identified, in both LASV and JUNV infections, and is thought to also contribute to
platelet abnormalities during infection (Cummins et al., 1989; Cummins, Molinas, et al.,
1990).
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1.6. Animal models of arenavirus infection
Upon introduction of an arenavirus to a susceptible human, a variety of both subclinical and clinical features can present. Likewise, amongst rodent species, different
routes of inoculation, as well different species and strains of virus, will cause a variety of
outcomes both in the wild and in laboratory settings (Buchmeier & Zajac, 1999). Animal
models have been established to recapitulate and investigate various aspects of human
disease including the immunological responses of both rodents and non-human primates,
vaccine efficacy, and antiviral screening. Many elegant studies have used LCMV
infection of mice to characterize numerous aspects of virology, immunology, and modern
medicine. The revelations, to name a few, include aspects of chronic viral infection,
antigen presentation, and cytotoxic T cell responses (Buchmeier & Zajac, 1999), and
have prompted the virus to be widely considered as the Rosetta stone of modern
immunology.
Given the biosafety requirements for most pathogenic arenaviruses (BSL4), closely
related arenaviruses (e.g. TCRV, Candid1, LCMV, PICV) have been used to understand
the disease course from a micro and macroscopic perspective (Vela, 2012). Animal
models include: inbred/outbred mice, Hartley guinea pigs, Strain 13 guinea pigs, Syrian
hamsters, rhesus macaques, cynomolgus macaques, African green monkeys, and common
marmosets. These animal models have been used to examine efficacy of vaccines,
antiviral compounds, and neutralizing antibodies (Vela, 2012).
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1.7. Arenavirus life cycle
The arenavirus lifecycle begins with an introduction of an infectious virus to a naïve
host. The surface glycoprotein, embedded in the host-acquired viral envelope,
interrogates the cell surface until a suitable receptor ligation event(s) can take place.
Following sufficient attachment, virions are endocytosed, and need to be trafficked to a
late endosome (LE). The acidic environment of the late endosome provides the cue for a
molecular rearrangement of the glycoprotein complex. The receptor binding subunit (GP1) is then shed from the complex, and a fusion peptide(s) is revealed on the
transmembrane stalk (GP-2) that is able to insert into the LE membrane and initiate the
fusion cascade. Successful viral to LE membrane fusion allows for the ejection of the
viral genome, in the context of a ribonucleoprotein (RNP) complex, to be released into
the cytoplasm. The RNP contains the minimal units required for transcription of genomic
RNA, and replication of genome segments (genome, NP, L). Translation of viral proteins
is proceeded by a highly dynamic assembly and staging event presumed to take place at
the plasma membrane. Newly synthesized viral proteins and genomes are able to then
passively bud from the plasma membrane, in the form of infectious viral particles,
without destruction of the infected cell (Botten et al., 2013; Botten et al., 2007).
1.8. Arenavirus gene structure and replication
The arenavirus genome, though classified as negative sense (Leung, Ghosh, &
Rawls, 1977), has both a negative (-) and positive (+) encoding polarity on each of the
two genomic segments: the small (3 kb S segment) and large (~7 kb L segment). The S
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segment contains the (+) GP coding region, the (-) NP coding region, and is separated by
an intergenic region (IGR) that is thought to form a hairpin structure involved in
transcriptional termination (Auperin, Romanowski, Galinski, & Bishop, 1984; Harnish,
Dimock, Bishop, & Rawls, 1983; Riviere et al., 1985). The 3` and 5` untranslated
region(s) (UTR) on each segment contains a 19 nt long, complementary termini that are
proposed to form a pan-handle structure. The L segment encodes the matrix protein (Z) in
the (+) and the L protein - RNA dependent RNA polymerase (RdRp) in the (-) with
similar

UTR

and
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features

S segment (~3.5 kb)
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et
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1983)

(see

figure
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Figure 1.1 Arenavirus genome
Adapted from Botten et al., 2013. The arenavirus genome is bisegmented and ambisense.
The protein coding regions (shaded arrows) within each RNA segment are separated by
the noncoding IGR that forms a terminating hairpin structure. The termini of each
segment contain untranslated regions UTRs involved in genome packaging
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The arenavirus genome, upon entry into a host cell cytoplasm, is acted upon by the
viral RdRp to facilitate the process of making sub-genomic viral mRNA, viral
complementary (vc) RNA, as well as viral genomic sense RNA copies. This process
requires first the translation of message sense NP and L, which after sufficient
accumulation then support vcRNA synthesis from which GP and Z message can later be
transcribed (Botten et al., 2013; Franze-Fernandez et al., 1987; Meyer, de la Torre, &
Southern, 2002). Translation of NP is thought to facilitate a read-through of the
polymerase along the viral RNA (i.e. transcriptional antiterminator) (Tortorici et al.,
2001). Accumulation of Z has been shown, in-vitro, to inhibit the activity of the
polymerase, and thus may play the role of transcriptional and replicative repressor
(López, Jácamo, & Franze-Fernández, 2001). The dynamics of vRNA and viral antigen
have been interrogated in-vivo using in-situ hybridization and immunocytochemistry
techniques (Oldstone & Buchmeier, 1982; Valsamakis et al., 1986), which revealed the
transient nature of glycoprotein expression, along with early and consistent maintenance
of NP, and novel mechanisms of truncated interfering RNAs.

24

Translation

NP mRNA

5’ cap

3’

1

Transcription

3’

NP

GPC

2

5’ (-) vRNA

Replication
3’ (+) vcRNA

5’
NP

GPC

3

Transcription

GPC mRNA

3’

5’ cap

Translation

Figure 1.2 Arenavirus genome replication and transcription strategy

Adapted from Botten et al., 2013. This figure illustrates the steps carried out by the viral
polymerase to carry out a successful round of replication, which begins with (1) synthesis
of subgenomic RNAs needed for transcription of NP mRNA. (2) Newly translated NP
facilitates the read-through of the IGR by the polymerase to generate a full length
antigenomic RNA, and (3) which then serves as a template for transcription of GP
mRNA.

1.9. Arenavirus anatomy
Arenaviruses are structurally simple viruses. Genetically, they maintain a bisegmented, ambisense, single stranded RNA genome that codes for a total of four
proteins. The most abundant viral protein, the nucleoprotein (NP), encapsidates the viral
genome and is found clustered within the interior cavity of the virion. The viral
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polymerase (L), also packaged within the virion, is responsible for all genomic
transcription and replication events. The viruses are enveloped, which is derived from the
plasma membrane of infected cells as they passively bud out into extracellular space in a
process driven by the viral matrix protein, Z. The virions themselves are considered
highly pleomorphic and range in size from ~ 90-300 nm in diameter. The membrane of
the virions are decorated with the viral envelope glycoprotein (GP) which is derived from
a cellular precursor, GPC, and is later processed into the multifunctional stable signal
peptide (SSP), GP-1 receptor binding subunit, and the GP-2 transmembrane stalk. The
name arenavirus, originally coined arenovirus, (latin Arenosus, meaning sandy) was
agreed upon by Rowe et al. (1970) due to the unique granules observed within the cavity
of budding virions when ultrathin sections of infected cells were viewed under a
transmission election microscope. These granules were later defined as ribosomes, whose
presence today remains an enigma. The incorporation of these cellular factories within
the virions, however, is a harbinger of a far more elaborate and elusive network of
cellular machinery involved in the biogenesis and transmission of this group of viruses
(Murphy, Webb, Johnson, Whitfield, & Chappell, 1970; Rowe et al., 1970).
The limited arenaviral proteome (NP, L, Z, and GP) implies that these proteins must
be: (i) highly multi-functional, and (ii) able to congregate and re-purpose a network of
cellular proteins to carry out the obligatory steps in the viral lifecycle, without destroying
integral and vital cellular functions. Much effort has gone into understanding the core
function of each viral protein in replication of the virus (i.e genome packaging, receptor
binding, budding etc) (Buchmeier, 2002; Buchmeier, Elder, & Oldstone, 1978; Burns &
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Buchmeier, 1991; Pinschewer, Perez, & de la Torre, 2003). Scientists now are beginning
to unravel the cellular synthetic machinery hijacked by the individual proteins as well as
their mechanisms of action (Lucas T. Jae et al., 2013; Klaus et al., 2013; Madakasira
Lavanya, Christian D. Cuevas, Monica Thomas, Sara Cherry, & Susan R. Ross, 2013;
Debasis Panda et al., 2011).

Figure 1.3 Arenavirus anatomy.
Mature arenavirus virions contain an envelope derived from the plasma membrane of an
infected cell (blue shading) that is decorated by a tripartite glycoprotein complex
consisting of the GP-1 ectodomain, the GP2 transmembrane domain, and the myristolated
bitopic SSP. The inner leaflet of the plasma membrane is deformed into the curved shape
via association of the myristolated matrix protein Z (yellow). The interior cavity of the
virus contains the RNP consisting of the viral RNA genome ( L and S segment- red loop)
encapsulated by the NP (green). Each genome segment also contains the RdRp L (red and
green). The virions also contain interior host derived ribosomes of unknown function (red
and pink), as well as the intracellular cargo receptor ERGIC-53 (brown).
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1.9.1. NP
The viral NP (ca~65 kDa), in addition to its canonical role of genome packaging
and transcriptional regulation (Pinschewer et al., 2003), has been recently shown to play a
role in subverting and manipulating innate immunological recognition. Structural studies
of LASV NP revealed amino-terminal cap binding capabilities (7-methyl guanosine
triphosphate) thought to be involved in cap snatching (Linda Brunotte et al., 2011; Qi et
al., 2010) and carboxy terminal exonuclease activity that is specific for dsRNA (Hastie,
Kimberlin, Zandonatti, MacRae, & Saphire, 2011; Hastie, King, Zandonatti, & Saphire,
2012; Jiang et al., 2013). T
via recognition of dsRNA by cytosolic RNA sensors, retinoic acid-inducible gene 1, and
melanoma differentiation-associated protein 5 (RIG I and MDA5), and inhibits the
translocation of IFN regulatory factor 3 (IRF3). Interestingly, LCMV NP was found to
directly complex with both RIG-I and MDA5 (Zhou et al., 2010). NP mediated inhibition
of IFN activity has been shown for most arenaviruses (Martínez-Sobrido et al., 2009).
TCRV NP IFN suppression is currently under debate (Jiang et al., 2013; MartínezSobrido, Giannakas, Cubitt, García-Sastre, & de la Torre, 2007), and likewise the
residues involved in the active site of the DEDDh exonuclease domain are highly
conserved. LCMV NP was also shown to
, a prequel to its
nuclear translocation and IFN activation program (Pythoud et al., 2012)
and transcriptional activity is likewise inhibited by NP (Rodrigo et al., 2012), further
highlighting the multifactorial immune suppression ability of the NP molecule, and the
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arenavirus limited proteome. An additional innate immune aversion tactic is postulated
for Junín virus NP, which is hypothesized to act as an anti-apoptotic molecule, via
inhibition of Caspase 3 activation (Wolff, Becker, & Groseth, 2013).
1.9.2. Z
Originally identified as an 11kDa really interesting new gene (RING) domain
containing protein (Salvato, Schweighofer, Burns, & Shimomaye, 1992; Salvato &
Shimomaye, 1989), Z has since been shown to be a core structural virion protein that is
anchored to the viral membrane via a myristolation addition at the N-terminus (Perez,
Greenwald, & de la Torre, 2004), GP (Capul et al., 2007), NP (Ortiz-Riano, Cheng, de la
Torre, & Martinez-Sobrido, 2011), and L (Jacamo, Lopez, Wilda, & Franze-Fernandez,
2003; Kranzusch & Whelan, 2011). Z, the viral matrix protein, is minimally capable of
forming virus-like particles (VLPs) that are morphologically identical to bona-fide
virions (Eichler et al., 2004) and is also known to be curiously multifunctional despite its
small size. Its primary function lies in orchestrating the deformation of the plasma
membrane leading to the budding event, a process that involves recruitment of tumor
susceptibility gene 101 (Tsg101) and members of the endosomal sorting complexes
required for transport (ESCRT) pathway (Perez, Craven, & de la Torre, 2003). LCMV Z,
along with NP, has been shown to be involved with recruiting ALG2-interacting protein
X (ALIX/AIP1) during budding (Shtanko, Watanabe, Jasenosky, Watanabe, & Kawaoka,
2011). Interestingly, New World arenavirus Z proteins also have dedicated immunemodulatory features similar to NP, and act as IFN antagonists via RIG-I binding and
sequestration from MAVS (Fan, Briese, & Lipkin, 2010). Association of Z with
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translational machinery (e.g. EIF4E) is proposed to interfere with its 5’ 7-methyl G cap
binding potential (100-fold reduction), thereby repressing host cell protein synthesis
(Kentsis et al., 2001; Volpon, Osborne, Capul, de la Torre, & Borden, 2010). Ribosomal
protein P0 was also found to interact with Z in the nuclear compartment, and also gets
packaged into virions (Borden, CampbellDwyer, Carlile, Djavani, & Salvato, 1998),
however, the consequence of this interaction remains largely unknown. Z is also
proposed to possess anti-apoptotic capabilities via cytoplasmic re-routing of
Promyelocytic leukemia protein (PML) through a direct interaction (Borden, Campbell
Dwyer, & Salvato, 1998). Curiously, PML null mice are more susceptible and generate
higher titers earlier during the acute phase of replication, which suggested PML
recruitment provides a means of delayed CTL response in PML

-/-

mice (Bonilla et al.,

2002). Alternative proposals suggest it may also regulate the interferon sensitivity of
virus, and or regulate the transcriptional activity of the polymerase via Z (Djavani et al.,
2001).
1.9.3. L
The large arenavirus L protein (ca. 250kDa) contains an RdRp, the enzyme
responsible for all RNA replication and transcription activity in the viral lifecycle
(Buchmeier, de la Torre, & Peters, 2007; Lukashevich et al., 1997). Due to the large size
of the protein, and difficulties procuring it, little is known about the cellular activities of
L outside of genome maintenance and transcription. Within virions, it is the lowest copynumber protein amongst the viral proteome, and is found in complex with the RNPs.
When present in virions, it is thought to be locked in a catalytically inert state via Z
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mediated repression (Kranzusch & Whelan, 2011). Domain predictions segregate the
protein into four domains (I-IV) (L. Brunotte et al., 2011). Synthesis of arenavirus
mRNA is thought to occur via a small 5` cap of cellular origin, hypothesized to be
“snatched” in a mechanism similar to other negative sense viruses (e.g. bunyavirus RdRp
and influenza virus PA) (Morin et al., 2010). Accordingly, domain N1 of L contains a
putative class II endonuclease implicated in the retrieval of caps via downstream
liberation of RNA (Morin et al., 2010). Interestingly, mutations mapped to L provide a
replicative benefit to LCMV in certain cell types (e.g. macrophages) (Bergthaler et al.,
2010), however, the mechanism behind this replication enhancement remains obscure
(Bergthaler, Merkler, Horvath, Bestmann, & Pinschewer, 2007). Genetic studies of
virulent versus avirulent Pichinde virus have also revealed a number of pathogenic
substitutions in the polymerase (Lan, McLay, Aronson, Ly, & Liang, 2008) indicating
alternative functions may exist.
1.10. Arenavirus glycoproteins
Arenavirus glycoproteins (ca. 65-75 kDa) form ~ 10nm trimeric and tripartite (SSPGP1-GP2) club-like projections on the surface of virions that facilitate the attachment of
virus to cell surface receptors (

-DG (Cao et al., 1998), TfR1 (Radoshitzky et al.,

2007), Axl, Tyro3, LseCTIn, DC-SIGN (Shimojima, Ströher, Ebihara, Feldmann, &
Kawaoka, 2011), and L-SIGN (Martinez et al., 2013)). Arenavirus glycoproteins also
enable the annealing of viral membrane to cellular membranes following endocytosis
(Borrow & Oldstone, 1994; Fields, Knipe, & Howley, 2007). The primary GP role is that
of viral sentinel protein which is able to interrogate and engage with the surface of
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available cells, and thereby is the principle protein responsible for arenavirus tropism and
downstream pathogenesis (Oldstone & Campbell, 2011). Its biogenesis requires an
elaborate interplay with the synthetic machinery of host cells requiring sequential
proteolysis, coordinated multimerization and folding, asparagine-linked glycosylation,
myristolation, and targeted intracellular transport. There is limited information known
about the cellular proteins orchestrating events involved in GP biogenesis, outside of the
enzymes required for proteolysis, and the receptors involved in GP mediated viral entry.
Our studies have illustrated the depth of cellular machinery involved in the intracellular
biogenesis of viral glycoproteins, some of which have may have dual roles in intracellular
vs extracellular processes (Klaus et al., 2013).
1.10.1. Glycoprotein biogenesis: formatting of the complex
The arenavirus glycoprotein complex is synthesized inside of cells as a single
precursor polypeptide (Buchmeier & Oldstone, 1979; Clegg & Lloyd, 1983; Gangemi,
Rosato, Connell, Johnson, & Eddy, 1978; Harnish, Leung, & Rawls, 1981). Following
insertion into the ER by its signal peptide, two proteolytic maturation events are carried
out by cellular proteases: (1) the signal peptidase (SP) cotranslationaly processes the
growing peptide, and (2) the subtilisin kexin isozyme 1/ site-1 protease (SKI-1/S1P
herein referred to as S1P) forms the GP-1/GP-2 functional subunits. The three part
structure is strictly conserved across the arenaviridae. Additional domains lie within each
subunit, of which a handful of known functions are currently attributed to. The
glycoprotein ectodomain forms a globular structure capable of binding to receptors, the
GP-2 stalk anchors the complex to the viral membrane and carries out fusion, and the
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SSP is involved in intracellular trafficking and has multiple roles in viral infectivity (See
figure 1.2).

Figure 1.4 Arenavirus GP schematic.
Adapted from Botten et al., 2013. Proteolytic sites are indicated by black arrows.
Specifically, the SSP is cleaved after AA 58 by the signal peptidase, and the GP1-GP2
consensus site is cleaved by site 1 protease after R[X]L[X] motif ending at aa ~251. The
SSP contains a pan-arenaviral G2 myristol addition required for infectivity, two
hydrophobic domains (H1 and H2) represented by black rectangles, which are each
thought to span the membrane, residues K33 (critical for pH of fusion activation) as well
as C57 (required for GP1-GP2 association). The GP-1 subunit contains the receptor
binding domain and seven N-linked glycosylation additions indicated by (Y). GP-2 codes
for the class I fusion structural elements including two sequential fusion peptides at the N
terminus indicated by dark grey boxes, and two heptad repeats indicated by [H] . GP-2
also utilizes 4 N-linked sugars as indicated (Y) and are from LASV GPC consensus sites
determined by Eichler et al. (2006). The GP-2 transmembrane (TMD) and C-teminal
domains (CTD) include discontinous SSP binding sites which may overlap or include a
Zinc-binding Domain (ZBD), which are hypothesized to contribute to folding, SSP
interactions, and fusion of Junín virus GPC ( York et al., 2007; Briknarova et al., 2010).
F427I indicates a GP2 transmembrane domain (TMD) attenuation marker found in Junín
virus by Albarino et al. (2011) also capable of attenuating LASV in-vitro.
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1.10.2. GP post-translational modifications
Arenavirus glycoprotein structure and function has been shown to be critically
dependent upon two known post translational modifications: asparagine linked
glycosylation and myristolation. Myristolation of the SSP will be discussed in a later
section. The presence and function of multiple mannose-rich N-linked sugars on GP
(Buchmeier & Oldstone, 1979) have been studied using a variety of techniques including:
chemical inhibitors of glycosylation, lectin binding, x-ray crystallography, site directed
mutagenesis, analysis of proteolysis, intracellular processing, fusion, and release of
infectious virus. Whilst a growing body of evidence supports the essential contribution of
these modifications, the exact composition of the carbohydrates, the enzymes involved in
their maturation, and the molecular mechanism by which they contribute to GPs
functions remain largely unknown (Bonhomme et al., 2011; Bonhomme, Knopp,
Bederka, Angelini, & Buchmeier, 2013; Bowden et al., 2009; Buchmeier & Oldstone,
1979; Burns & Buchmeier, 1993; Candurra & Damonte, 1997; Clegg, 1982; Damonte,
Mersich, & Candurra, 1994; Eichler, Lenz, Garten, & Strecker, 2006; Lucas T. Jae et al.,
2013; Mersich, Castilla, & Damonte, 1988; Parekh & Buchmeier, 1986; Parsy, Harlos,
Huiskonen, & Bowden, 2013; Silber, Candurra, & Damonte, 1993; Wright, Salvato, &
Buchmeier, 1989; Wright, Spiro, Burns, & Buchmeier, 1990b).
Investigations into the presence of carbohydrate additions to arenavirus
glycoproteins via radiolabeling of viral and cellular derived LCMV GP (GP1/GP2 and
GPC) performed by Buchmeier et al. identified a mannose-rich precursor GP molecule,
which incorporated additional 3H fucose and 3H galactose during its secretion as
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GP1/GP2 suggesting a degree of post-addition processing (Buchmeier et al., 1978;
Buchmeier & Oldstone, 1979). The glycans on LCMV constitute approximately 35% of
the molecular weight of the molecule (Wright et al., 1990b). Glycosidic mapping of
JUNV GP-1 also suggests that the N-linked sugars contain terminal mannose and
galactose, however, the level of fucose may have been substantially less using an
alternatively less sensitive technique (Sergio Grutadauria a, 1999). Early studies on
carbohydrate functions of LCMV GP maturation demonstrated tunicamycin addition, via
inhibition of the en bloc addition of core oligosaccharides onto GPC, greatly diminished
viral yield, and more specifically the cleavage of GPC into GP-1 and GP-2. This suggests
that glycosylation was a precursor to proteolytic maturation (Wright et al., 1990b).
Concomitant with the inhibition of cleavage following tunicamycin addition, there was
no detectable GP at the surface of cells and no virus could be concentrated from
conditioned cell medium, suggesting the addition of N-linked sugars affected an early
step in the assembly and maturation of the glycoprotein (Wright et al., 1990b). In support
of this, infectivity of the NW Junín virus was likewise substantially reduced, along with
proteolytic maturation when cultured in the presence of tunicamycin. The authors
however, in the latter study, presented data from concentrated radiolabeled virions that
still contained viral structural proteins but lacked the normal amount of glycosylated GP1. This indicates that some alterations in the requirements of N-linked sugars on GP may
exist among arenaviruses (Padula & Segovia, 1984). This is in agreement with previous
studies on the critical inclusion of glycosylation and its processing via demonstration of a
high molar glucosamine block on JUNV replication (Martinez Peralta, Leon, Coto, &
Laguens, 1979), as well as the role of terminal GP-1 sugars on adsorption (Raiger
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Iustman, Castilla, Meich, & Mersich, 1998). Silber et al. demonstrated via use of a
glucosidase I & II, as well as mannosidase I & II inhibitors that maturation of the GP
glycans to a complex form was largely irrelevant for infectivity (Silber et al., 1993).
Interestingly, in the same study, bromoconduritol, which inhibits the ER glucosidase II,
was able to reduce infectivity. In accordance with those findings for JUNV, recent studies
have shown that small molecules antagonizing glucosidases within the ER are promising
antiviral agents against multiple VHFs (Chang et al., 2013).
Sequence comparisons across OW and NW GPs reveal four conserved sites
within the GP-2 subunit, whereas GP-1 subunits maintain a degree of heterogeneity of Nlinked glycosylation sites in placement, number, and utility (Bonhomme et al., 2011;
Bonhomme et al., 2013; Briese et al., 2009). Genetic disruption of arenavirus N-linked
glycosylation sites (NLS) has revealed the importance of individual NLS to specific
features of glycoprotein maturation and glycoprotein specific functions within the viral
lifecycle (Bonhomme et al., 2011; Bonhomme et al., 2013; Eichler et al., 2006).
Bonhomme et al. (2011) identified in a prototypical LCMV GP the usage of eight of the
nine consensus NLS, which is in accordance with previous data from Wright et al.
(1990a) on LCMV NLS utilization (Bonhomme et al., 2011; Wright et al., 1990b).
Interrupting glycosylation, at several sites in LCMV and LASV GP-1, interfered with the
proteolytic maturation of the complex (Bonhomme et al., 2011; Eichler et al., 2006),
whereas alterations to LCMV GP-2 sites enhanced cleavage (Bonhomme et al., 2011).
Interestingly, disruption of several LCMV GP-1 glycosylation sites, interfered with the
fusion activity of GP-2, yet trafficked normally to the plasma membrane. Ablation of
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conserved N-terminal sites along with an N-terminal GP-2 site also restricted VLP
infectivity (Bonhomme et al., 2011). Several NLS have also been demonstrated to be
involved in cell-type specific fitness and tropism (e.g. primary macrophage versus neuron
cells), as recombinant LCMV lacking specific GP NLS revealed altered expression,
fusogenicity, and growth kinetics depending on the cell type (Bonhomme et al., 2013).
Using the recombinant virus bearing individual NLS mutations, the first 2 N-terminal
NLS, the most conserved of GP-1 sites, were found to be completely indispensable for
virus recovery (Bonhomme et al., 2013). Structural studies of MACV GP-1 crystalized at
1.7Å (Bowden et al., 2009) and in a co-crystal with transferrin receptor 1 (Abraham,
Corbett, Farzan, Choe, & Harrison, 2010) suggest that the NLS do not participate directly
in receptor interactions, and instead help to solubilize the GP. Limited mass spec analysis
of the glycopeptides did reveal substantial heterogeneity in the carbohydrate structures on
GP-1 (Bowden et al., 2009), however a recent GTOV GP-2 structure suggests that given
the packing and placement of GP-2 glycans, they are likely to be shielded from
modification and remain in a homogeneous structure (Parsy et al., 2013). In the study by
Parsy et al. the authors also suggest that the GP1-GP2 heterotrimer interface will require
the structural influence of the N-linked sugars, which supports the infectivity data
generated by Bonhomme et al. following NLS ablation.
Neutralizing epitopes on LCMV GP have been demonstrated to be structurally
upheld by both intramolecular GP-1 disulfide bridges and N-linked glycosylation (Wright
et al., 1989). LCMV GP-1 neutralizing epitope 1D requires minimally the core
oligosaccharide added within the ER to maintain the folding required to present the
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epitope properly. Interestingly, this same epitope is masked in other strains of LCMV by
the addition of a GP-1 glycosylation site following a single point mutation; thereby
extending the utility of N-linked glycosylation to not only assisting in folding, but in
hiding neutralizing antibody epitopes (Bonhomme et al., 2011; Wright et al., 1989).
Curiously, the immunosuppressive strain of LCMV (WE) lacks the GP1-D epitope, but
the immunological extent of this observation was not clear as the site is reported to be
genetically unstable (Parekh & Buchmeier, 1986).
1.10.3. Making the SSP
Following early GP mRNA translation, the arenavirus GP leader sequence,
termed Stable Signal Peptide (SSP), directs the nascent peptide into the lumen of the
rough Endoplasmic Reticulum (RER) presumably via the classical signal recognition
particle and translocase (Eichler, Lenz, Strecker, Eickmann, et al., 2003; Eichler, Lenz,
Strecker, & Garten, 2003; Froeschke, Basler, Groettrup, & Dobberstein, 2003). The SSP
has several distinguishing and unusual characteristics which set it apart from
conventional signal sequences. Signal Peptides are normally 18-30 residues long with an
N terminal positive residue, a hydrophobic stretch, and a C-terminal signal peptidase
cleavage site. The first glimpse of a potential nontraditional role for the arenavirus SSP
came about during investigations that revealed a major histocompatibility complex
(MHC) class I restricted immunodominant epitope present within the LCMV signal
peptide, conserved across all arenavirus species (Burns, 1993), that was processed in a
Transporter of Antigen Presentation (TAP) dependent process (Hombach, Pircher,
Tonegawa, & Zinkernagel, 1995; Hudrisier, Oldstone, & Gairin, 1997; Pircher et al.,
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1990). The amino acid sequence is curiously long (58 aa) (Eichler, Lenz, Strecker, &
Garten, 2003) and has a half-life of > 6 hours (Froeschke et al., 2003). The enhanced
stability and longevity can be ascribed directly to the SSP itself, rather than the remaining
GPC molecule, as it is maintained when expressed in isolation (Froeschke et al., 2003).
The signal peptide, in addition to its greater than normal length (58 vs 18-25 AA),
has an additional unusual molecular architecture, and rather than the prototypical single
pass cellular signal peptides, potentially crosses the membrane twice, courtesy of its two
hydrophobic domains. The bitopic peptide’s N and C termini, for JUNV GP, are thought
to lie within the cytoplasm (Agnihothram, York, Trahey, & Nunberg, 2007; Eichler et al.,
2004), separated by a short lysine (K33) containing loop crucial for setting pH
thresholding during activation of the fusion cascade (e.g. charge at position 33 determines
what pH fusion occurs at) (Saunders et al., 2007; York & Nunberg, 2006). Some
controversy remains as to the exact architecture of the SSP. Early studies with OW GPs
suggested a class II transmembrane topology (N term anchored) (Eichler, Lenz, Strecker,
Eickmann, et al., 2003; Froeschke et al., 2003), as well as two-pass with luminal termini
(Schrempf, Froeschke, Giroglou, von Laer, & Dobberstein, 2007) versus the more recent
bitopic –cytosolic termini arrangement (Agnihothram et al., 2007; Briknarova, Thomas,
York, & Nunberg, 2011). Following liberation from the pre-GPC peptide via the cellular
signal peptidase (Eichler, Lenz, Strecker, & Garten, 2003; York & Nunberg, 2007a),
rather than being degraded, the SSP will maintain a non-covalent association with the
arenavirus glycoprotein complex through the remainder of the viral life cycle (Froeschke
et al., 2003; York, Romanowski, Lu, & Nunberg, 2004). The multiple membrane
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spanning domains of the SSP are not each required for translocation of GPC, and each in
isolation will suffice, in addition to alternative signal peptides (e.g CD4, CD8, or FLUAV
HA) (Eichler, Lenz, Strecker, Eickmann, et al., 2003; Eichler et al., 2004; York et al.,
2004). However, proper proteolytic maturation of the GPC into GP-1 and GP-2 subunits
requires an intact arenavirus SSP, and, accordingly, can be segregated into proteolysis
and fusion influencing regions (Messina, York, & Nunberg, 2012). Further, the SSP can,
interestingly, be provided in trans to complement GPC translocated via an alternative
signal and restore downstream maturation and function (Agnihothram, York, & Nunberg,
2006; Eichler et al., 2004; Eichler, Lenz, Strecker, & Garten, 2003; Saunders et al., 2007;
York et al., 2004). Signal peptides from closely related arenavirus species (e.g. LASV
and LCMV) can also complement the alternative species GP (Eichler, Lenz, Strecker,
Eickmann, et al., 2003). However, more distantly related arenavirus SSPs (e.g. JUNV and
LASV) fail to properly restore functionality to the GP molecule, presumably via specific
signals in the GP2 transmembrane (TM) and C-terminal domain (CTD) (Agnihothram et
al., 2006; Albarino, Bird, Chakrabarti, Dodd, White, et al., 2011). Association of the SSP
with GP-2 is thought to facilitate the anterograde trafficking of GP-1/GP-2 via masking
of a dibasic ER retention signal in the GP-2 CTD, and thus implements a quality control
mechanism ensuring a properly assembled GP complex prior to anterograde movement
(Agnihothram et al., 2006; Burri et al., 2013).
The SSP is also post-translationaly modified at a pan-arenavirus N-terminal GP-2
site via a myristolation addition (York et al., 2004). The myristolation addition appears to
be irrelevant for assembly of the tripartite molecular arrangement, but is crucial for
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enabling downstream contributions of the SSP in GP function, namely fusion and
infectious particle formation (Saunders et al., 2007; Schrempf et al., 2007; York et al.,
2004). It is hypothesized that the myristolation could also assist in proper targeting of the
GP complex to sites of budding along with the myristolated Z molecule (Agnihothram et
al., 2006). The SSP invariant C-terminal C57 residue has also recently been shown to be
involved in the formation of a zinc finger domain in collaboration with GP-2 (Briknarova
et al., 2011; York & Nunberg, 2007b). This zinc-finger moiety is considered to play a
stabilizing role with the GP-2 CTD (Briknarova et al., 2011; York & Nunberg, 2007b),
which, in addition to interactions between the SSP K33 loop-GP2 ectodomain (York &
Nunberg, 2006, 2009) and first SSP hydrophobic region- GP2 TM domain, may become
active during the fusion cascade; however, the exact molecular mechanism and
chronology remains to be fully elucidated (Messina et al., 2012). In toto several lines of
evidence support the role of the SSP in the anterograde transport, proteolytic maturation,
fusion, and infectivity activities of the arenavirus GP (Nunberg & York, 2012). The role
of SSP in orchestrating the mature trimeric assembly of SSP-GP1-GP2, and its
functionality, is yet to be completely understood. However, elucidating SSP interactions
and functions provides fertile ground for therapeutic intervention. As such, several small
molecules have been identified that interfere with SSP-GP-2 based fusion activity
(Bolken et al., 2006; A. M. Lee et al., 2008; Thomas et al., 2011; York, Dai, Amberg, &
Nunberg, 2008).
1.10.4. SKI-1/S1P cleavage: creating the GP-1 ectodomain and GP-2 stalk
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Arenavirus GPs require sequential proteolysis in order to generate a functional
tripartite complex. The second proteolytic maturation event, the cleavage of GPC into
GP-1 and GP-2 subunits, is an absolute requirement for the activation of the metastable
fusion elements entrenched in GP-2 and the formation of the globular GP-1 ectodomain
containing the receptor binding determinants. GP-1 is formed from GPC by the
proteolytic cleavage of site 1 protease (S1P) (Lenz, 2001), a calcium-dependent cellular
endoprotease involved in sterol metabolism and the ER stress response (Seidah et al.,
1999). After separation from the parental precursor , mature GP-1 maintains a noncovalent association with GP-2 on virions until acid induced ejection begins inside of
endosomes (Burns & Buchmeier, 1991; Di Simone, Zandonatti, & Buchmeier, 1994).
Properly processed GP-1/GP-2 molecules are incorporated into arenavirus particles and
appear as evenly spaced club-like projections embedded in the membrane of virions,
extending ~ 5-10nm from their surface (Burns & Buchmeier, 1993; Kunz, Edelmann, de
la Torre, Gorney, & Oldstone, 2003; Neuman et al., 2005).
The timing and molecular mechanism involved in S1P proteolytic maturation of
arenavirus GPs has garnered much attention. The site for the cleavage event was initially
mapped to a nine amino acid peptide in LCMV GP and was determined to have a
conserved, but slightly degenerate sequence, amongst the Arenaviridae involving a
dibasic cluster (Buchmeier, Southern, Parekh, Wooddell, & Oldstone, 1987). Studies
examining post-translational processing of LCMV GP determined a cleavage event,
approximately in or transiting from, the late Golgi (Wright et al., 1990b). This was in
agreement with studies on JUNV GP processing, which demonstrated that cleavage
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could be inhibited via disruption of ER to Golgi trafficking through the use of monensin,
BFA, and temperature shifts (Candurra & Damonte, 1997; Damonte et al., 1994). The
GPC cleavage site was further narrowed to a four amino acid motif in LASV GP
(RRLL), spanning residues 256-260 (Lenz, ter Meulen, Feldmann, Klenk, & Garten,
2000). An investigation of LASV GP also first revealed the enzyme S1P was responsible
for the maturation cleavage of GPC into GP-1 and GP-2. Cleavage could be specifically
blocked via calcium ionophores (S1P requires Ca2+ for proteolysis), but was insensitive
to BFA (Lenz, 2001). This suggested the location of maturation cleavage was either ER
or cis-Golgi, in contrast to the findings for LCMV GP (Beyer, Popplau, Garten, von
Laer, & Lenz, 2003; Wright et al., 1990b) and JUNV GPs. These were thought to occur
later in transit through the Golgi/trans Golgi after the glycan additions became complex
(Damonte et al., 1994). LCMV was subsequently and quizzically also found to be a
substrate for S1P (Beyer et al., 2003), along with the NW HF arenavirus GPs (Rojek,
Lee, Nguyen, Spiropoulou, & Kunz, 2008). The differences in subcellular locations of
cleavage were attributed to subtle changes in the cleavage consensus site. LASV GP
contains a tetra peptide (RRLL) that resembles the autocatalytic site C embedded within
the protease, which is acted on early in the secretory pathway (e.g. ER), whereas the
JUNV GP site RSLK more closely resembles the autoprocessing site B (Pasquato et al.,
2011). Given the conservation of arenavirus GPC usage of S1P, mechanistic insight into
the substrate selection may be gleaned from the evolutionary history of S1P and rodent
maintenance of arenaviruses. Accordingly, a recent study demonstrated that a wood rat
allele of S1P with reduced activity provided a means of protection against persistent, but
not acute infection with LCMV in a tissue specific fashion, in bone marrow derived
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dendritic cells (Popkin et al., 2011), which are known to be dysregulated during
persistence (Borrow, Evans, & Oldstone, 1995; Popkin et al., 2011; Sevilla, Kunz,
McGavern, & Oldstone, 2003). The extent of S1P function in the arenavirus lifecycle
will require further studies, but has been greatly hampered by the lack of a tractable
animal model due to embryonic lethality following gene deletion (Mitchell et al., 2001).
Maturation cleavage has been proposed to be an absolute requirement for
incorporation of glycoprotein species into arenavirus particles (Stefan Kunz et al., 2003;
Lenz, 2001), and for cell-to-cell spread of virus (Rojek, Lee, et al., 2008). Interestingly,
unprocessed GPC has been shown to traffic to the plasma membrane in certain
circumstances: following production in S1P-deficient Chinese Hamster Ovary (CHO)
cells, during expression of cleavage defective GP mutants, following exposure of cells to
calcium ionophore additions (Beyer et al., 2003; Stefan Kunz et al., 2003; Rojek, Lee, et
al., 2008). However, GP produced in these environments, is not efficiently incorporated
into virions, which still bud with normal quantities of viral structural proteins. Thus,
cleavage and plasma membrane trafficking are not predicated upon each other, per se, as
it has also been shown that removal of the GP-2 CTD dibasic cluster, reported in JUNV
to mediate anterograde trafficking via SSP masking, will negate cleavage of LCMV and
LASV GP (Agnihothram et al., 2006; Stefan Kunz et al., 2003; Schlie et al., 2009;
Schlie, Strecker, & Garten, 2010). The role of cleavage has been ascribed to activation of
the fusion machinery in the GP-2 subunit (Klewitz, Klenk, & ter Meulen, 2007).
However, its role in targeting and packaging of GP into virions remains under
investigation (Beyer et al., 2003). Inhibiting the cleavage event has, however, through
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the use of reverse genetic systems and small molecules, shown promise as an anti-viral
tactic (Maisa, Stroher, Klenk, Garten, & Strecker, 2009; Pasquato, 2006; Rojek et al.,
2010).
The association of arenavirus GP’s with S1P has additional implications with
regard to the role of S1P in the ER stress response, or the unfolded protein response
(UPR). Synthetic peptides corresponding to the LASV GP recognition site (RRLL) are
able to inhibit S1P-based cleavage of pro-activating transcription factor 6 pro-(ATF6) in
CHO cells (Pasquato, 2006). Following the accumulation of unfolded proteins in the ER,
ATF6 dissociates from BiP/GRP78 (both ER-resident chaperones capable of sensing
folding capacity), undergoes

sequential proteolysis by S1P and S2P, and becomes

nATF6, which translocates to the nucleus and initiates a branch of the UPR (Pasquato,
2006; Pasquato et al., 2011) (reviewed in (Chakrabarti, Chen, & Varner, 2011)).
Moreover, the LCMV GP has been shown to be a selective inducer of the ATF6mediated UPR, independent of the other viral structural proteins. This response occurs
during the acute phase of infection, when GP expression is highest. The response is
thought to enhance the folding capacity within the ER which may be required for
efficient viral replication (Pasqual, Burri, Pasquato, de la Torre, & Kunz, 2011b). An
additional hypothesis is that the selective induction of the ATF6-mediated UPR
facilitates the upregulation of ERGIC-53 (Nyfeler, Nufer, Matsui, Mori, & Hauri,
2003b), which which we show in Chapter 2 to enhance arenavirus replication in a GPspecific fashion (Klaus et al., 2013).
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1.10.5. GP assembly and virion release
Assembly of arenavirus particles has been observed, via thin sectioning of
infected cells, to take place at the plasma membrane, and in some instances, at
intracellular locations (Murphy et al., 1970). Electron dense club-like projections have
been shown to protrude from an engorged plasma membrane laden on the inner leaflet
with matrix protein. The RNPs are shepherded into particles via an ill-described
mechanism along with host ribosomes. Limited information exists as to the cellular
factors involved in the assembly and release of particles; however, the viral matrix
protein is widely accepted as the driving force of arenavirus budding (Fehling, Lennartz,
& Strecker, 2012). The role of GP in polarized budding will be discussed more in detail
in the following section (1.11).
Given the myristolation requirement for proper function of both the glycoprotein
and matrix protein of arenaviruses, several investigations have followed lipid
requirements for arenavirus assembly. Junín virus GP was observed to cluster in discrete
sections at the surface of cells when expressed in isolation, a feature commonly
associated with lipid microdomains (Agnihothram et al., 2009). Through the use of nonionic detergents, which are commonly used to identify cholesterol rich lipid rafts, it was
demonstrated that Junín virus GP is located in detergent soluble fractions of cell
membranes, indicating no association with the detergent resistant membrane (DRM)
fractions (Agnihothram et al., 2009). These findings, however, were contested in later
studies that demonstrated cholesterol depleting drugs led to a substantial reduction in
surface presentation and solubility of JUNV GP, as well as release of NP-containing
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particles (Cordo, Valko, Martinez, & Candurra, 2013). Further studies of LASV GP using
similar DRM extraction methods demonstrated a lack of association with DRMs
indicating both Old and New world arenaviruses assemble in detergent soluble fractions
(Schlie et al., 2009). Furthermore, the clustering of GP at the membrane was found to
occur independent of the G2A myristolation addition in Junín virus SSP (Agnihothram et
al., 2009). Immunogold labeling of GP-1 at the cell surface, which was visualized by
transmission electron microscopy, confirmed discrete clustering of GPC into
microdomains of approximately 120-160nM (Agnihothram et al., 2009). Interestingly,
GPC, when expressed in isolation, was found in areas containing localized membrane
curvature reminiscent of budding sites, thereby suggesting matrix-independent budding
(Agnihothram et al., 2009) which has also been observed for LASV GP (Schlie, Maisa, et
al., 2010). Curiously, in this same study, the authors were unable to demonstrate
colocalization of the matrix protein with the glycoprotein at the surface, which does not
support evidence provided by a number of studies which have demonstrated the
interactions of GP and Z (Luis M. Branco et al., 2010; Capul et al., 2007; Casabona,
Levingston Macleod, Loureiro, Gomez, & Lopez, 2009; Neuman et al., 2005; Schlie,
Strecker, et al., 2010). Treatment of purified LASV virions, or VSV psuedovirus particles
decorated with LASV GP, with cholesterol sequestering drugs, causes a profound
reduction in infectivity that can be restored via exogenous cholesterol (Schlie et al.,
2009). This finding suggests that budding, though not from cholesterol rich DRMs,
occurs in non-raft cholesterol containing microdomains.
1.10.6. GP-1 form and function
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The arenavirus GP-1 subunit contains the majority of neutralizing antibody
epitopes as well as the sequence controlling receptor binding for arenaviruses (Cresta,
Padula, & de Martinez Segovia, 1980; Oldstone, 1992; Parekh & Buchmeier, 1986;
Sanchez et al., 1989; Wright et al., 1989). Therefore GP-1 largely controls the initial
cellular tropism and downstream pathology of arenaviruses (Oldstone & Campbell,
2011). Several studies have shown the importance of this decision making capabilities
inherent in GP-1. In particular, studies of LCMV infection of inbred mice have
illustrated how a single amino acid substitution in GP-1 can alter the tropism of the
virus, and elicit strikingly different outcomes (e.g. persistence vs acute vs death of
animal) (Ahmed, Salmi, Butler, Chiller, & Oldstone, 1984; Kunz, Sevilla, McGavern,
Campbell, & Oldstone, 2001; Salvato, Borrow, Shimomaye, & Oldstone, 1991; Sevilla
et al., 2003; Sullivan et al., 2011; Teng, Borrow, Oldstone, & de la Torre, 1996). A
substitution found at position 260 (F L) changes the tropism (LCMV Arm to clone 13
transition) from red to white splenic pulp areas (macrophage-tropic to dendritic cell tropic). In accordance with this, an acutely cleared virus becomes immunosuppressive
and establishes persistence (Ahmed & Oldstone, 1988; Borrow et al., 1995; Sevilla et al.,
2000)

-DG,

a surface molecule highly expressed on dendritic cells (Sevilla et al., 2003; Smelt et al.,
2001). Further, LCMV WE GP-1 mutation S153 F enables the virus to replicate within
the growth hormone (GH) producing cells of the anterior pituitary (Oldstone et al.,
1982), resulting in GH deficiency and hypoglycemia (Teng et al., 1996). A number of
point mutations have been identified in variants of LCMV, yet most seem to alter the
nature of the residue at position 260. Heterogeneity in NW arenavirus GP-1 molecules
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have also been implicated in disease alterations (i.e. Junín attenuation) in both rodents
and humans (Flanagan et al., 2008; Scolaro, Mersich, & Damonte, 1990; Zhang,
Marriott, & Aronson, 1999). Studies mapping the determinants of NW arenavirus GP-1
molecules with the transferrin receptor 1 (TfR1) have demonstrated how limited
alterations to the GP or the receptor can change the tropism of the virus for cells bearing
TfR1 (Abraham et al., 2010; Abraham et al., 2009; Martin et al., 2009; Oldenburg,
Reignier, Flanagan, Hamilton, & Cannon, 2007; Radoshitzky et al., 2008; Reignier et al.,
2008).
In addition to its well supported role in receptor binding, additional alternative
functions for LASV GP-1 have been suggested following plasmid driven expression in
HEK293T cells. A series of truncations and deletions of GP-1 and GP-2 revealed
alterations in the kinetics of GP-1 release, as well as a potential GP-1 chaperone function
for GP-2. This model suggests that the proteolytic maturation and glycosylation profile
of GP-2 are contingent upon association with GP-1 through the latter half of the
secretory pathway, as expression of GP-2 alone resulted in a protein that was
inefficiently expressed, had a heterogeneous glycosylation pattern, and was transported
poorly (Luis M. Branco et al., 2010; Illick et al., 2008). Further, the shed GP-1 (sGP)
was shown to move independently of the GP2-SSP complex after cleavage (Burri et al.,
2013). Contradictory studies examining JUNV entry found GP-1 to retain the GP
complex in a mechanism involving stabilization by SSP of the intact GP1-GP2 complex
(York et al., 2008). As such, alternative functions may be different between OW and
NW GP-1 subunits. Interestingly, secreted or shed LASV GP-1 has been reported to
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contain distinct glycosylation patterns (Branco & Garry, 2009) based on binding to the
mannose specific lectin Galanthus nivalis agglutinin (Van Damme, Allen, & Peumans,
1987). Whether or not LASV GP-1 shedding outside of the late endosome has a
functional role in vivo is yet to be determined. Analysis of serum from very early time
points of suspected LF patients did, interestingly, provide initial evidence for the
presence of sGP prior to synthesis of whole virus in-vivo (L. M. Branco et al., 2010).
A recent study also suggested that LASV GP is capable of forming virus like
particles (VLPs) independent of the matrix protein. Further, the GP in these studies,
when co-expressed with the remaining structural proteins, directed the assembly and
release of VLPs from the apical surface of a polarized epithelial cell line (Schlie, Maisa,
et al., 2010). The solitary expression of Z exhibited a bipolar release of VLPs, suggesting
that GP may play a crucial role in setting the appropriate time and place for budding of
infectious virus to occur (Schlie, Maisa, et al., 2010).
1.10.6.1.

GP-1 receptor binding domain

Arenavirus GP-1 structural features have been characterized both by electron
microscopy (Burns & Buchmeier, 1993; Neuman et al., 2005) and more recently by xray crystallography either in isolation (Bowden et al., 2009) or with one of its cognate
surface receptors (TfR1) (Abraham et al., 2010). Despite the sequence heterogeneity
amongst GP-1 subunits, inherent in the receptor binding differences, the core
architecture is thought to remain similar (Bonhomme et al., 2013). The globular domain,
seen by EM in a cup-like arrangement in both OW and NW GPs, has a similar concave
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arrangement made up of a series of beta-sheets stretching 6-7 nm across. The entire spike
is thought to be composed of three GP1/GP2 heterodimers (Neuman et al., 2005).
1.10.6.2.

OW arenavirus receptor interactions

The receptor utilized by OW arenaviruses, in particular LASV and LCMV, was of
great interest to virologists, yet its identification remained elusive for a number of years.
Borrow et al., using an enzymatic process of surface molecule elimination (e.g. protease,
lipase, glycosylase), narrowed the search down to a glycosylated proteinaceous surface
molecule (Oldstone, 1992). In a seminal study by Cao et al. using the virus overlay
protein blot Assay (VOPBA), the alpha-dystroglycan molecule was found to be an
obligate receptor for several species of OW arenaviruses including several strains of
LCMV, as well as LASV, and MOBV, and surprisingly, the NW clade C arenavirus
OLIV (Cao et al., 1998). The additional NW arenavirus LATV from clade C was also
-DG using a similar VOPBA approach (Spiropoulou, Kunz, Rollin,
Campbell, & Oldstone, 2002).
The dystroglycan complex is synthesized as a precursor molecule that is

extracellular matrix proteins (laminin, agrin, perlecan, and neurexins) to the actin
cytoske

-DG is the soluble extracellular protein of the

complex that is non-

-DG protein (Barresi

& Campbell, 2006)

-DG molecule was found to be dispensable for arenavirus

binding and

-

-DG to the TM

domain of PDGF receptor still facilitated entry (Kunz, Campbell, & Oldstone, 2003).
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-DG that binds arenavirus glycoproteins overlaps with that of
its cellular ligands (Kunz et al., 2001). As such, it has been demonstrated that arenavirus
binding can displace the cellular ligands (e.g. laminin). This phenomenon is hypothesized
to dysregulate cellular junctions, which could contribute to viral pathogenesis,
particularly of the endothelium (Oldstone & Campbell, 2011).
In follow-up studies, strains of LCMV were identified with little or no binding
-DG. These strain-specific GP alterations were found to have implications in
the tropism and disease outcome when introduced to mice. The GP changes have been
minimally mapped to the F260L mutation (Kunz et al., 2001; Smelt et al., 2001; Sullivan
et al., 2011) and S153F (Sevilla et al., 2000; Teng et al., 1996). These findings were
further corroborated by an

-DG-independent entry of different

strains of LCMV which strongly suggested the use of alternate receptors (Kunz, Sevilla,
Rojek, & Oldstone, 2004). It is likely that additional viral and host factors contribute to
both tropism and pathogenesis as viruses with markedly different disease potential in
humans have been

-DG.

In support of the notion that arenaviruses can utilize alternative receptors or coreceptors to gain access to cells (Reignier et al., 2006), in a recent study utilizing cDNA
libraries derived from Vero, Cercopithecus aethiops, and human liver cells were
transduced into immortalized T lymphocytes, which are refractory to infection under
normal conditions, and were later screened for entry of LASV and LCMV GP
psuedotypes (Shimojima & Kawaoka, 2012; Shimojima et al., 2011). The authors
id

-DG independent entry of

authentic LASV including liver and lymph node sinusoidal endothelial calcium
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dependent lectin (LSECtin), Axl, Dendritic cell-specific intercellular adhesion molecule3-grabbing non-integrin (DC-SIGN), and Tyro3 (Shimojima et al., 2011). In contrast to
the in vitro demonstration of enhanced entry of LCMV GP psuedovirus, another study
found that the TAM receptor Axl failed to influence LCMV infection in Axl-deficient
mice (Sullivan, Welch, Lemke, & Oldstone, 2013). LASV usage of DC-SIGN was
confirmed in an additional study using chimeric LCMV bearing LASV GP and authentic
LASV virions. In these studies entry was found to be critically dependent upon the
mannose rich GP1 ectodomain. Accordingly, use of free mannan or chelators could
specifically block binding to DC-SIGN, but not

-DG (Goncalves et al., 2013).

Interestingly, DC-SIGN-mediated entry was found to be dependent upon the actin
-DG mediated entry (Goncalves et al., 2013).
-DG itself is dysregulated during infection via a mechanism
proposed to prevent super-infection (Rojek, Campbell, Oldstone, & Kunz, 2007). Key Omannosylation events taking place within the Golgi involving the (LARGE) molecule, a
putative glycosyltransferase involved in the O-mannosylation of the receptor, lead to a
GP-dependent inhibition of this post-translational modification (PTM) event. This in turn
-DG without interfering with its surface presentation.
The PTM of the receptor is required for both virus and ECM ligands to bind (Hara et al.,
2011; Imperiali, Spörri, Hewitt, & Oxenius, 2008; Imperiali et al., 2005; Kunz et al.,
2005; Rojek, Spiropoulou, Campbell, & Kunz, 2007). Interestingly, recent genomic
surveys in Africa have identified SNPs within the LARGE gene [and also dystrophin
(DMD), a -DG interacting molecule] demonstrating evidence for positive selection
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(Sabeti et al., 2007). It has been hypothesized that these polymorphisms may protect
against LASV infection (Oldstone & Campbell, 2011).
1.10.6.3.

NW arenavirus receptor interactions

The identity of a high affinity surface receptor for NW arenaviruses, like that of
their OW counterparts, was of great interest to the arenavirus feild. Early attempts at
deducing the nature of the receptor relied upon enzymatic digests of cell surface
molecules and yielded a proteinaceus molecule that required glycosylation. However,
studies by Rojek et al. using a broader range of glycosidases and mutant CHO cells
deficient in GalNac and Gal, contested glycosylation requirements - albeit on a different
cell type (Raiger Iustman, Candurra, & Mersich, 1995; Raiger Iustman et al., 1998;
Rojek, Spiropoulou, & Kunz, 2006). In an elegant series of experiments by Rojek and
colleagues, they determined that a common receptor was utilized by the South American
HF arenaviruses, and that inactivated heterologous clade B virus competition was
possible, albeit at high PFU/cell ratios. These data also suggested that the common
receptor was also highly expressed and abundant on numerous cell types (Rojek et al.,
2006). The human transferrin receptor 1 (hTfR1) was identified in 2007 by Radoshitzky
and colleagues, using a recombinant MACV GP1 molecule fused to an immunoglobulin
Fc probe, as being the cellular receptor for several pathogenic NW clade B arenaviruses
(e.g. MACV, JUNV, GTOV, and SABV) (Radoshitzky et al., 2007). TfR1 is a receptor
ubiquitously expressed across most tissues. It ferries transferrin bound in its holo (Fe3+)
bound form into cells via clathrin-dependent endocytosis, and has been suggested to
deliver this cargo ultimately to the mitochondria, or to unload TF-Fe3+ in the acidic
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environment while traversing late endosomes (Eckenroth, Steere, Chasteen, Everse, &
Mason, 2011). Later genetic studies mapping the binding sites revealed an apical portion
of the receptor that was distinct from its TF binding pocket. The ligation of TfR1 by
arenavirus GPs, therefore, does not interfere with the normal function of this otherwise
critical receptor involved in iron homeostasis (Demogines et al., 2013; Radoshitzky et al.,
2007; Sheftel, Mason, & Ponka). The relationship between TfR1 and zoonotic viruses
has, however, left its mark on the genome of not only the rodent reservoirs, but also the
human genome. A seminal study published by Demogines et al. revealed ongoing
positive codon selection in TfR1 genes across multiple mammals that correspond to sites
of arenavirus GP contact (Demogines et al., 2013). Importantly, the authors also
identified positive selection specifically within areas of GP1 that faced the receptor,
rather than GP2, thereby, providing additional support to receptor-mediated,
evolutionarily-induced, selective pressure (Demogines et al., 2013).
A number of studies have investigated non-TfR1 based entry in NW pathogenic
arenaviruses (e.g. JUNV) (Cuevas, Lavanya, Wang, & Ross, 2011; Flanagan et al., 2008).
Similar to OW arenavirus GPs, it was recently shown that both DC-SIGN and L-SIGN
could facilitate the entry of JUNV pseudoparticles (Martinez et al., 2013). The authors
propose that both DC-SIGN and L-SIGN are capable of binding to a terminal mannose
residue on GP-1 (Martinez et al., 2013) (likewise in support of the data provided by
Goncalves et al.). Accordingly, increasing concentrations of mannan were able to block
entry of virus into cells. A growing number of viral envelope glycoproteins (e.g. human
immunodeficiency virus (HIV), Dengue virus (DENV), severe acute respiratory
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syndrome coronavirus (SARS CoV), influenza A viruses (FLUAV) and ebola virus
(EBOV)) have been identified that are able to use these C-type lectins as attachment
factors suggesting a common underlying mechanism of carbohydrate dependent capture
(Han, Lohani, & Cho, 2007; Lin et al., 2003; Tassaneetrithep et al., 2003). This
mechanism is dependent upon maintenance of a high mannose structure, as a complex Nlinked structure is not recognized by these lectins.
Attachment to host cells by NW arenaviruses has also been demonstrated to occur
via T-cell Immunoglobulin and Mucin-domain containing proteins (TIM1, 3, and 4) in a
mechanism involving phosphatidyl serine (PS) present on the viral envelope (Jemielity et
al., 2013). In support of this mechanism, studies have visualized the presence of PS on
PICV infected cells as well as on the outer leaflet of virions (Soares, King, & Thorpe,
2008). Interestingly, a chimeric mouse/human monoclonal antibody recognizing PS via

effect in a guinea pig model of PICV infection.
1.10.7. GP-2
Synthesis of the arenavirus GP-2 subunit, as in GP-1 biogenesis, requires
proteolysis via SP and S1P. GP-2 anchors the maturing glycoprotein complex to the host
membrane via its transmembrane domain and maintains a non-covalent interaction with
the peripheral GP-1 and SSP subunits, as it traverses the exocytic pathway to the plasma
membrane and, ultimately, to the extracellular space in the context of mature virions.
Targeting, folding determinants, and pathogenicity factors have been genetically mapped
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to the GP-2 subunit and to its core fusion machinery (Agnihothram et al., 2006; Eschli et
al., 2006; Gallaher, DiSimone, & Buchmeier, 2001; York, Agnihothram, Romanowski,
& Nunberg, 2005). As such, the arenavirus GP-2 subunit is a class I viral fusion protein,
based on homology prediction to other class I viral fusion proteins (Gallaher et al.,
2001), which are responsible for acid-induced annealing of viral to endosomal
membranes (Castilla, 1996; Castilla, Mersich, & Damonte, 1991; Di Simone &
Buchmeier, 1995; Di Simone et al., 1994) that facilitate the injection of the viral genome
into the cytoplasmic space (Borrow & Oldstone, 1994; Disimone & Buchmeier, 1993;
Quirin et al., 2008).
1.10.7.1.

GP-2 ectodomain (fusion domain)

The GP-2 subunit is arguably the most dynamic of the viral proteome. Its
maturation and function requires a profound molecular arrangement beginning with an
SSP-primed metastable arrangement and ending in the classical type I fusion protein 6
helix coiled-coil in the post-fusion state. Gallaher et al. using a bioinformatics approach,
assigned LCMV and LASV GP to the family of class I fusion proteins based on heptad
repeat regions predicted to form characteristic 6-helix bundles found in GP-2, similar to
Ebola and influenza fusion proteins (Gallaher et al., 2001). The authors in the same study
were able to generate peptides from the 2nd hydrophobic heptad region (aa 326-355) that
were able to form helices in solution in support of the notion. Genetic studies of the
fusion machinery within GP-2 of LASV, LCMV, and JUNV also identified the two
adjacent N-terminal heptad repeats and their ability to form distinctive trimers (Eschli et
al., 2006; Klewitz et al., 2007; York et al., 2005). A 4.1 Å crystal structure of GTOV
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GP2 (Parsy et al., 2013) and a 1.8 Å structure of LCMV GP2 (Igonet et al., 2011)
(aa312-438) have confirmed the presence of trimeric protomers which formed the postfusion hairpin structure typical of the class. A unique feature of the arenavirus GP-2
fusion architecture is the presence of 2 N-terminal GP-2 fusion peptides (Glushakova,
Lukashevich, & Baratova, 1990; Glushakova et al., 1992) that are normally covered by
the globular GP1 head of the spike in a prefusion metastable state. The arenavirus fusion
machinery is also unique in its requirement of the SSP to maintain the metastable form
(described in 1.10.3). The fusion peptides lie at the N-terminus and are followed by the
two antiparallel helices which fold together to form the coiled-coil hairpin structure, a
thermodynamically favorable arrangement that is thought to facilitate the removal of
water molecules between membrane leaflets prior to fusion pore formation (Nunberg &
York, 2012; York et al., 2010).
1.10.7.2.

GP-2 transmembrane domain (TMD)

A recent investigation of the attenuation process in a vaccine strain of Junín Virus,
Candid1, (Albarino et al., 1997; Ghiringhelli, Riverapomar, Lozano, Grau, &
Romanowski, 1991; Pablo Daniel Ghiringhelli, 1997; Scolaro et al., 1990) which varies
from its parental virulent strain by a total of 13 residues, revealed a single substitution in
the transmembrane domain (F427I) of GP-2 to be responsible for the severely attenuated
phenotype of the vaccine in mice (Albarino, Bird, Chakrabarti, Dodd, Flint, et al., 2011).
The authors utilized a reverse genetics strategy to generate viruses representing the
unique attenuation mutations and found the F426I mutation to be solely responsible for
the decreased virulence. The same mutation when placed in the LASV GPC utilizing an
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HIV psuedotyping system, displayed reduced infectivity in vitro, supporting a novel and
critical role of the arenavirus GP-2 TMD in the viral lifecycle.
In a recent report the I427 residue of Candid1 GP-2 was also demonstrated to confer
the ability of neutral pH-induced cell-cell fusion (Droniou-Bonzom et al., 2011).The
authors proposed a model by which this change from the parental virulent virus alters the
metastable arrangement of the prefusion complex, allowing for premature conformational
rearrangement required for fusion, and thereby contributing to the decreased infectivity in
their assays (Droniou-Bonzom et al., 2011).
1.10.7.3.

GP-2 carboxy-terminal domain (CTD)

The carboxy terminal domain (CTD) of Junín Virus GP-2 was recently reported to
contain a series of 6 cysteine and histidine residues conserved across both Old and New
world Arenaviruses (York & Nunberg, 2007b). Residues H447, H449, C455, H459,
C467, and C469 similar to those required to form zinc fingers were found to bind Zn2+
with a kD of 1nM. Mutation of these residues abolished the interaction of the SSP with
the GP1/GP2 complex in trans-complementation assays and inhibited the proteolytic
maturation of the complex as well as the membrane fusion activity of GPC (York &
Nunberg, 2007b). A structure of the ZBD was recently determined using NMR
spectroscopy of residues 445-485 of the Junín Virus GP-2 CTD which confirmed the
presence of the ZBD and highlighted the necessity of the conserved H and C residues in
coordinating 2 Zn2+ ions within a novel fold (Briknarova, Thomas, York, & Nunberg,
2010). The authors propose a model where the 2 Zn2+ molecules are responsible for
bridging with the conserved C57 residue on the SSP thereby stabilizing the complex. It
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remains to be determined if this structure is indeed a requisite of GP-2 SSP association
across other Old and New World arenaviruses.
Involvement of the GP-2 CTD of both LASV (Schlie, Strecker, et al., 2010) and
LCMV (Stefan Kunz et al., 2003), however, have been demonstrated to be involved in
determining the cleavage state of the GPC. The studies support a model where specific
residues located within the CTD of GP-2 are responsible for stabilizing the conformation
of the glycoprotein in a permissive state for cleavage by SKI/S1P. Differences have been
demonstrated in the utility of the CTD between OW and NW arenaviruses. Specifically,
mutations of conserved residues spanning 463-491 were shown to inhibit cleavage of
LASV (Schlie, Strecker, et al., 2010) and LCMV GPC (Stefan Kunz et al., 2003),
whereas mutations in the JUNV GP-2 CTD (Agnihothram et al., 2006) were permissive
for cleavage. Several explanations may account for these differences. The use of a Cterminal epitope tag may have altered the native ultrastructural conformation of the
recombinant JUNV GP-2 used, or the sensitivity at which the protein could be detected in
the assays used. Alternatively NW arenaviruses may have evolved independent functions
for the CTD in maintaining the stability of the glycoprotein complex. The inability of the
CTD mutants to facilitate fusion, however, supports the hypothesis that cytoplasmic
residues can signal through the transmembrane domain and modulate features of the viral
life cycle.

1.11.

Determinants of entry
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Entry of arenaviruses involves a growing number of recognized receptors and surface
molecules mentioned in the previous s

-DG, Axl, Tyro3, DC-SIGN, L-

SIGN, LsECTIN, and TIM family proteins) and their ability to interact with the virion
embedded glycoproteins. A number of other protein and lipid cellular factors have also
been described that contribute to the entry events. Early work to describe arenavirus entry
featuring the prototype LCMV observed its uptake into cells, by EM, via smooth-walled
and clathrin independent vesicles that were internalized via a process insensitive to
cytochalasin disrupted actin filaments (Borrow & Oldstone, 1994). These entities have
been described more thoroughly in the intervening years through use of specific
endosomal markers. The fusion cascade for both OW and NW arenaviruses is known to
be inhibited via the addition of lysomotropic agents such as ammonium chloride, which
prevents the acidification of the maturing endosomes (Castilla et al., 1991; Lukashevich,
1989). The ammonium chloride block for JUNV could be overcome if the media was
buffered to low pH, suggesting that under these circumstances fusion could take place at
the plasma membrane (Castilla, Mersich, Candurra, & Damonte, 1994).
1.11.1. Clathrin, caveolin, and cholesterol
The entry mechanisms between OW and NW arenaviruses are divergent, which is
consistent with the biological properties of their cognate receptors. The high affinity
-DG, currently has no known endocytic mechanism.
JUNV and consequently TfR1 enter into cells via clathrin mediated endocytosis (CME)
(Martinez, Cordo, & Candurra, 2007). Accordingly, drugs that inhibit clathrin coated pit
(CCP) formation on the plasma membrane inhibited JUNV and TCRV particle entry into
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clathrin coated vesicles. The authors did note, however, that at high MOI an alternate
route of entry occurred that was sensitive to nystatin, a cholesterol sequestering drug
(Martinez et al., 2007)

-DG-dependent

LCMV entry using MOIs ranging from 10-100 (Shah, Peng, & Carbonetto, 2006). The
-DG is not associated with DRMs, but remained sensitive to
agents capable of perturbing cholesterol at the plasma membrane (Shah et al., 2006).
Shah et al. also demonstrated that movement of the DG complex to cholesterol rich
fractions was not observed following DG ligation by LCMV, indicating that post-receptor
ligation trafficking to DRMs was likely not taking place. The authors posited that
cholesterol could be involved in coordinating signaling events proceeding ligation, prior
to entry (Shah et al., 2006).
Vela et al. provided additional data supporting the role of cholesterol in arenavirus
entry by demonstrating that both PICV and LASV entry was diminished in the presence
(Vela, Zhang, Colpitts, Davey, & Aronson, 2007). Interestingly,

addition of virus, suggesting the defect, though occurring early, may also occur postattachment. The exact influence of non-raft cholesterol in arenavirus entry remains
unknown. Vela et al. also demonstrated that entry of both LASV and PICV pseudoviruses
occurred independent of caveolae, highlighting independence from the endocytic route
involving lipid rafts. Following expression of a dominant negative EGFR pathway
substrate clone 15 (Eps15) GFP fusion protein, a critical component involved in clathrincoated pit assembly, the authors observed a defect in entry of both PICV and LASV
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pseudovirus, suggesting use of a clathrin-dependent endocytic route (Vela et al., 2007).
These data also suggest that entry pathways may differ greatly between LCMV and
LASV (i.e. clathrin-independent vs clathrin-dependent endocytosis). Rojek et al. refined
the entry model for LCMV to include one that utilized non-raft cholesterol, specifically
not for attachment, but rather for the internalization of virus using a thiol-sensitive
biotinylated virus uptake assay (Rojek, Perez, & Kunz, 2008). The authors also tested the
cellular requirements of LCMV entry pathways: caveolae-dependent via expression of a
caveolin-1 dominant negative mutant cav-1Y14F, siRNA against CAV1, and cell lines
naturally lacking cav1 and 2, the GTPase dynamin I and II dominant negative mutants
(blocks both clathrin and caveolinblock CCP formation), and found entry of LCMV to be independent of both caveolae and
clathrin-dependent entry pathways (Rojek, Perez, et al., 2008).
Several studies have thus demonstrated a discreet role for cholesterol in the
internalization and assembly of arenaviruses. In addition to the entry event it was recently
determined that treatment of purified virions (native LASV particles or LASV GP
pseudotyped VSV) with cholesterol also greatly restricted infectivity in a reversible
manner (Schlie et al., 2009). The role of virion contained-cholesterol can be restricted, in
part, to the incorporation of the glycoprotein into the envelope. The contribution of
cholesterol in the post attachment of arenaviruses remains to be fully described.

1.11.2. Other factors
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JUNV entry has been shown to require clathrin-mediated endocytosis (Martinez et
al., 2007), in a process that also requires actin polymerization and microtubule dynamics.
The OW pathogenic arenaviruses LCMV and LASV have been reported to use both
clathrin-dependent (Vela et al., 2007) as well as clathrin-, caveolin-, dynamin-, and
macropinocytosis/actin-independent pathways (Quirin et al., 2008; Rojek & Kunz, 2008).
Differences in cell type and virus likely play a role in the emphasis of entry routes. To
date, little information is known regarding the endocytic machinery and trafficking
determinants. A study using rLCMV bearing the LASV GP (rLCMV-LASV GP) entry
routes identified some influence of Rab5 but not Rab7 (following expression of DN
mutants) suggesting an unusual mechanism of delivery to a late endosomal compartment
that may bypass early endosomes (Rojek, Sanchez, Nguyen, de la Torre, & Kunz, 2008).
This entry route is also independent of actin, but requires an intact microtubule network
up to and including entry and post-fusion steps (Rojek, Sanchez, et al., 2008).
Interestingly, the kinetics of entry for both LASV pseudovirus as well as authentic
Candid1virions are very similar despite the differences in trafficking patterns and optimal
fusion pH (4.5 vs 5.5) (Klewitz et al., 2007; York & Nunberg, 2006). Quirin et al. while
monitoring Rab5- and Rab7-GFP fusion proteins during LCMV entry observed some
colocalization of virus with both Rab5-positive and Rab7-positive (early and late)
endosomes. However, expression of DN mutants of Rab5 and Rab7 caused little (20%
Rab5) to no defect in replication. Following additional imaging of early and late
endosomal markers in tandem with CME directed siRNA knockdown, the authors
concluded that LCMV can use a CME dependent entry route through both early and late
endosomes, however, the majority of incoming virus enters in a CME-independent route
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that circumvents the early endosome (Quirin et al., 2008). This unusual route of entry
was expanded upon by Pasqual et al., who demonstrated LCMV and rLCMV-LASVGP
entry occurs through the multivesicular body (MVB) compartment en-route to late
endosomes (Pasqual, Rojek, Masin, Chatton, & Kunz, 2011). Further, the authors
demonstrated the activity of PI3K, involved in generating the PI3P lipid requirements of
MVB, along with LBPA, a lipid concentrated during ILV morphogenesis, are critical
factors in OW arenavirus entry, suggesting a crucial role for MVBs. RNAi knockdown of
ESCRT complex 0- III proteins (e.g. Hrs, Tsg101 which is also involved in budding, Vps
22 & 24, and Alix) all restricted, in part, entry as well. The authors propose a model
whereby incoming LCMV bypasses early endosomes, and transiently passes through the
MVB utilizing the ESCRT network en-route to late endosomes; a process dependent
upon the microtubule transport (Pasqual, Rojek, et al., 2011). The authors also posit a
very clear and plausible benefit to this unusual route of entry where the incoming virus
circumvents detection by Toll-like receptors found within early endosomes, which would
coincide with the lacking early immune response to LCMV and LASV.
1.11.3. Polarization
The use of cell lines to study entry, however, often fails to take into account the 3dimensional architecture and polarization requirements of the complex tissue that virus
comes into contact with in vivo. As such, the distribution of OW and NW arenavirus
receptors and their usage in terms of polarity have been a topic of debate. Functional
-

-DG at the basolateral surface of

cells, consistent with its role in organizing basement membranes. In contrast, other
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studies have described a bipolar distribution of the OW receptor (Dylla, Michele,
Campbell, & McCray, 2008). A recent study demonstrated that basolateral infection by
LASV resulted in a substantial increase of virus uptake compared to apical infection in
polarized Madine-Derby canine kidney (MDCK) cells (Schlie, Maisa, et al., 2010). This
finding was confirmed using LCMV and JUNV applied to primary human epithelial cells
(Dylla et al., 2008). This contradicts an earlier report for apically-dependent binding of
JUNV by Cordo and colleagues (Cordo, Cesio y Acuna, & Candurra, 2005). The authors,
however, noted that entry could occur in a non-polarized fashion suggesting perhaps
diffusion of virus-receptor complexes following binding.
Despite discrepancies in the route of entry and release current models agree on a
polarized entry and release of both OW and NW arenaviruses. Further investigation of
the requirements for polarization in vivo will be required to substantiate these
contradictory findings and reconcile them with observations of primary cellular targets
initiating human infection including macrophages and dendritic cells.
1.12.

Overview of endomembrane protein trafficking

Arenavirus glycoproteins need to traverse the highly dynamic endomembrane system
present in eukaryotic cells. Our understanding of the processive maturation is limited to a
few key parts. In order to discuss the proteomics blue-print laid out in this dissertation,
and the influence of the ERGIC-53 cargo receptor complex, we must first discuss in more
detail some of the basic and more elaborate factors governing protein folding,
modification, and trafficking within the confines of the cell. The ability to selectively
identify and traffic cargo within a cell, facilitates and underlies a dynamic necessity for
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protein concentration within the membranous systems of eukaryotic cells. Specialized
transport systems have facilitated the growth and divestment of compartmentalized
faculties within cells that require a multitude of growth and survival signals as well as the
ability to ascertain and respond to the repertoire of extracellular stimuli. Selectively
transporting and maintaining proteins within the endomembrane system also allows for a
dynamic and well-coordinated (usually) maturation of cargo destined for sites containing
machinery involved in post-translational modifications that ensure the timing, folding,
and function of the target molecules.
Protein folding and trafficking within the endomembrane system begins within the
Endoplasmic Reticulum (ER) where both co- and post-translational modifications arise.
In many cases asparagine-linked glycosylation consensus sites (NLS) (NxS/T) receive a
covalent en-bloc addition of a 14 piece high-mannose oligosaccharide unit. This glycan
moiety enters the molecule into the calreticulin-calnexin cycle, to ensure proper folding
via recognition of hydrophobic patches, which are characteristic of misfolded proteins,
utilizing a repeated addition and removal of a terminal glucose residue (Hammond,
Braakman, & Helenius, 1994). Following correct folding and disulfide linkage, proteins
are either transported further through the secretory pathway, retained within the ER or
retrieved soon after exit (e.g. KDEL receptor retrieval) (Munro & Pelham, 1987; Pelham,
1988), or are shunted into an ER-assisted degradation pathway (ERAD) whereby proteins
are reverse translocated and targeted for destruction via the proteasome (Wiertz et al.,
1996). Approximately one-third of all mammalian proteins are synthesized into the ER
and become glycosylated. Therefore, the complex interplay of chaperones, isomerases,
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lectins, and glycosyltransferases ensures not only the primary folding, but the functional
retention versus degradation or passage of massively complex molecules destined either
for an intracellular membranous compartment, the plasma membrane, or the extracellular
space (Fiedler & Simons, 1995).
Forward trafficking of proteins has been proposed to occur either via a non-specific
bulk flow mechanism (Pfeffer & Rothman, 1987; Wieland, Gleason, Serafini, &
Rothman, 1987) or one that requires specific intramolecular signals selectively
recognized by transport receptors (Kelly, 1985; Palade, 1975). Transport receptors can
assist in concentrating soluble cargo proteins within specialized exit domains of the ER
termed ER exit sites (ERES) (Palade, 1975). Glycoproteins, if selected for anterograde
movement, maintain a limited amount of primary information in the carbohydrate
structure whilst in the ER. However, additional enzymes, concentrated within the Golgi
cisterna, chemically and functionally elaborate the signature entrenched within the glycan
structure (Helenius & Aebi, 2001; Reuter & Gabius, 1999). An outstanding question of
cellular biologists’ remains unanswered in regard to the glycosylation pathway: why does
the cell build up a carbohydrate modification in the ER, only to tear it down and build
anew later in the pathway (Hammond et al., 1994; Helenius & Aebi, 2001)? The energy
devoted to creating and maintaining the glycosylome suggests a key and fundamental
purpose that remains to be fully described.
1.12.1. Lectins
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A key group of molecules involved in the biogenesis of cellular glycoproteins are the
lectin family of proteins. Originally identified by plant biologists as early as 1888 (Lis &
Sharon, 2007), this diverse class of typically non-enzymatic, carbohydrate binding
molecules have provided cellular biologists, immunologists, and biochemists with
powerful tools to purify, biochemically examine, and track the glycosylation profile of
proteins inside and outside of the secretory pathway (Lis & Sharon, 2007). The
abundance of cellular glycoproteins, as such, requires a complex array of lectins, and
their specific activities. Intracellular lectins are thought to be intimately involved in
decoding the glycosylated messages embedded within the changing structure of glycans
within each membranous compartment. This class of proteins is evolutionarily conserved
from archaea to mammals. Thus, the study of lectins has also facilitated the study of the
co-evolution of carbohydrate structure and function (Reuter & Gabius, 1999).
1.12.1.1.

Common structural features, nomenclature, and function

Lectins can be complex multi-domain proteins that function within a variety of
environments including the secretory pathway, at the surface of cells, or in the
extracellular space. Despite substantial heterogeneity via their modular domain
structures, a single domain, the carbohydrate recognition domain (CRD) facilitates that
sugar binding activity on most lectins. Accordingly, lectins can be characterized by the
structural features of the CRD into a more discreet grouping (Varki, Etzler, Cummings, &
Esko, 2009). Animal lectins are primarily segregated into C-type, Galectins, I-type, Ltype, P-type, and R-type (Dodd & Drickamer, 2001). For the purposes of the dissertation
C-type, Galectins, and L-type lectins will be briefly discussed. C-type lectins are a broad
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superfamily of proteins, characterized initially by their requirement for calcium ions for
binding to sugars. Functions of this superfamily include pathogen clearance, endocytosis,
and cell adhesion. This superfamily includes collectins, endocytic receptors, selectins, as
well as lymphocyte lectins (Varki et al., 2009). The first animal lectin discovered, hepatic
asialoglycoprotein receptor, belongs to this grouping. C-type lectins have been
increasingly demonstrated to be involved in host-pathogen interactions (i.e. DC-SIGN
has been shown to facilitate entry of a number of enveloped RNA viruses). Galectins are
commonly found to bind to beta galactosides, but have other known high and low affinity
interactions. Though the most widely expressed group of lectins across organisms, very
few Galectins have been found in humans with examples being Galectins 1 and 3. Their
physiological roles are not well described, but are thought to be involved in basement
membrane interactions (Cummings & Liu, 2009; Tellez-Sanz, Garcia-Fuentes, & VargasBerenguel, 2013). L-type, or leguminous, lectins were originally isolated from
leguminous plant seeds, and were known for their hemagglutinating abilities via binding
to cell surface glycans. Many lectins in this family contain a “jelly-roll” fold, however,
this fold has been found across disparate primary sequences (e.g. Galectin-3) and species
(e.g. the Rotavirus spike protein VP4) (Etzler, Surolia, & Cummings, 2009).

1.13.

ERGIC-53 and the intermediate compartment
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Outside of CRT and CNX, arguably the most well studied mammalian lectin is the
Endoplasmic Reticulum Intermediate Compartment Protein of 53 kilo Daltons (ERGIC53). The uninspiring name harbors a wealth of knowledge acquired by multiple
generations of scientists probing the inner coming and goings of the secretory pathway.
The protein is hypothesized to be an intracellular cargo receptor that facilitates the
anterograde movement of a select subset of glycosylated cellular glycoproteins by
binding to them via its, calcium-sensitive lectin function and coat protein interactions
(see Figure 1.5). The protein is highly conserved across species from humans to yeast,
and yet is paradoxically unessential (its loss in humans, though tolerated, is not without
consequence). By studying its trafficking patterns and ligand selections, scientists have
been able to synthesize a more comprehensive model of selective/receptor mediated
protein trafficking within the early secretory pathway. Further, the loss of ERGIC-53 or
its cofactor, multiple coagulation factor deficiency protein 2 (MCFD2), result in the
Combined Deficiency of Factor V and Factor VIII (F5F8D), yet this happens without
gross alteration of the machinery in the early secretory pathway. The majority of cellular
glycoproteins cycle and are secreted normally, and other than the bleeding abnormalities,
F5F8D patients live normal lives. Through the study of this biological conundrum,
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Figure 1.5 Recycling of ERGIC-53 in the early secretory pathway.

The early secretory pathway, comprised of the ER, ERGIC, and Golgi network provides
the structural and biochemical cues for the cycling of ERGIC-53. Cargoes (depicted as
FV & FVIII (red lumenal molecules)) are concentrated within specialized ER exit site
(ERES) domains (1) with the help of the soluble, calcium-binding, cofactor MCFD2
(yellow lumenal molecule). Hexameric, cargo loaded ERGIC-53 (bown transmembrane
molecule), via c-terminal FF – COPII (blue) interactions, and with the help of the suboptimal TM length, is able to overcome the ER retention signal strength and traffic
forward to the ERGIC (2). Fusion of ERGIC-53 positive carrier vesicles introduces the
cargo receptor to an environment that is substantially lower in calcium concentrations,
and subtly lower in pH (the green gradient represents changing chemical composition of
the pathway). The composition of the ERGIC is hypothesized to act as the cue to dislodge
calcium from the ERGIC-53 receptor complex, which reversibly attenuates its lectin
activity and causes cargo release (3). COPI (purple) complexes assemble onto new
ERGIC-53 sites via the dilysine (KK) c-terminal retrieval signal, and facilitate the Golgiindependent retrograde trafficking of the cargo receptor (4).
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ERGIC-53 was identified by several independent groups via complimentary
approaches. Schweizer and colleagues, following immunization of mice with material
from enriched Golgi fractions of human Caco-2 cells, proceeded with the immunologic
identification of an ~ 53 kDa protein and thus preceded its provenance as marker to a
network of vesicular tubular clusters at the cis-face of the Golgi, to be later termed the
ERGIC (Schweizer, Fransen, Bachi, Ginsel, & Hauri, 1988). The protein was
biochemically characterized as a non-glycosylated integral membrane protein containing
a short cytoplasmic tail, and found capable of forming long lasting dimers and hexamers
(a half-life of several days is suggested). Saraste et al., using a similar approach in rat
pancreatic cells, identified a protein of a similar nature dubbed p58 (Saraste, Palade, &
Farquhar, 1987). Following its further genetic characterization, p58 was identified as the
rat homologue of ERGIC-53 (Lahtinen, Hellman, Wernstedt, Saraste, & Pettersson,
1996). A third group identified a protein termed MR60 from a human promyelocytic cell
line that bound a mannose column in a divalent cation-dependent fashion (Pimpaneau,
Midoux, Monsigny, & Roche, 1991) that was also determined to be ERGIC-53 (Arar et
al., 1995). In the intervening years, ERGIC-53 orthologues have been identified from a
variety of species covering the spectrum from C. elegans to humans, suggesting a highly
evolutionarily conserved protein (C. Appenzeller, H. Andersson, F. Kappeler, & H. P.
Hauri, 1999a).
The ability to reproducibly isolate and identify this intermediate compartment via
ERGIC-53 has since facilitated the biochemical investigation of its purpose (Schweizer,
Matter, Ketcham, & Hauri, 1991). The identity of the intermediate compartment is
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biochemically unique relative to the ER, ERES, and Golgi stacks. Alterations not only in
protein content (Breuza et al., 2004; Klumperman et al., 1998a; Schweizer et al., 1991),
but in lipid content (Ben-Tekaya, Kahn, & Hauri, 2010), and tonic qualities (e.g. ion
concentrations and pH) have been identified (Paroutis, Touret, & Grinstein, 2004;
Pezzati, Bossi, Podini, Meldolesi, & Grohovaz, 1997). Several hypotheses regarding the
genesis and function of the compartment have been tested experimentally in vivo, as well
as in vitro (e.g. maturation model versus stationary model) (Zeuschner et al., 2006).
Schweizer and colleagues, using Vesicular stomatitis virus G (VSV G) as a marker along
with a temperature shift characterized the ERGIC-53 compartment as an intracellular site
where anterograde trafficking halts at 15° (e.g.15° compartment) (Schweizer et al., 1991).
Upon rewarming, Klumperman and colleagues demonstrated that the ERGIC-53 positive
structure was also involved in a Golgi-independent retrograde trafficking process to the
ER (Klumperman et al., 1998a). The compartment has also been demonstrated to be a site
of coat protein sorting. COPII anterograde moving vesicles ferrying cargo from ERES
fuse with the adjacent ERGIC (Aridor, Bannykh, Rowe, & Balch, 1995), while COP I
vesicles exit towards either ER (retrieval carrier vesicles) or towards the Golgi (Nickel &
Brügger, 1999; Scales, Pepperkok, & Kreis, 1997). Live cell imaging studies using an
ERGIC-53 GFP fusion protein highlighted the active qualities of the compartment. The
GFP-ERGIC-53 positive structure, though highly dynamic, was indeed a stationary
compartment (Ben-Tekaya, Miura, Pepperkok, & Hauri, 2005a) rather than one rapidly
formed and decomposed, as had been formerly proposed (Scales et al., 1997). The
localized movement of ERGIC-53 positive net-stationary (mobile-yet permanent) clusters
and the anterograde and retrograde transporting vesicles were shown to be dependent
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upon microtubules (Ben-Tekaya et al., 2005a) and (Cole, Sciaky, Marotta, Song, &
Lippincott-Schwartz, 1996; Lippincott-Schwartz et al., 1990). The majority of ERGIC-53
is localized to the intermediate compartment. When it does escape the ER-ERGIC
cycling, it is generally limited to the first cisterna of the Golgi (Klumperman et al.,
1998a). The cycling of ERGIC-53 will be discussed more in detail in a later section
(section 1.13.1.3).
1.13.1. ERGIC-53 the lectin: structural and biochemical features
ERGIC-53, along with its closely related resident Golgi homologues

vesicular

integral membrane protein of 36 kDa (VIP36), ERGIC-53-like (ERGL), and VIP-36-like
(VIPL), is categorized as an L-type lectin based on homology of its CRD to leguminous
lectins and to some extent mammalian galectins (Arar et al., 1995; Fiedler & Simons,
1994). The protein consists of approximately 510 amino acids in humans and consists of
a signal sequence, a large lumenal segment subdivided into a CRD and helical region, a
transmembrane domain, and a cytoplasmic tail (see figure 1.6).
1.13.1.1.

ERGIC-53 CRD

ERGIC-53 contains a large, ER-lumenal CRD encompassing ~240 amino acids (31285) which contain all the information necessary for, minimally, in vitro carbohydrate
binding. Extensive structural and biochemical studies have determined: the residues
involved in binding to carbohydrate ligands (Zheng et al., 2013), separate structures with
(Velloso, Svensson, Pettersson, & Lindqvist, 2003b) and without (Velloso et al., 2003b)
Ca2+, and residues binding to the soluble EF-hand protein MCFD2 (Nishio et al., 2010;
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Wigren, Bourhis, Kursula, Guy, & Lindqvist, 2010) . The CRD folds into

-sandwhich,

-sheet (Velloso et al., 2003b). Removal of
-

-4) (Zheng, Liu, Yuan, Zhou, & Zhang,

2010) or structurally distant Ca2+ binding residues (N156A and D181) (Zheng et al.,
2013) are thought to create structural reformations causing collapse of the ligand binding
site.
Carboxy -Terminal Domain
(Targeting / Trafficking)

Cytoplasm

Transmembrane Domain
Cysteines (oligomerization)

Lumen

Helical Region
Carbohydrate
MCFD2 binding
Recognition Domain
Mannose binding
(CRD)
Ca2+ binding

Figure 1.6 ERGIC-53 structural features.
This schematic depicts a hexameric ERGIC-53 molecule inserted into a membrane. The
known functional regions are listed in the approximate areas (not drawn to scale). The Nterminus lies within the lumen of the ER/ERGIC and the C-terminus is exposed to the
cytoplasm. The carbohydrate recognition domain (bulbous white central region) contains
residues controlling binding to calcium, carbohydrates, and MCFD2. The helical stem is
thought to be involved in oligomerization and peptide binding. Two oligomerization
critical cysteins are depicted as yellow ovals. The transmembrane domain has also been
suggested to be involved in trafficking via a mechanism involving a sub-optimal length.

Following extensive examinations of its sugar binding capabilities, it was determined
to be a mannose specific lectin (in vitro binding) in the presence of calcium and at the
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approximate pH of the ER (Itin, Roche, Monsigny, & Hauri, 1996), and was able to
recognize the man8/9 structures when bound to calcium in vivo and in vitro (Itin et al.,
1996; Kamiya et al., 2008; Moussalli et al., 1999a; Zheng et al., 2013). This feature is
one that separates ERGIC-53 biochemically from VIP-36, which has been proposed to
bind to mannose in a calcium-independent fashion (Hara-Kuge, Ohkura, Seko, &
Yamashita, 1999; Kamiya et al., 2008), and from the yeast orthologues, of ERGIC-53,
Emp46p, which utilizes K+, and Emp47p binds carbohydrate independent of metal ion
cofactors (Satoh et al., 2007). ERGIC-53’s N-terminal (ER-lumenal) carbohydrate
recognition domain contains conserved residues involved in sugar binding amongst other
L- lectins. When these restudies are disrupted (e.g. N156A and D121 mutations) the
sugar binding features are lost (Itin et al., 1996; Nyfeler, Michnick, & Hauri, 2005;
Nyfeler, Reiterer, et al., 2008a; Zheng, Liu, Yuan, et al., 2010). Another feature of the
unique CRD of ERGIC-53 is its broader specificity for high mannose carbohydrate
structures relative to other L-type lectins, and its inability able to discriminate between
glucosylated and deglucosylated forms of high-mannose in vitro (Kamiya et al., 2008).
The mannose binding capabilities (and structure) of ERGIC-53 were determined to
be sensitive to not only calcium (Velloso et al., 2003b), but also to the pH of the
environment (Appenzeller-Herzog, 2003). Binding of ERGIC-53 to mannose on a
column was found to drop precipitously below the ER pH range (7-7.4). Further, by
neutralizing the acidification of the ERGIC using chlorquine (albeit nonspecifically), the
authors demonstrated impairment in the release of ERGIC-53 specific cargo in cells. The
authors proposed a model by which ERGIC-53’s lectin activity reversibly facilitates
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cargo loading and unloading based on pH - potentiated calcium binding. Within the ER,
at a neutral pH, the lectin activity is optimal and glycoprotein binding can occur. As
ERGIC-53 reaches the ERGIC, a subtle drop in pH was proposed to cause a critical pH
sensing histidine (His178) to become protonated and dislodge calcium from the lectin
(Appenzeller-Herzog, 2003). Contradictory evidence has also been provided as to the role
of pH in cargo loading and unloading. Zheng et al., via a crystallographic analysis of the
CRD in complex with terminal high-mannose type mannans, proposed that His178, rather
than functioning as a pH switch, directly engaged in polar interactions with the hydroxyls
present on the carbohydrate (Zheng et al., 2013). Further, the authors could not find any
evidence of pH regulation in binding of ERGIC-53’s CRD to mannose, however, in
contradiction to the studies by Appenzeller et al., who used a full length ERGIC-53, the
latter study by Zheng and colleagues examined the CRD independently (Zheng et al.,
2013).
ERGIC-53’s method of recognizing cargo proteins was later extended when
evidence was provided that illustrated that, in addition to the mannose requirement for
binding cargo, a beta-hairpin peptide structure also contributed to ligand selection
(Appenzeller-Herzog, Roche, Nufer, & Hauri, 2004). This composite glycan-peptide
recognition motif suggested that ERGIC-53 was capable of adding an additional layer of
selectivity in cargo transported from the ER that had not only been successfully trimmed
by the CRT-CNX cycle, but also correctly folded such that its peptide conformation
matches that of the ERGIC-53 pocket (Appenzeller-Herzog et al., 2004). However, the
glucose trimming requirement for selection of cargo contradicts studies done on purified
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CRD (Kamiya et al., 2008) and suggests that additional signals may be involved in
binding.
1.13.1.2.

ERGIC-53 stalk

The CRD is followed by a 210 residue helical-rich stalk that separates its lectin
activity from the membrane and is able to form disulfide linked dimers and hexamers
(Hauri, Kappeler, Andersson, & Appenzeller, 2000a; Schweizer et al., 1988). The stalk
contains four predicted alpha-helices thought to form a coiled-coil (Lahtinen, Svensson,
& Pettersson, 1999). Embedded within this helical region are four cysteine residues, two
of which are critical (aa 466 and 475) in the formation of dimers and hexamers (C.
Appenzeller et al., 1999a; Lahtinen et al., 1999; Zheng, Liu, Yuan, et al., 2010).
Interestingly, in order to form a completely monomeric ERGIC-53 the two cysteines
must be removed along with the helix region, suggesting some intramolecular peptide
interactions also facilitate oligomerization (E. P. A. Neve, U. Lahtinen, & R. F.
Pettersson, 2005; Zheng, Liu, Yuan, et al., 2010). Oligomerization has been proposed to
be a requisite for anterograde trafficking (C. Appenzeller et al., 1999a; Lahtinen et al.,
1999), and for binding to specific ligands (Carrière, Piller, Legrand, Monsigny, & Roche,
1999; Nufer, Kappeler, Guldbrandsen, & Hauri, 2003). A membrane proximal glutamine
residue has also been proposed to play a role in ER-retention, although the exact
mechanism by which it contributes has remained obscure (Kappeler, Klopfenstein,
Foguet, Paccaud, & Hauri, 1997).
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1.13.1.3.

ERGIC-53 transmembrane domain, carboxy terminus, and transport

ERGIC-53, a type I transmembrane protein, encodes a short 18 residue membrane
spanning domain (TM), that in cooperation with the short 12 amino acid C-terminal tail
(CT), largely determines the subcellular trafficking of the protein . However, some
lumenal residues have also been shown to contribute as well (Kappeler et al., 1997b)
(Itin, Foguet, Kappeler, Klumperman, & Hauri, 1995; Itin, Schindler, & Hauri, 1995a).
These features control ER retention, retrieval, as well as anterograde trafficking with the
assistance of two coatomer proteins (COP I and COPII), as well as a network of
microtubules, motor proteins (presumably), and a network of regulatory molecules that
are still largely unknown (Haines et al., 2012; Itin, Schindler, et al., 1995a; Kappeler, Itin,
Schindler, & Hauri, 1994a; Nufer et al., 2003; Schindler, Itin, Zerial, Lottspeich, &
Hauri, 1993; E. J. Tisdale, H. Plutner, J. Matteson, & W. E. Balch, 1997). The length of
the transmembrane domain, rather than its specific chemical identity, has been proposed
to augment the efficiency of ER exit via a suboptimal-length based mechanism, and
swapping of the TM with that of CD4 removes the retention signal completely (Felix
Kappeler & Hauri, 1997; Itin, Foguet, et al., 1995).
The C-terminal tail of ERGIC-53 ends with a KKFF tetrapeptide that contains
anterograde (FF) and retrograde (KK) signals (Andersson, Kappeler, & Hauri, 1999; E. J.
Tisdale et al., 1997). The dilysine motif has been recognized as an ER-retention signal
(Andersson et al., 1999) and interacts with COPI (Kappeler et al., 1997b; E. J. Tisdale et
al., 1997). However, retention can be separated from binding to COPI (Andersson et al.,
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1999). Mutating ERGIC-53’s dilysine signal to SS, or removing the cytoplasmic tail
completely, resulted in the exposure of the molecule on the surface of cells. Surprisingly,
overexpression of the WT protein also resulted in surface exposure in a population of
~25% of the cells (Itin, Kappeler, Linstedt, & Hauri, 1995; Kappeler et al., 1994a). This
was proposed to occur via saturation of the ER retention system (Kappeler et al., 1994a),
but may also involve additional targeting mechanisms (Itin, Schindler, et al., 1995a).
Surprisingly, the protein at the surface, when labeled with antibodies, was efficiently
endocytosed in a process that utilized the C-terminal KKFF motif (Itin, Kappeler, et al.,
1995; Kappeler et al., 1994a). Transfer of the KKFF containing C-terminal sequence to
CD4 also facilitated its trafficking to the surface, whereas the dilysine motif followed by
di-alanine (KKAA) is restricted to the ER, confirming that the dilysine motif acts not
only in COPI-retrieval (Itin, Schindler, et al., 1995a), but also is involved in ER retention
(Andersson et al., 1999). The retention was not a side effect per se of lacking an exit
signal (FF), but rather, it is a bona-fide retention signal as proteins given a poly A tail
wer
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retained molecules bearing the KKAA signal (Andersson et al., 1999). A more recently
proposed mechanism for ER-retention of ERGIC-53 involves its interaction with VIPL,
which contains a double arginine retention signal (Nufer et al., 2003; Qin et al., 2012).
Interestingly, an antibody against the C-terminus of ERGIC-53 was found to block
coatomer exchange at the level of the ERGIC, concentrating the protein there via COPI
retrieval blocking (E. J. Tisdale et al., 1997). A recent proteomics based study identified a
number of cellular proteins bound specifically to the tail of ERGIC-53. The authors noted
that UBDX, a p97 adaptor protein, formed a complex with p97/VCP (vasolin containing
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protein), that they propose regulates tail binding proteins, and thus, recycling potential of
the protein. Accordingly, they discovered that this complex was able to influence the
post-ERGIC movement of ERGIC-53 to an area near the cell periphery (Haines et al.,
2012) suggesting a complex and regulated post-ERGIC trafficking mechanism may exist.
The two C-terminal phenylalanines have been demonstrated to facilitate anterograde
trafficking of ERGIC-53. In vitro binding studies demonstrated selective binding of these
peptides to the Sec23p subunit of the COPII complex (Kappeler et al., 1997b), and that
lack of this binding due to a KKAA mutation results in a blockage of anterograde
movement of ERGIC-53. Expression of the KKAA construct restricted movement of the
recombinant protein and the endogenous pool, and so acts in a dominant negative
fashion. Accordingly, immunoprecipitation of recombinant KKAA ERGIC-53 via its
myc tag enabled purification of endogenous ERGIC-53 and recombinant protein,
suggesting heterodimer/heterohexamer complexes form (Kappeler et al., 1997b;
Vollenweider, Kappeler, Itin, & Hauri, 1998a). Interestingly, during in vitro binding
assays, the KKAA peptide bound more efficiently to coatomer proteins, which could
provide an additional mechanism whereby it’s trafficking is restricted to the ER
(Kappeler et al., 1997b). It should be noted that restriction of ERGIC-53 to the ER did
not disrupt the architecture or function of the secretory pathway, based on maintenance
and location of fiducial protein markers of ER, and Golgi apparatus, and via analysis of
glycoprotein secretion.
Given the connection between ERGIC-53 protein levels and its intracellular
localization, a number of studies were focused on determining its genetic regulatory
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mechanisms. Several ER stressors have been shown to upregulate ERGIC-53 either from
a transcriptional level (e.g. induction of the ATF6 branch of the unfolded protein
response via transcription factor binding to an ER stress response element (ERSRE))
(Nyfeler et al., 2003b; Renna, Caporaso, Bonatti, Kaufman, & Remondelli, 2007) or from
a translational level (e.g. heat shock induction via a ribosomal shunting mechanism)
(Spatuzza et al., 2004). Raising the temperature to 42° C redistributes ERGIC-53 to a
more peripheral site (along with MCFD2). These latter studies failed to examine potential
surface decoration of ERGIC-53 though, as was reported earlier following its enhanced
expression. A phenotypic alteration has yet to be established under these circumstances
of increased transcription or translation, outside of increases to the folding capacity of the
ER during stress. Further, two proteomic reports have also identified ERGIC-53 within
purified preparations of exosomes via a highly sensitive mass spectroscopy approach
(Conde-Vancells et al., 2008; Gonzalez-Begne et al., 2009). The presence of the protein
within extracellular vesicles has no currently ascribed function, and no current
mechanism has been proposed to explain how ERGIC-53 is trafficked or targeted to sites
of exosome formation.
1.13.2. ERGIC-53 the cargo receptor
The structural and biological features of ERGIC-53 led researchers initially to
predict its role as a cargo receptor (Schweizer et al., 1988). The lumenal CRD, type I
transmembrane feature of the protein, and the ability of its C-terminus to interact both
with COPII and COPI proteins, fit the criteria for selection criteria for a cargo receptor.
This class of proteins is able to connect soluble cargo proteins to COPI/II molecules and
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to selectively move their cargo in the early secretory pathway (Hauri et al., 2000a;
Mitrovic, Ben-Tekaya, Koegler, Gruenberg, & Hauri, 2008; Nyfeler et al., 2003b;
Nyfeler, Reiterer, et al., 2008a; B. Nyfeler, B. Zhang, D. Ginsburg, R. J. Kaufman, & H.
P. Hauri, 2006). Evidence to support this claim was substantiated by Vollenweider et al.
when they noticed a specific deficiency of a 57 kDa secreted protein following the
expression of ER-restricted ERIGC-53 mutant (KKAA). Isolation of the protein with the
mannose-specific lectin ConA and tryptic sequencing led to the identification of the first
soluble glycosylated ligand, cathepsin (CTSC), a lysosomal targeted protease, that
required ERGIC-53 for its efficient export (Vollenweider et al., 1998a). In a related study
Appenzeller and colleagues identified an additional cathepsin, Z, (CTSZ), that was also
found to require the cargo receptor for its efficient transport (Appenzeller-Herzog, 2003;
C. Appenzeller, H. Andersson, F. Kappeler, & H.-P. Hauri, 1999). Analysis of these
cargoe

-peptide along

with the high-mannose glycan previously mentioned (Appenzeller-Herzog et al., 2004; C.
Appenzeller et al., 1999a; Vollenweider et al., 1998a). Using a protein complementation
assay (PCA) featuring a split YFP molecule, Nyfeler and colleagues identified an
additional ligand alpha-1 antitrypsin (Nyfeler, Reiterer, et al., 2008a). Also using a
similar PCA approach, Chen et al., identified Mac-2BP as another glycosylationdependent ERGIC-53 cargo (Chen, Hojo, Matsumoto, & Yamamoto, 2013).
1.13.3. ERGIC-53 and F5F8D
Originally described in 1954 (Oeri, Matter, Isenschmid, Hauser, & Koller, 1954),
Combined Factors V and VIII Deficiency is a type of mild hemophilia with specific
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deficiencies in both antigen and activity of these two clotting factors. The disease
manifests as deficits in the serum levels of coagulation factor V (FV) and VIII (FVIII) at
approximately 5-30% of normal values. Inefficient secretion of these two protease
cofactors causes a notable impairment in the activation of both thrombin and coagulation
factor Xa (Camire & Bos, 2009; Spreafico & Peyvandi, 2008). The mild bleeding
abnormalities can present as easy bruising, epistaxis, menorrhea, and gingival bleeding.
Treatments are encouraged only as needed, and include fresh frozen plasma (FFP) and/or
recombinant factor. Treatments are common following trauma such as dental extraction,
child birth, and circumcision (Zhang, 2009).
The underlying genetic cause for this type of rare hemophilia remained a mystery for
nearly five decades. Using a homozygosity mapping technique developed by Lander and
Botsein to study genetic disorders in children born of consanguinity (Lander & Botstein,
1987), a flurry of rapid publications first by Nichols and colleagues, and later by
Neerman-Abez and colleagues, narrowed the loci responsible for the disease to a region
on chromosome 18 (Neerman-Arbez et al., 1997; Nichols et al., 1997). In a seminal
study, Nichols et al., through the use of positional cloning, identified the locus
responsible for causing the rare hemophilia (F5F8D omim 227300) to a region on the
long arm of chromosome 18 containing the gene lectin mannose binding protein 1
(LMAN1), the gene encoding ERGIC-53 (Nichols et al., 1998).
The homozygous recessive syndrome was identified amongst Jews of Middle Eastern
decent, and soon after additional affected families were identified in northern regions of
Italy, Iran, and Pakistan (Neerman-Arbez et al., 1999). The disease is considered
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extremely rare in the general population with incidence of ~ 1:1,000,000. Interestingly, in
areas where consanguinity is commonplace, the incidence is approximately 1:100,000. In
the intervening years since its initial discovery, multiple founder mutations have arisen
suggesting a more widespread basis than was originally hypothesized (Sirachainan et al.,
2005; Zhang, 2009; Zhang et al., 2006; Zhang et al., 2008; Zhang, Zhou, Yang, & Xiong,
2009). ERGIC-53 null populations have since been documented on most continents
(Antarctica has thus far been excluded) (Spreafico & Peyvandi, 2008), and instances of
compound heterozygousity leading to a clinical cases have also emerged (Farah et al.,
2006; Ge et al., 2010; Patel, Liu, Lager, Malkovska, & Zhang, 2013). To date there are
nearly 50 known disease causing mutations in the ERGIC-53 gene and over 500
polymorphisms have been recorded in NCBI.
Biochemical and cellular studies have focused on identifying the mechanism by
which lack of ERGIC-53 contributes to F5F8D. In an elegant series of experiments,
Mousalli and colleagues demonstrated that ERGIC-53 was acting as a cargo receptor
required for the ER to Golgi trafficking of the clotting factors (Moussalli et al., 1999a).
The authors provided evidence that the ER-ERGIC recycling of ERGIC-53, as well as the
FV/FVIII N-linked glycans, were necessary for efficient secretion of the clotting factors
(Moussalli et al., 1999a). Biochemical evidence supports a direct binding of ERGIC-53 to
FVIII; however, FV binding has not been demonstrated in vitro (Cunningham MA,
2003). Zheng and colleagues recently described specific residues of ERGIC-53 (e.g.
His178 and Gly 241/252) crucial for binding to FVIII (Zheng et al., 2013). The exact
mechanism by which the ERGIC-53 cargo receptor complex facilitates the secretion of
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FV and FVIII is currently unknown. The phenotypic impairment of FV/VIII secretion is
not absolute following its loss, suggesting that either a redundant pathway exists, or that
FV/FVIII may leak out via bulk flow (Moussalli et al., 1999a).
1.13.4. MCFD2 and F5F8D
Nearly five years after the discovery of the genetic basis for F5F8D, clinicians and
scientists remained intrigued about the remaining 30% of F5F8D patients, whose ERGIC53 gene remained normal. In 2003, a study by Zhang and colleagues brought to light the
nature of the disease in the remaining population of F5F8D patients. The genetic
abnormalities pointed to a gene on chromosome 2, and subsequently became known as
multiple coagulation factor deficiency protein 2 (MCFD2) (Bin Zhang et al., 2003).
MCFD2 encodes for a soluble 16 kDa protein found in the lumen of the ER that contains
a disordered N terminal region, followed by 2 C-terminal EF-hands separated by a short
linker region. These EF hands become ordered when calcium is bound, and subsequently
disorder without the metal cation (Nishio et al., 2010).
MCFD2 forms a 1:1 calcium-dependent stoichiometric cargo receptor complex with
ERGIC-53 (Bin Zhang et al., 2003; Zhang, Kaufman, & Ginsburg, 2005b). In addition to
the biochemical interaction, interestingly, the genetic regulation of MCFD2 has been
demonstrated to follow closely that of ERGIC-53 (e.g. both proteins are upregulated
during stress) (Spatuzza et al., 2004). Genetic and structural studies have mapped the
residues responsible for mediating the interaction to the first beta sheet in ERGIC-53
(residues 47-60), as well as multiple regions in MCFD2 (e.g. both EF-hands) (Wigren et
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al., 2010; Zheng, Liu, Zhou, & Zhang, 2010), in addition to the C-terminal 3 residues
(Nyfeler, Kamiya, et al., 2008). Missense mutations in MCFD2 causing F5F8D have
been demonstrated to abolish its interaction specifically with ERGIC-53, a result that has
been proposed to occur via gross alterations in the tertiary structure of the protein (Hamza
et al., 2012). The interaction of MCFD2 and FV/FVIII occurs independently of ERGIC53, as such, mutations affecting its binding to ERGIC-53 do not ablate its interaction with
clotting factors (Zheng, Liu, Zhou, et al., 2010). The cargo receptor complex formed by
MCFD2 and ERGIC-53 has thus far been demonstrated to be important only in the
trafficking of FV and FVIII, as well as the more recently described Mac-2BP (Chen et al.,
2013)

-1 antityrpsin are able to be ferried forward without

the need for MCFD2 (B. Nyfeler et al., 2006).
1.13.4.1.

MCFD2 outside of F5F8D

MCFD2 has recently been demonstrated by several groups to be a secretory
protein (Liu et al., 2013; Toda et al., 2003). In addition to its role in recruiting and
binding coagulation factors with ERGIC-53, it has been demonstrated to become Oglycosylated and secreted into the extracellular space (B. Nyfeler et al., 2006). The
secreted protein has been found to have a phenotypic influence on the maintenance and
differentiation of neuronal stem cells. It is currently unknown how MCFD2 is exerting
this influence, and if sMCFD2 is indeed a physiological phenomenon, or an artefactual
event resulting from overexpression in a tissue culture system. Nyfeler et al., following
knockdown of ERGIC-53 noticed that the MCFD2 molecule was secreted, suggesting an
ERGIC-53 retention of MCFD2 (B. Nyfeler et al., 2006). An outstanding question left
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unanswered hinges upon this predicament. The answer will be of great interest to not
only the study of receptor mediated transport (e.g. ERGIC-53:MCFD2 receptor biology),
but also to elucidating signal transduction involved in maintenance of adult stem cells,
and lastly, its potential role as a therapeutic agent for a variety of maladies (to be
discussed within the confines of chapter 3).
1.13.5. Final remarks on the ERGIC-53 cargo receptor complex
The ERGIC-53 MCFD2 cargo receptor complex has been studied extensively in
vitro, in cells, but to only a limited extent within a complex organism. A mouse LMAN1
knockout model yielded a partial recapitulation of human disease with plasma levels of
FV and FVIII at approximately 50% of wt (Zhang et al., 2011). The authors of the study
also noted alterations in liver accumulation of alpha-1 antitrypsin. Of the proteins found
to bind to either ERGIC-53, MCFD2, or the ERGIC-53-MCFD2 complex, only the
clotting factors have been demonstrated to be disrupted in people lacking either of these
two functional proteins. A recent series of studies demonstrated that ERGIC-53 is
involved in the efficient polymerization and secretion of IgM in concert with Erp44.
However, the authors noted no overt immunological defects in F5F8D patients could be
detected in their limited study. An additional manuscript by these authors on the topic is
pending and will be of great interest to the community at large (Anelli et al., 2007; M.
Cortini & R. Sitia, 2010).
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2.1. SUMMARY
Arenaviruses and hantaviruses cause severe and often fatal diseases in humans. Little is
known regarding host proteins required for their propagation. We identified human
proteins that interact with the glycoproteins (GPs) of a prototypic arenavirus and
hantavirus and show that the lectin ERGIC-53 - a cargo receptor required for cellular
glycoprotein trafficking within the early exocytic pathway - associates with arenavirus,
hantavirus, coronavirus, orthomyxovirus, and filovirus GPs. ERGIC-53 binds to
arenavirus GPs through a lectin-independent mechanism, traffics to arenavirus budding
sites, and is incorporated into arenavirus particles. ERGIC-53 is required for arenavirus,
coronavirus, and filovirus propagation; in its absence, GP-containing virus particles form,
but are noninfectious due, in part, to their inability to attach to host cells. Thus, we have
identified a class of pathogen-derived ERGIC-53 ligands, a lectin-independent basis for
their association with ERGIC-53, and a role for ERGIC-53 in the propagation of several
highly pathogenic RNA virus families.
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2.2. HIGHLIGHTS
Identification of host protein partners of arenavirus and hantavirus glycoproteins
(GPs)
ERGIC-53 associates with viral GPs via a lectin-independent mechanism
ERGIC-53 is critical for arenavirus, coronavirus, and filovirus propagation
ERGIC-53 is a virion component; in its absence virions form, but are
noninfectious
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2.3. INTRODUCTION
Arenaviruses and hantaviruses are rodent-borne, negative-sense RNA viruses that cause
significant morbidity and mortality in humans (Buchmeier et al., 2007; Schmaljohn and
Nichol, 2007). Most pathogenic arenaviruses are associated with severe hemorrhagic
fever syndromes in humans. Examples include the New World arenaviruses Junin virus
(JUNV), Machupo virus (MACV), and Guanarito virus (GTOV), which are the etiologic
agents of Argentine, Bolivian, and Venezuelan hemorrhagic fevers, respectively, as well
as Lassa virus (LASV), an Old World arenavirus that causes Lassa Fever along the coast
of West Africa (Buchmeier et al., 2007). Additionally, lymphocytic choriomeningitis
virus (LCMV) can cause aseptic meningitis in immunocompetent individuals and is a
potent teratogen (Buchmeier et al., 2007). LCMV and Dandenong virus (DANV), an
LCMV-like

virus,

are

also

responsible

for

a

nearly

uniform

lethality

in

immunosuppressed recipients of virus-infected tissues (Fischer et al., 2006; Palacios et
al., 2008).

Hantaviruses cause two human illnesses: hemorrhagic fever with renal

syndrome in the Old World and hantavirus cardiopulmonary syndrome (HCPS) in the
New World (Schmaljohn and Nichol, 2007). Sin Nombre virus (SNV) and Andes virus
(ANDV) are the primary etiologic agents of HCPS in North and South America,
respectively, and are associated with a fatality rate of 35 - 39% (da Rosa Elkhoury et al.,
2012; MacNeil et al., 2011). U.S. Food and Drug Administration (FDA)-approved
vaccines or effective antivirals do not currently exist for the prevention and/or therapeutic
treatment of arenavirus or hantavirus disease.
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Arenaviruses and hantaviruses each encode an envelope glycoprotein (GP) that
decorates the surface of the virion and functions to mediate attachment and entry of
virions into permissive host cells. Each GP is encoded as a precursor (GPC) that is
proteolytically processed into mature subunits. The arenavirus GPC is post-translationally
modified to yield a stable signal peptide (SSP) as well as GP1 and GP2 subunits (Lenz et
al., 2001), whereas the hantavirus GPC is co-translationally processed into G1 and G2
subunits (Lober et al., 2001). In each case, the GP subunits form a mature GP complex
(SSP-GP1-GP2 for arenaviruses; G1-G2 for hantaviruses) that facilitates receptor binding
and entry (Buchmeier et al., 2007; Schmaljohn and Nichol, 2007).
Relatively little is known regarding interactions that arenavirus or hantavirus GPs
have with host proteins or the importance of such interactions for viral replication and
disease pathogenesis. Herein, we utilized a proteomics approach to comprehensively
identify human proteins that interact with GPs encoded by a prototypic arenavirus or
hantavirus. We show that the ER-Golgi intermediate compartment 53 kDa protein
(ERGIC-53) - an intracellular cargo receptor that facilitates the anterograde transport of a
limited number of glycoprotein ligands in the early exocytic pathway (Appenzeller et al.,
1999) - has a conserved interaction with GPs encoded by multiple families of RNA
viruses and is essential for the formation of infectious arenavirus, coronavirus, and
filoviruses in a GP-specific manner. Our results suggest that loss of ERGIC-53 or its
functionality leads to the formation of GP-containing virions that are defective in their
ability to attach to permissive host cells.
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2.4. RESULTS

2.4.1. Identification of Cellular Proteins that Associate with Arenavirus and
Hantavirus GPs and Choice of ERGIC-53
To identify human proteins that associate with arenavirus and hantavirus GPs we used an
approach that featured affinity purification (AP) of biotinylated viral proteins (LCMV GP
to represent arenaviruses or ANDV GP for hantaviruses) in complex with host proteins
followed by mass spectrometry to identify host protein partners as described in Figure
S1A and the Extended Experimental Procedures. We identified a number of host proteins
that associated with LCMV GP (n = 309), ANDV GP (n = 134), or both GPs (n = 51)
(Figures 1A-C, S1B, and S1C; Tables S1A-C). As shown in Figure S1D and Table S1D,
host proteins that associated with both GPs were enriched for processes involving the ER,
protein folding, and vesicular transport. The LCMV GP-only partners were enriched for
processes that included the ER, the proteosome, and nuclear import while the ANDV GPonly partners were enriched for protein translation and ribosome biogenesis. We were
particularly interested in the subset of proteins that interacted with both GPs as they could
serve as broad-spectrum antiviral targets. Of these, we chose ERGIC-53 for further study
based upon several criteria. First, the ERGIC-53 - viral GP interaction is physiologically
plausible (e.g. each protein traffics within the exocytic pathway; ERGIC-53 is a
mannose-specific lectin (Itin et al., 1996) and the viral GPs are mannosylated
(Schmaljohn et al., 1986; Wright et al., 1990). Second, based on its identification as a
cargo receptor within the exocytic pathway (Appenzeller et al., 1999), we hypothesized
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that ERGIC-53 could be required for GP maturation and therefore might be critical for
viral propagation. Finally, ERGIC-53 is an attractive target because loss of this protein or
its normal function is well tolerated both in vitro (Mitrovic et al., 2008; Nyfeler et al.,
2006; Vollenweider et al., 1998) and in vivo (Khoriaty et al., 2012).

2.4.2. Confirmation that ERGIC-53 Has a Conserved Association with GPs
Encoded by Multiple Pathogenic Arenaviruses and Hantaviruses
We next wished to determine whether ERGIC-53 could associate with additional GPs
encoded by arenaviruses (LASV, MACV, JUNV strain XJ, JUNV strain Candid #1
(C#1), and Whitewater Arroyo virus (WWAV)) or hantaviruses (SNV). Each viral GP
tested, when serving as bait, was able to co-precipitate ERGIC-53 (Figure 1D, 1F-H,
S1E, and data not shown). Likewise, ERGIC-53 was able to co-precipitate each GP
screened (Figures 1E, 1I-K, S1F-I, and data not shown). For the arenavirus GPs, only the
full length GPC was co-precipitated as prey. A full length hantavirus GPC cannot be
recovered as this protein is co-translationally cleaved into G1 and G2 subunits prior to
synthesis of a full length GPC species (Lober et al., 2001). As shown in Figure 1L, we
further verified the specificity of the ERGIC-53 - JUNV C#1 GP interaction by showing
both proteins strongly colocalize within a structure that we putatively identify as the
ERGIC; both proteins also preferentially concentrate in this structure.
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2.4.3. ERGIC-53 Is Required for Arenavirus Propagation
We conducted a series of viral challenge studies to determine how various manipulations
of ERGIC-53 might impact the ability of arenaviruses (JUNV C#1 or DANV) to release
infectious progeny. Partial silencing of ERGIC-53 expression via siRNA transfection led
to a considerable reduction in the release of infectious JUNV C#1 (24 hr pi, 39.6%
decrease, p = 0.03; 48 hr pi, 64% decrease, p = 0.02; 72 hr, 51% decrease, p = 0.01)
(Figures 2A and S2A) whereas increased expression of WT ERGIC-53 enhanced release
of infectious JUNV C#1 (24 hr pi, 48% increase, p = 0.025; 48 hr pi, 68% increase, p =
0.004 ) (Figures 2B and S2B). Expression of an ER-restricted, dominant negative (DN)
mutant of ERGIC-53 (Vollenweider et al., 1998) resulted in a pronounced reduction in
the release of infectious JUNV C#1 (48 hr pi, 90.5% decrease, p = 1.4 x10-8; 72 hr pi,
99.8% decrease, p = 3.2 x 10-4) (Figures 2C and S2C), DANV (95% reduction, p = 0.003)
(Figures 2D and S2D), and LCMV strain Armstrong 53b (data not shown). These
experiments clearly demonstrate that ERGIC-53 is required for the propagation of New
World and Old World arenaviruses.

2.4.4. The Release of Infectious JUNV C#1 Is Restricted in Cell Lines Derived from
ERGIC-53 Null Individuals
Humans with homozygous null mutations in LMAN1 (lectin, mannose binding 1), the
gene encoding ERGIC-53, have combined deficiency of factor (F)V and FVIII (F5F8D,
OMIM 227300), a mild bleeding disorder characterized by reduced levels of circulating
FV and FVIII (Nichols et al., 1998). We therefore conducted challenge studies featuring
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B cells derived from LMAN1+/+ (2829-D) and LMAN1-/- (CRC-78 and CRC-79)
individuals. The two LMAN1-/- individuals, despite being from separate families (A2 and
A12 in (Neerman-Arbez et al., 1999), encode an identical null mutation (c.822-1G>A
splice site mutation) that abrogates expression of ERGIC-53. Significantly less infectious
virus was released from each of the LMAN1-/- cell lines when compared to the LMAN1+/+
control cells (96% and 97% decrease for CRC-78 and CRC-79, respectively; p < 0.0001
for each) (Figures 2E and S2E).

2.4.5. ERGIC-53’s Influence on JUNV Replication Is Specific and Can Be
Minimally Mapped to the JUNV GP
To determine the specificity of ERGIC-53’s impact on arenavirus replication we

a recombinant VSV that does not encode its native glycoprotein (G) and accordingly
cannot form infectious particles unless a suitable viral glycoprotein (e.g. VSV G or
JUNV GP) is provided in trans (Whitt, 2010). There was no difference in the formation

ERGIC-53 backgrounds (Figures 3A and S3A). This may be due to the fact that VSV G
does not associate with ERGIC-53 in co-immunoprecipitation assays (Figures 3E and
3F).
impaired in cells expressing DN ERGIC-53 compared to the WT ERGIC-53 cells (80%
reduction; p = 0.001) (Figures 3B and S3B). These experiments demonstrate that ERGIC53’s impact on arenavirus propagation is specific and can be minimally restricted to the
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GP itself.

Importantly, the fact that ERGIC-53 does not associate with VSV G

demonstrates the specificity of its interaction with arenavirus and hantavirus GPs.

2.4.6. ERGIC-53 Broadly Associates with Viral Class I Fusion Proteins and Is
Required for the Propagation of Coronaviruses and Filoviruses.
We next screened for an association between ERGIC-53 and class I fusion GPs encoded
by coronaviruses (the severe acute respiratory syndrome coronavirus (SARS CoV) spike
protein (S)), orthomyxoviruses (the H1N1 influenza virus A/WSN/33 hemagglutinin
protein (HA)), and filoviruses (the Ebola (EBOV) and Marburg virus (MARV) GPs).
Each GP, when used as bait, was able co-precipitate ERGIC-53 (Figures 3G and 3I).
Reciprocally, ERGIC-53 was able to co-precipitate the uncleaved, precursor GP from
each virus (Figures 3H and 3J). T
with either the SARS CoV S or EBOV GP was significantly impaired in cells expressing
DN ERGIC-53 compared to the WT ERGIC-53 cells (81% reduction, p = 0.03 for SARS
CoV; 70% reduction, p = 0.0002 for EBOV) (Figures 3C, 3D, S3C, and S3D). In
summary, ERGIC-53 has a conserved interaction with class I fusion GPs and is required
for the propagation of coronaviruses and filoviruses in a GP-specific manner.

2.4.7. Trafficking of JUNV C#1 GP or hTfR1 to the Plasma Membrane Is Not
Influenced by ERGIC-53
To determine how the loss of ERGIC-53 function impaired the formation of infectious
arenavirus particles we first tested whether ERGIC-53 could be a bona fide cargo
receptor required for the proper anterograde trafficking of JUNV GP (Appenzeller et al.,
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1999). Cells expressing WT or DN ERGIC-53 were infected with JUNV C#1 and
screened for surface expression of JUNV C#1 GP. Interestingly, GP surface staining was
equivalent in both the WT and DN ERGIC-53 transfected cells in terms of the frequency
of cells with GP expression (46% WT versus 47% DN) as well as the intensity of GP
staining (median fluorescence intensity (MFI) 348 WT versus 363 DN) (Figure 4B).
Confocal microscopy analysis revealed a similar result (Figure 4A). The DN ERGIC-53
had no impact on the ability of hTfR1 - the surface receptor required for GP-mediated
JUNV entry into host cells (Radoshitzky et al., 2007) - to traffic to the cell surface
(Figure S4). In summary, cells expressing DN ERGIC-53 have normal surface expression
of hTfR1, manifest no defect in viral entry of WT JUNV C#1 particles, and display no
defect for GP synthesis or its trafficking to the plasma membrane.

2.4.8. The DN ERGIC-53 Mutant Does Not Impair Proteolytic Processing of JUNV
GPC or the Incorporation of GP Species into Virus-Like Particles (VLPs)
Cells expressing WT or DN ERGIC-53 were transfected with plasmids encoding the
JUNV matrix protein, Z, and JUNV XJ GP to allow for VLP formation and release.
Expression of DN ERGIC-53 did not impair the generation of GP2 from GPC in cells or
the incorporation of GP2 into VLPs (Figure 4C).

2.4.9. Loss of ERGIC-53 Leads to the Formation of Virus Particles that Are
Noninfectious
In Figures 2E and S2E we show that JUNV C#1 is impaired in its ability to release
infectious progeny from LMAN1-/- cells. To determine whether this was due to i) a
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general deficiency in JUNV particle release or ii) the release of defective particles, we
concentrated virions from the supernatants of LMAN1+/+ (2829-D) or LMAN1-/- (CRC-78)
cells and screened them for infectious virus, viral genome, and viral structural proteins.
We found no discernible difference in the quantity of viral proteins (GP1, nucleoprotein
(NP), or Z) released from LMAN1+/+ or LMAN1-/- cells (Figure 4D) despite a nearly 10fold reduction in infectious virus titer from LMAN1-/- cells (Figure 4E). Additionally, the
LMAN1-/--derived particles contained viral genomic RNA with a 6.4-fold higher ratio of
genome to infectious virus compared to LMAN1+/+ particles (Figure 4F). Lastly, the
LMAN1-/- particles also exhibited a specific defect in attachment to host cells (52%
reduction compared to LMAN1+/+ particles) (Figure 4G). In summary, loss of ERGIC-53
expression does not impact the ability of JUNV to generate particles containing viral
structural proteins or genome, but rather renders the particles themselves noninfectious
due, in part, to a defect in their ability to attach to permissive host cells.

2.4.10. ERGIC-53 Traffics to Sites of JUNV Assembly and Is Incorporated into
Virions
Based on our finding that ERGIC-53 was detectable in concentrated supernatant
preparations from JUNV C#1-infected cells (Figure 4D) we hypothesized that ERGIC-53
might be packaged into viral particles. We first addressed whether ERGIC-53 trafficking
was altered during infection by surface labeling cells with antibodies specific for JUNV
C#1 GP and ERGIC-53. We observed discrete JUNV C#1 GP puncta of ~200 to 400 nm
at the plasma membrane that we suggest are putative sites of viral assembly and budding
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(Figure 5B). Strikingly, ERGIC-53 formed puncta of the same size, shape, and position
as GP (Figure 5B). In contrast, ERGIC-53 was not detectable at the plasma membrane of
uninfected cells (Figure 5B). This altered trafficking is specific as calreticulin (CRT),
another Ca2+-binding lectin of the exocytic pathway, did not similarly redistribute to the
plasma membrane following infection (Figure 5C). The intracellular distribution of
ERGIC-53 did not change between mock- or JUNV C#1-infected cells (Figure 5A). We
next captured JUNV particles using an anti-GPC/GP1 antibody and found that ERGIC-53
was detectable in JUNV particles via Western blot (Figure 5D). ERGIC-53 also
colocalized with JUNV NP in viral particles adhered onto cover slips (Figure S5). Thus,
during arenavirus infection, ERGIC-53 traffics to sites of viral assembly and budding and
is incorporated into virions.

2.4.11. The JUNV GP - ERGIC-53 Interaction Requires a Unique Region of
ERGIC-53’s Carbohydrate Recognition Domain (CRD) and Occurs
Independently of ERGIC-53’s Ability to Oligomerize, Traffic, or Bind
Mannose, MCFD2, or Ca2+
To determine the molecular basis for ERGIC-53’s association with viral GPs, we
screened a panel of ERGIC-53 mutants (described in detail in Figure S6 and in (Zheng et
al., 2010)), for their ability to associate with the JUNV C#1 GP. As shown in Figure 6, of

C#1 GP. Interestingly, despite the requirement of the CRD for binding, the association of
ERGIC-53 with JUNV C#1 GP does not appear to be lectin-mediated as mutations that
disrupt ERGIC103

disrupt its interaction with JUNV C#1 GP. Likewise, the association does not appear to
require Ca2+-

DN ERGIC-53 (KKAA) results also suggest that trafficking beyond the ER is not
required for the interaction.
GP-interacting domain on ERGIC-53 lies within the C-terminal 185 amino acids of the
CRD (residues 84 - 269).

2.5. DISCUSSION

Arenaviruses and hantaviruses are significant human pathogens for which FDA-approved
vaccines or effective antivirals do not exist. Their proteomes consist of only four
proteins. While functional roles have been defined for each viral protein, their
interactions with host proteins, and the importance of these interactions for viral
replication and disease pathogenesis, remain largely unknown. In the current study we
addressed this deficiency by providing a comprehensive viral GP - human protein
interactome map using GPs encoded by a representative arenavirus and hantavirus. We
identified ERGIC-53 as a potential antiviral target based upon its ability to associate with
GPs encoded by several families of pathogenic RNA viruses and its clear role in the
propagation of arenaviruses, coronaviruses, and filoviruses.

We demonstrate that

ERGIC-53 is not required for the formation of GP-containing arenavirus particles, but
rather their infectiousness. We also show that ERGIC-53 traffics to sites of arenavirus
104

budding and is incorporated into virions. Finally, we provide insight into the molecular
basis for the GP - ERGIC-53 interaction by showing that the C-terminal region of
ERGIC-53’s CRD is required for the interaction independent of ERGIC’s ability to
oligomerize, traffic, or bind mannose, MCFD2, or Ca2+.
ERGIC-53 is a nonglycosylated, hexameric type I integral membrane protein that
functions as a cargo receptor for soluble glycoproteins within the early exocytic pathway.
Its lumenal domain contains a CRD with homology to leguminous lectins and
mammalian galectins; it selectively binds to high mannose glycans in a pH- and Ca2+dependent manner (Appenzeller-Herzog et al., 2004; Appenzeller et al., 1999; Itin et al.,
1996). Only five glycoproteins - FV and FVIII (Moussalli et al., 1999; Nichols et al.,
1998), the cathepsins C and Z (Appenzeller et al., 1999; Vollenweider et al., 1998), and
alpha-1 antitrypsin (Nyfeler et al., 2008) - have been shown to require ERGIC-53 for
their efficient anterograde trafficking. Typically ERGIC-53 captures its cargo proteins in
the ER via its lectin activity and releases them in the ERGIC, presumably due to the
lower pH of this compartment (Appenzeller-Herzog et al., 2004; Appenzeller et al.,
1999). In the case of FV and FVIII, MCFD2 is also required for trafficking of these
proteins independent of ERGIC-53 (Zhang et al., 2003). Because ERGIC-53 and MCFD2
directly interact, it has been suggested that they form a mature cargo receptor required for
efficient FV/FVIII trafficking (Nyfeler et al., 2006; Zhang et al., 2005). Importantly,
while loss of ERGIC-53 expression or function impairs movement of its specific ligands,
the overall architecture of the exocytic pathway is maintained and major glycoproteins
still traffic normally (Mitrovic et al., 2008; Nyfeler et al., 2006; Vollenweider et al.,
105

1998). Indeed, humans with homozygous null mutations in ERGIC-53 or MCFD2,
despite having F5F8D - a condition that features mild to moderate bleeding symptoms
due to reduced levels of circulating FV/FVIII (~5 to 30% of normal) - are generally
healthy and lead normal lives provided they receive FV/FVIII supplementation following
trauma (Khoriaty et al., 2012). These observations clearly suggest that ERGIC-53 is
dispensable in humans and therefore represents a viable antiviral target.
Our studies demonstrate that ERGIC-53 associates with a class of pathogenderived ligands, specifically GPs encoded by arenaviruses, hantaviruses, coronaviruses,
orthomyxoviruses, and filoviruses (Figures 1, 3G-J, S1E-I, and data not shown). We
show that, with the exception of the hantavirus GPs, ERGIC-53 preferentially interacts
with the uncleaved, precursor GP, but not the proteolytically processed GP subunits
(Figures 1I-K, 3H, 3J, S1F-H, and data not shown). In the case of the arenaviruses, this
finding strongly suggests that the interaction takes place in the ER and/or ERGIC, prior
to proteolytic cleavage of GPC into GP1/GP2 by the SKI-1/SP1 protease, which is
thought to occur in the Golgi (Lenz et al., 2001; Wright et al., 1990). Indeed, imaging of
JUNV C#1-infected cells revealed that GP and ERGIC-53 both concentrate in the ERGIC
(Figure 1L and 5A). It was recently reported that the HIV glycoprotein Env can also
associate with ERGIC-53 (Jager et al., 2012).
Based on previous studies we initially hypothesized that the ERGIC-53 - GP
interaction would be mediated by ERGIC-53’s CRD binding to one or more high
mannose glycans on the viral GPs. Our results demonstrate that while ERGIC-53’s CRD
is indeed critical for the interaction, its lectin- and Ca2+-binding functions are completely
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dispensable (Figures 6 and S6). Consistent with this claim, we also found the interaction
to be unaffected by competition with free mannose, manipulation of Ca2+, changes in pH
(as low as 5.0), or deglycosylation of the JUNV or ANDV GP (data not shown). In
summary, our studies reveal that the molecular basis for ERGIC-53’s interaction with
JUNV GP is different from any of its previously characterized partners; only the Cterminal region of ERGIC-53’s CRD (residues 84 to 269) is critical for the interaction
whereas ERGIC-53’s ability to oligomerize, traffic, or bind mannose, Ca2+, or MCFD2
are not.
Movement of ERGIC-53 within the exocytic pathway is controlled by at least
three targeting determinants that work in concert with two types of vesicular coats
(COPII and COPI) to mediate ER retention, ER exit, and retrieval from post-ER
compartments (Hauri et al., 2000; Nufer et al., 2003). ERGIC-53 preferentially
accumulates in the ERGIC and recycles between this compartment and the ER (BenTekaya et al., 2005; Klumperman et al., 1998). Under normal conditions, ERGIC-53 does
not appear to traffic beyond the cis-Golgi. However, following its overexpression via
plasmid, ERGIC-53 can traffic to the plasma membrane, presumably due to saturation of
COPI (Kappeler et al., 1994). JUNV C#1 infection induces a striking redistribution of a
portion of the intracellular pool of ERGIC-53 to the plasma membrane, where it strongly
colocalizes with GP at putative sites of viral assembly and budding (Figure 5B).
Furthermore, ERGIC-53 is packaged into arenavirus particles (Figures 5D and S5), which
may indicate that it is required for virion structure/function.
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The mechanism by which ERGIC-53 traffics to the plasma membrane during
JUNV C#1 infection is unclear, but one possibility is that ERGIC-53 expression increases
during JUNV infection and that saturation of COPI allows ERGIC-53 to traffic, perhaps
independent of its interaction with JUNV GP, beyond the ERGIC/cis-Golgi area to reach
the plasma membrane. In support of this idea, infection with the related arenavirus
LCMV triggers the activating transcription factor 6 (ATF6)-arm of the unfolded protein
response (UPR) (Pasqual et al., 2011), which is known to increase ERGIC-53 expression
(Nyfeler et al., 2003). Indeed, LCMV infection of nonhuman primates results in increased
transcription of ERGIC-53 (Djavani et al., 2009). Alternatively, it is also possible that
JUNV GP functions as a cargo receptor to facilitate the movement of ERGIC-53 beyond
the ERGIC/cis-Golgi to sites of viral assembly and budding.
How does ERGIC-53 impact arenavirus replication? We initially hypothesized
that ERGIC-53 was acting as a bona fide cargo receptor required for the anterograde
movement of GP out of the ER and ultimately to the plasma membrane. This idea proved
incorrect as expression of the ER-restricted, DN ERGIC-53 mutant had no impact on the
ability of GP to reach the plasma membrane (Figures 4A and 4B). Likewise, there was no
disruption of either the proteolytic processing of GPC into GP1/GP2 or ability of these
GP species to be incorporated into VLPs (Figure 4C). Additionally, the DN ERGIC-53
mutant had no impact on the ability of WT JUNV C#1 particles to enter cells (Figures 4A
and 4B) or on the level of expression of hTfR1 at the plasma membrane (Figure S4). To
formally test whether ERGIC-53 is required for the release of viral particles, we
challenged normal or ERGIC-53 null cell lines with JUNV C#1 and found similar
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quantities of viral particles in the supernatants from each cell line (Figure 4D). However,
despite equivalent particle release, the null cell-derived particles were ~10-fold less
infectious (Figure 4E), demonstrating that ERGIC-53 is essential for the infectivity of
JUNV C#1 particles. Therefore, in the absence of ERGIC-53, arenavirus particles are
produced in normal quantities, but are defective in the early phase of replication. Our
results suggest that this defect minimally exists at the level of virus attachment to the host
cell (Figure 4G). It is possible that this defect may also impair other steps of viral entry
such as endocytic uptake of particles into host cells and/or fusion and release of genome
into the cytoplasm (see Figure 7 for our proposed model).
How does ERGIC-53 mechanistically impact the infectiousness of arenavirus
particles? ERGIC-53 itself may be a critical structural component of the virion, perhaps
by acting as a co-receptor required for virion attachment to host cells. Direct support for
this idea is our finding that ERGIC-53 is a component of virions (Figures 5D and S5) and
that virions lacking ERGIC-53 are defective (Figures 4D-G). Additionally, less infectious
virus was produced in our challenge studies featuring the ER-restricted, DN ERGIC-53
mutant (Figures 2C, 2D, 3B, S2C, S2D, and S3B) or ERGIC-53 siRNA (Figures 2A and
S2A). Conversely, overexpression of WT ERGIC-53 leads to increased trafficking of
ERGIC-53 to the plasma membrane (Kappeler et al., 1994), which could lead to more
ERGIC-53 being incorporated into particles and explain the increased release of
infectious virus seen under these conditions (Figures 2B and S2B). Alternatively,
ERGIC-53 could be required to traffic and/or recruit cellular proteins that are critically
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required for virion structure and function or for the proper maturation of the arenavirus
GP (e. g. glycan maturation or other posttranslational modifications).
The protein partners of arenavirus and hantavirus GPs identified in this study help
advance our understanding of how these viruses interact with host cell machinery to
facilitate GP biogenesis and other aspects of the viral lifecycle. As the GPs themselves
are likely to be highly multifunctional due to the small size of their respective proteomes,
the identified partners may also help elucidate additional functions for each GP. Each
partner represents a candidate target for future antiviral screening. Indeed, four additional
proteins identified in our study - stromal cell derived factor 4 (SDF4), archain 1
(ARCN1), coatomer protein complex, subunit alpha (COPA), and renin receptor
(ATP6AP2) - were recently shown to be required for LCMV and VSV replication (Panda
et al., 2011). These examples clearly highlight the feasibility and utility of using a
proteomics-based approach to identify candidate antiviral targets.
In conclusion, ERGIC-53 represents a potential antiviral target because of its
clearly demonstrated importance for the replication of pathogenic arenaviruses,
coronaviruses, and filoviruses and the fact that loss of this protein or its function is well
tolerated in humans (Khoriaty et al., 2012). Furthermore, in the case of the arenaviruses,
targeting ERGIC-53 function with an antiviral could be expected to set up an ongoing
immunizing therapy as defective, but presumably immunogenic, viral particles would be
released during the course of treatment. While ERGIC-53 represents a potential broadspectrum antiviral target for arenaviruses, coronaviruses, and filoviruses, it may also be
required for additional human pathogens such as the New World hantaviruses,
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orthomyxoviruses, or retroviruses based upon its conserved interaction with their GPs
(Figures 1D, 1E, 3I, 3J, and S1I) (Jager et al., 2012) or for DNA viruses based on the
finding that a murine gamma herpes virus was negatively impacted by silencing of
ERGIC-53 (Mages et al., 2008). Based on our finding that JUNV propagation is impaired
in cells from ERGIC-53 null individuals, future studies should also address whether
exposure to rodent-borne viruses such as the arenaviruses has exerted a selective pressure
to maintain ERGIC-53 mutations within the human population as a means to confer
resistance to infection. Additionally, while bleeding is not a major cause of morbidity or
mortality during arenavirus or hantavirus infection, it is also interesting to consider that
viral GPs, by interacting with ERGIC-53, may disrupt ERGIC-53’s normal cargo
receptor function for FV and FVIII, contributing to some of the hemorrhagic
manifestations seen following infection with these viruses, which can include
deficiencies in the levels and/or activity of circulating FV or FVIII (Lee, 1987; Lee et al.,
1989; Schwarz et al., 1972). The interaction of ERGIC-53 with the filovirus GPs is
particularly intriguing considering the prominent coagulation abnormalities observed
during human infection (Feldmann and Geisbert, 2011). Finally, our studies and others
(Gonzalez-Begne et al., 2009) have shown that ERGIC-53 is actively secreted from cells
in viral particles and/or cellular exosomes and strongly suggest that it has important roles
outside of its normal distribution within the exocytic pathway, perhaps outside of the cell
where, in the case of arenaviruses, coronaviruses, and filoviruses, it may influence the
endocytic pathway-driven process of viral entry.
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2.6. EXPERIMENTAL PROCEDURES

Cells, Viruses, Antibodies, Plasmids, siRNAs, and Transfections
A full description of the cells (HEK 293T cells, Vero E6 cells, and B lymphoblastoid
cells from either normal or ERGIC-53 null individuals), viruses (DANV, JUNV C#1, and

in the Extended Experimental Procedures.

Affinity Purification, Immunoprecipitation, Mass Spectrometry, Virus/VLP
Concentration, and Western Blot
To affinity purify viral GPs for the identification of human protein partners via mass
spectrometry or validation of protein partners via Western blot, HEK 293T cells were cotransfected with a plasmid that encodes each respective viral GP with a C-terminal HA
epitope tag and a biotin acceptor peptide (BAP), and a second plasmid that encodes the
bacterial biotin ligase BirA to facilitate biotinylation of the viral GPs. Two days later,
biotinylated GPs and associated host proteins were affinity purified from whole cell
lysates using magnetic streptavidin beads and separated on polyacrylamide gels for either
Western blot analysis to confirm bait/prey purification or Coomassie staining for mass
spectrometry analysis. To determine the identity of cellular proteins captured, each
Coomassie-stained gel lane was cut into sections for in-gel, trypic digestion and mass
spectrometry analysis.
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Immunoprecipitation of viral GPs or ERGIC-53 was accomplished by incubating
clarified whole cell protein lysates with antibodies specific for each respective protein
followed by magnetic Protein G beads. To purify intact JUNV C#1 particles, supernatants
were collected at 72 hr post-inoculation, clarified, and incubated with either an anti-GP
antibody or an isotype control antibody followed by magnetic protein G beads.
Immunopurified proteins or viral particles were then washed, eluted from beads, and
electrophoresed on polyacrylamide gels for Western blot analysis.
JUNV C#1 virions and VLPs were concentrated via ultracentrifugation through a
20% layer of sucrose.
For Western blot analysis, protein lysates were separated by SDS-PAGE using
Novex 4-20% Tris-Glycine polyacrylamide gels. Protein transfer to nitrocellulose
membranes was accomplished using the iBlot Gel Transfer Device and iBlot Transfer
Stack nitrocellulose membranes from Invitrogen (Carlsbad, CA). Proteins were detected
using either chemiluminescence or an Odyssey Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE).
Full details of these approaches are described in the Extended Experimental
Procedures.

Confocal Immunofluorescence Microscopy

113

A Zeiss LSM 510 Laser Scanning Confocal Microscope was used to visualize internal or
surface expression of ERGIC-53, CRT, JUNV NP and/or JUNV GP in cells or virions.
Colocalization analysis was done using the Zeiss AIM software package as described in
the Extended Experimental Procedures.

Flow Cytometry
An LSRII (BD Biosciences, San Jose, CA) was used to enumerate the frequency and
intensity of JUNV GP or hTfR1 staining at the plasma membrane or Myc-tagged WT
and/or DN ERGIC-53 internally in HEK 293T cells as described in the Extended
Experimental Procedures.

Viral Challenge Assays
Viral challenge assays were performed to evaluate how various manipulations of ERGIC53 (siRNA silencing of ERGIC-53, overexpression of WT ERGIC-53, expression of DN
ERGIC-53, or loss of ERGIC-53 expression due to null mutation of LMAN1) would

VSV G, JUNV XJ GP, SARS CoV S, or EBOV GP). At each time point examined in the
various assays, supernatants and cells were collected (from each replicate well) to
measure infectious virus or protein expression levels, respectively. Infectious virus load
was determined via plaque assay for JUNV C#1 and DANV while GFP-positive foci
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etermined using the
unpaired Student’s t test. Quantitative RT-PCR was used to determine copy number of
JUNV C#1 S segment genomic viral RNAs. Virus attachment to cells was determined
through a virus-cell binding assay. A full description of each challenge assay can be
found in the Extended Experimental Procedures.
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2.9. FIGURE LEGENDS
Figure 2.1 Identification of Human Proteins that Associate with Arenavirus and
Hantavirus GPs
(A and B) HEK 293T cells were co-transfected with a pCAGGS plasmid encoding each
respective viral GP with a C-terminal HA epitope tag and a biotin acceptor peptide
(BAP), along with a second plasmid that encodes BirA, a bacterial biotin ligase, to ensure
biotinylation of the viral GPs. As a control, cells were co-transfected with the BirA
plasmid and an empty vector. Biotinylated GPs and associated host proteins were affinity
purified (AP) from cell lysates (input) using magnetic streptavidin beads and separated on
polyacrylamide gels for Western blot analysis to verify purification of the various GP
species (GPC, GP1, and GP2 for LCMV; G1 and G2 for ANDV) and Coomassie staining
for mass spectrometry analysis. Each Coomassie-stained gel lane was cut into sections
for in-gel, trypic digestion and mass spectrometry analysis as described in the Extended
Experimental Procedures (See Figure S1A for the proteomics workflow, Figures S1B and
S1C for cut maps, Tables S1A-C for a list of the proteins, and Table S1D and Figure S1D
for results of a functional clustering analysis).
(C) Venn diagram representing the number of identified host proteins associated with
LCMV GP, ANDV GP, or both GPs.
(D-G, I, and J) ERGIC-53 has a conserved association with arenavirus and hantavirus
GPs. HEK 293T cells were transfected with a pCAGGS plasmid encoding the indicated
viral GPs with a C-terminal HA epitope tag and a BAP or, as a control, an empty
pCAGGs plasmid. In panels D, F, and G, cells were also transfected with the BirA
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plasmid to ensure biotinylation of each GP. Viral GPs (D, F, and G) or ERGIC-53 (E, I,
and J) were AP or immunoprecipitated, respectively, as bait from cell lysates. Input
lysates and purified bead fractions were screened for ERGIC-53 (D, F, and G) or viral GP
species (G2 for hantaviruses; GPC and GP2 for arenaviruses) (E, I, and J) as prey via
Western blot. See Figures S1E-I for screening of additional GPs.
(H and K) HEK 293T or Vero E6 cells were infected with JUNV C#1 and JUNV GP (H)
or ERGIC-53 (K) was immunoprecipitated from cell lysates. Input lysates and purified
bead fractions were screened for ERGIC-53 (H) or JUNV C#1 GP species (GPC and
GP1) (K) as prey via Western blot.
(L) ERGIC-53 and JUNV C#1 GP concentrate in the same intracellular structure. JUNV
C#1-infected HEK 293T cells were fixed, permeabilized, and stained for JUNV C#1 GP
(green) and ERGIC-53 (red). Colocalization between GP and ERGIC-53 is displayed as
white pixels in the colocalization mask. The histogram shows background gating (white
lines) and specific immunofluorescence signal for JUNV GP (region 1), ERGIC-53
(region 2) or colocalized GP and ERGIC-53 (region 3) (78.6% of ERGIC-53 signal
colocalized with GP signal; 52.2% of GP signal colocalized with ERGIC-53 signal).
Scale bar, 20 µm.

Figure 2.2 ERGIC-53 is Required for Arenavirus Propagation
(A) Silencing ERGIC-53 expression impairs the release of infectious JUNV C#1. HEK
293T cells were transfected with an ERGIC-53-specific siRNA or a scrambled, negative
control siRNA and challenged 72 hr later with JUNV C#1. Supernatants and cell protein
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lysates were screened for JUNV C#1 plaque forming units (PFU) via plaque assay and
ERGIC-53 or calreticultin (CRT) via Western blot. Data are presented as mean PFU ±
SEM relative to the empty vector transfected wells and are the summation of 2
independent experiments (24 & 48 hr pi n = 5, 72 hr n = 6).
(B) Overexpression of WT ERGIC-53 enhances infectious JUNV release. HEK 293T
cells were transfected with a plasmid encoding Myc-tagged, WT ERGIC-53 or, as a
control, an empty plasmid; 48 hr following transfection these cells were challenged with
JUNV C#1. Supernatants and cell protein lysates were screened for JUNV C#1 PFU via
plaque assay and Myc-ERGIC-53 or CRT via Western blot. Data are presented as mean
PFU ± SEM relative to the empty vector transfected wells and are the summation of 2
independent experiments (n = 6 at each time point).
(C and D) Restriction of ERGIC-53 to the ER impairs the release of infectious JUNV
C#1 and DANV. HEK 293T cells were transfected with a plasmid encoding Myc-tagged
DN ERGIC-53 or, as a control, an empty plasmid; 24 hr later cells were challenged with
JUNV C#1 (C) or DANV (D). Supernatants and cell protein lysates were screened for
PFU via plaque assay and Myc-DN ERGIC-53 or CRT via Western blot. Data are
presented as mean PFU ± SEM relative to the empty vector transfected wells and are
representative of 2 independent experiments (n = 12 or n = 6 per experiment for JUNV
C#1 or DANV, respectively).
(E) Release of infectious JUNV C#1 is impaired in ERGIC-53 (LMAN1-/-) null cells.
EBV-transformed B cells from LMAN1+/+ (2829-D) and LMAN1-/- (CRC-78 and CRC-79)
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individuals were challenged with JUNV C#1. Supernatants and cell protein lysates were
screened for JUNV C#1 PFU via plaque assay and ERGIC-53 or actin via Western blot.
Data are presented as mean PFU ± SEM relative to the LMAN1+/+ cells and are
representative of 2 independent experiments (n = 3 per condition per experiment).
(A - E) *p < 0.05, **p < 0.01, ***p < 0.001, determined using the unpaired Student’s t
test. Note that Western blot results from representative lysates are shown; the full panel
of lysates is displayed in Figure S2.

Figure 2.3 ERGIC-53 Broadly Associates with Class I Viral Fusion GPs and
Influences the Propagation of JUNV, SARS CoV, and EBOV in a GP-Specific
Manner
(A - D) ERGIC-53 is required for the production of infectious viral particles in a GPspecific manner. HEK 293T cells were initially transfected with a plasmid encoding
Myc-tagged WT or DN ERGIC-53, then 24 hr later with a plasmid encoding VSV G,
JUNV XJ GP, SARS CoV S, or EBOV GP. Twenty-four hr following the final
transfection,
were screened for infectious

. Supernatants and cell protein lysates
particles pseudotyped with the indicated viral GP

via focus assay and Myc-ERGIC-53 (WT or DN) or CRT via Western blot (see Figure S3
for blots), respectively. Data are presented as mean infectious units ± SEM relative to the
WT ERGIC-53 vector transfected wells and are representative of 2 independent
experiments (n = 3 wells per condition per experiment). *p < 0.05, **p < 0.01, ***p <
0.001, determined using the unpaired Student’s t test.
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(E and F) ERGIC-53 does not associate with VSV G. HEK 293T cells were transfected
with a plasmid encoding VSV G or an empty plasmid and either VSV G (E) or ERGIC53 (F) was immunoprecipitated as bait from cell lysates (input). Immunoprecipitated bead
fractions were screened for ERGIC-53 (E) or VSV G (F) as prey via Western blot.
(G-J) ERGIC-53 has a conserved association with class I viral fusion GPs. HEK 293T
cells were transfected with a plasmid encoding WT ERGIC-53 and a pCAGGS plasmid
encoding the indicated viral GPs with a C-terminal HA epitope tag and BAP or an empty
pCAGGs plasmid. In panels G and I, cells were also transfected with the Bir A plasmid to
ensure biotinylation of each GP. Viral GPs (G and I) or ERGIC-53 (H and J) were AP or
immunoprecipitated, respectively, as bait from cell lysates. Input lysates and purified
bead fractions were screened for ERGIC-53 (G and I) or viral GP species (full length S
and the processed S2 subunit for SARS CoV; full length HA0 and the processed subunit
HA2 for influenza virus A/WSN/33; and full length GP0 and the processed GP2 subunit
for EBOV and MARV) (H and J) as prey via Western blot. Data are representative of 2
independent experiments.

Figure 2.4 Loss of ERGIC-53 Function Does Not Inhibit the Formation of GPContaining Arenavirus Particles but Instead Renders Them Noninfectious
(A and B) The ER-restricted, DN ERGIC-53 does not impair trafficking of JUNV C#1
GP to the plasma membrane. HEK 293T cells were transfected with a plasmid expressing
WT or DN ERGIC-53, then inoculated 24 hr later with JUNV Candid #1 or not (mock),
and collected 72 hr later to visualize internal rERGIC-53 and surface JUNV GP staining
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via confocal immunofluorescence microscopy (GP, red; Myc-ERGIC-53, green) (A) or
FACS (B). In B, the histograms are gated on Myc-positive cells and show the percentage
of transfected cells with GP staining (grey = mock infected; white = JUNV C#1 infected).
The median fluorescence intensity (MFI) is reported. Scale bars, 20 µm. Surface
expression of hTfR1 is not altered by DN ERGIC-53 (Figure S4).
(C) The DN ERGIC-53 mutant does not impair proteolytic processing of JUNV GPC or
the incorporation of GP species into virus-like particles (VLPs). HEK 293T cells were
transfected with a plasmid expressing WT or DN ERGIC-53, then 24 hr later with
plasmids encoding the JUNV Z and XJ GPC proteins, respectively, to permit the
formation of VLPs. Cells and supernatants (concentrated via ultracentrifugation through
sucrose) were screened for the presence of various GP species (the C-terminally FLAGtagged precursor GPC or proteolytically processed GP2) or actin via Western blot. The
data are representative of 2 independent experiments.
(D - G) JUNV C#1 generates GP-containing virus particles that are noninfectious in
ERGIC-53 null cell lines. B cells derived from LMAN1+/+ (2829-D) and LMAN1-/- (CRC78) individuals were challenged with JUNV C#1 or not and supernatants from these cells
were concentrated through sucrose and screened for viral proteins (GP1, NP, and Z),
ERGIC-53, or actin via Western blot (D), JUNV C#1 plaque forming units (PFU) via
plaque assay (E), the ratio of S segment genomic RNA copies, as measured by
quantitative RT-PCR, to PFU (F), or attachment to host cells (G). All values are reported
relative to the LMAN1+/+ particles. Statistics are not shown because the values in panels
D-G were derived from the same individual preparation of either LMAN1+/+- or LMAN1-/125

-derived viral particles. For the attachment assay, virions were allowed to bind to cells at
4oC for 1.5 hr. Following washes to remove unbound particles, bound virus was
enumerated on the basis of viral S segment genomic RNA copies detected via
quantitative RT-PCR. The data in panels D-F are representative of 2 independent
experiments.

Figure 2.5 ERGIC-53 Traffics to Sites of Arenavirus Budding and Is Incorporated
into Virions
(A-C) ERGIC-53 traffics to sites of arenavirus budding. JUNV C#1- or mock-infected
HEK 293T cells were screened for either internal (A) or surface (B and C) expression of
JUNV GPC/GP1 and ERGIC-53 (A and B) or JUNV GPC/GP1 and CRT (C) via
confocal microscopy. Scale bars, 10 µm (white), 20 µm (red), and 300 nm (yellow).
(D) ERGIC-53 is a component of arenavirus particles. An anti-GP1 antibody was used to
immunoprecipitate viral particles from supernatants of JUNV-infected or mock-infected
Vero E6 cells. An irrelevant, species-matched antibody was also used for
immunoprecipitation

from

the

JUNV-infected

supernatants.

Cell

lysates

and

immunoprecipitated protein fractions were screened for viral proteins (GP1, NP, and Z)
and ERGIC-53 via Western blot under non-reducing conditions. Data are representative
of 2 independent experiments. ERGIC-53 was also detectable in JUNV C#1 particles via
confocal microscopy (Figure S5).
Figure 2.6 The C-Terminal Region of ERGIC-53’s CRD Is Required for the
ERGIC-53 - JUNV GP Interaction
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(A) Depiction of ERGIC-53 mutants used in this study. SS, signal sequence; F, Flag
epitope tag; TM, transmembrane. See Figure S6 for a detailed description of each mutant.
(B) HEK 293T cells were co-transfected with the BirA plasmid, a plasmid encoding
JUNV C#1 GP with a C terminal HA tag and BAP, and a plasmid encoding the indicated
ERGIC-53 mutants with an N-terminal FLAG tag. JUNV GP species (GPC and GP2)
were AP as bait from cell lysates. Input lysates and captured bead fractions were screened
for ERGIC-53 (prey) and, as a control, CRT (prey) via Western blot. The data are
representative of 2 independent experiments.
Figure 2.7 Proposed Model Depicting the Role of ERGIC-53 in JUNV Propagation
Under WT conditions (top half of left cell), the arenavirus GP undergoes a series of
maturation steps within the early exocytic pathway (1), including proteolytic cleavage
and trafficking to the plasma membrane where it is incorporated into newly forming viral
particles (2) that bud out of the cell (3). The GP on newly formed particles then attaches
to its cellular receptor (4), which permits endocytic uptake of particles into endosomes
(5) where low pH leads to GP2-mediated fusion of the viral and endosomal membranes
and, ultimately, release of viral genome into the cytoplasm (6). In the absence of ERGIC53 (null) or in the presence of the ER-restricted, DN ERGIC-53 (DN) (bottom half of left
cell), GP is still proteolytically processed, trafficked to the plasma membrane, and
incorporated, along with other viral structural proteins and viral genome, into budding
particles (1-3). These particles, however, lack ERGIC-53 and are defective in their ability
to attach to host cells (4). They may have deficiencies in other early replication events (5
and 6) as well.
127

128

Figure 2.1 Identification of Human Proteins that Associate with Arenavirus and
Hantavirus GPs
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Figure 2.2 ERIGC-53 is Required for Arenavirus Propagation.
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Figure 2.3 ERGIC-53 Broadly Associates with Class I Viral Fusion GPs and
Influences the Propagation of JUNV, SARS CoV, and EBOV in a GP-Specific
Manner
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Figure 2.4 Loss of ERGIC-53 Function Does Not Inhibit the Formation of GPContaining Arenavirus Particles but Instead Renders Them Noninfectious
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Figure 2.5 ERGIC-53 Traffics to Sites of Arenavirus Budding and is Incorporated
into Virions
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Figure 2.6 The C-Terminal Region of ERGIC-53’s CRD is Required for the
ERGIC-53 –JUNV GP interaction
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Figure 2.7 Proposed Model Depicting the Role of ERGIC-53 in JUNV Propagation
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Figure S1. Proteomics Workflow, Cut Map of Coomassie-Stained Gels Containing
Human Proteins Purified in Complex with LCMV GP or ANDV GP, Functional
Clustering Analysis of Host Protein Partners, and Additional Viral GPs that
Associate with ERGIC-53, Related to Figure 1
(A) Workflow for identification of human proteins that associate with the GPs encoded
by LCMV and ANDV. HEK 293T cells were co-transfected with a plasmid encoding
each respective viral GP with a C-terminal HA epitope tag and a biotin acceptor peptide
(BAP), along with a second plasmid that encodes BirA, a bacterial biotin ligase, to ensure
biotinylation of the viral GPs. As a control, cells were co-transfected with the BirA
plasmid and an empty vector. Two days later, biotinylated GPs and associated host
proteins were affinity purified (AP) from whole cell lysates using magnetic streptavidin
beads and separated on 4-20% polyacrylamide gels for Coomassie staining. To determine
the identity of cellular proteins captured, each Coomassie-stained gel lane was cut into
sections (see dashed lines) for in-gel, tryptic digestion and mass spectrometry analysis as
described in the Extended Experimental Procedures.
(B and C) Cut maps of the affinity purified LCMV GP (B) and ANDV GP (C) samples
following SDS-PAGE and Coomassie staining.
(D) NIH DAVID functional clustering identifies enriched protein functional categories
from proteomic datasets representing proteins identified binding to both LCMV and
ANDV GP proteins, LCMV GP alone, or ANDV GP alone. Official gene symbols (see
Tables S1A-S1C) of these data sets were entered into NIH DAVID, searched under
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medium stringency choosing Homo sapiens as background. Functional clusters showing
four-fold or more increases were chosen for display here. Functional clusters were
simplified by providing labels 1-14 above (see Table S1D for details). The percent of
proteins (average of functional cluster subsets) in each data set in each of these categories
is provided as well as the relative enrichment of a given cluster relative to the human
proteome. Note that one protein may be found in more than one category. Also note that
because the size of each dataset is different a category may show a higher percentage, but
a lower enrichment when compared to the same category in a different data set.
(E) HEK 293T cells were transfected with the BirA plasmid and a modified pCAGGS
plasmid encoding WWAV GP with a C-terminal HA epitope tag and BAP or, as a
control, an empty pCAGGS plasmid. Whole cell lysates (input) were collected 2 days
later and incubated with streptavidin beads to isolate each biotinylated GP species (GPC
and GP2). Input lysates and captured bead fractions were screened for GP species (GPC
and GP2) (bait) and ERGIC-53 (prey) via Western blot.
(F - I) HEK 293T cells were transfected with a plasmid encoding the indicated viral GPs
with a C-terminal HA epitope tag or an empty plasmid. Two days later ERGIC-53 was
immunoprecipitated from whole cell lysates (input). Inputs and immunoprecipitated bead
fractions were screened for ERGIC-53 (bait) and the various GP species (GPC and GP2
for arenaviruses; G2 for hantaviruses) (prey) via Western blot.
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Figure S2. ERGIC-53 is Required for Arenavirus Propagation, Related to Figure 2
(A) Silencing ERGIC-53 expression impairs the release of infectious JUNV C#1 (related
to Figure 2A). HEK 293T cells were transfected with an ERGIC-53-specific siRNA or a
scrambled, negative control siRNA and challenged 72 hr later with JUNV C#1 at an MOI
of 0.1. Supernatants and cell protein lysates were collected at 24, 48, and 72 hr postinoculation (pi) and screened for JUNV C#1 plaque forming units (PFU) via plaque assay
and ERGIC-53 or CRT (loading control) via Western blot (each lane represents an
individual well). Data are presented as mean PFU ± SEM relative to the empty vector
transfected wells and are the summation of 2 independent experiments (24 & 48 hr pi n =
5, 72 hr n = 6).
(B) Overexpression of WT ERGIC-53 enhances infectious JUNV release (related to
Figure 2B). HEK 293T cells were transfected with a plasmid encoding Myc-tagged, WT
ERGIC-53 or, as a control, an empty plasmid; 48 hr following transfection these cells
were challenged with JUNV C#1 at an MOI of 0.1. Supernatants and cell protein lysates
were collected at 24, 48, and 72 hr pi and screened for JUNV C#1 PFU via plaque assay
and Myc-ERGIC-53 or CRT (loading control) via Western blot (each lane represents an
individual well). Data are presented as mean PFU ± SEM relative to the empty vector
transfected wells and are the summation of 2 independent experiments (n = 6 per time
point).
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(C and D) Restriction of ERGIC-53 to the ER impairs the release of infectious JUNV
C#1 and DANV (related to Figures 2C and 2D, respectively). HEK 293T cells were
transfected with a plasmid encoding Myc-tagged DN ERGIC-53 or, as a control, an
empty plasmid; 24 hr later cells were challenged with JUNV C#1 (C) or DANV (D) at an
MOI of 0.1 or 0.001, respectively. Supernatants and cell protein lysates were collected at
the indicated times pi and screened for PFU via plaque assay and Myc-DN ERGIC-53 or
CRT (loading control) via Western blot (each lane represents an individual well). Data
are presented as mean PFU ± SEM relative to the empty vector transfected wells and are
representative of 2 independent experiments (n = 12 or n = 6 per experiment for JUNV
C#1 or DANV, respectively).
(E) Release of infectious JUNV C#1 is impaired in ERGIC-53 (LMAN1-/-) null cells
(related to Figure 2E). B cells from LMAN1+/+ (2829-D) and LMAN1-/- (CRC-78 and
CRC-79) individuals were challenged with JUNV C#1 at an MOI of 1. Supernatants and
cell protein lysates were collected at 48 and 72 hr pi and screened for JUNV C#1 PFU via
plaque assay and ERGIC-53 or actin (loading control) via Western blot (each lane
represents an individual well). Data are presented as mean PFU ± SEM relative to the
LMAN1+/+ cells and are representative of 2 independent experiments (n = 3 per condition
per experiment).
(A - E) *p < 0.05, **p < 0.01, ***p < 0.001, determined using the unpaired Student’s t
test.
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Figure S3. ERGIC-53’s Influence on JUNV, SARS CoV, and EBOV Propagation is
Specific and Can Be Minimally Mapped to the viral GP, Related to Figure 3
(A - D) HEK 293T cells were initially transfected with a plasmid encoding Myc-tagged
WT or DN ERGIC-53, then 24 hr later the WT and DN ERGIC-53 cells were transfected
with a plasmid encoding VSV G (A), JUNV XJ GP (B), SARS CoV S (C), or EBOV GP
(D). Twenty-four hr following the final transfection, cells were challenged with VSV G
at an MOI of 2. Supernatants and cell protein lysates were collected 24 hr later and
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screened for infectious VSV G particles pseudotyped with VSV G, JUNV XJ GP, SARS
CoV S, or EBOV GP via focus assay and Myc-ERGIC-53 (WT or DN) or CRT (loading
control) via Western blot (each lane represents an individual well), respectively. Data are
presented as mean infectious units ± SEM relative to the WT ERGIC-53 vector
transfected wells and are representative of 2 independent experiments (n = 3 wells per
condition per experiment). *p < 0.05, **p < 0.01, ***p < 0.001, determined using the
unpaired Student’s t test.

Figure S4. The ER-Restricted, DN ERGIC-53 Does Not Impair Trafficking of
hTfR1 to the Plasma Membrane, Related to Figure 4
HEK 293T cells were transfected with a plasmid expressing WT ERGIC-53 or the DN
ERGIC-53 mutant and 72 hr later incubated at 4oC with an anti-hTfR1 antibody to stain
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for surface expression of hTfR1 and then fixed, permeabilized, and incubated with an
anti-Myc antibody to stain for internal Myc-ERGIC (WT or DN). The histograms are
gated on Myc-positive cells and show the percentage of transfected cells with hTfR1
staining (grey shaded = isotype-matched IgG control antibody signal; white = hTfR1
signal). The median fluorescence intensity (MFI) is reported for each condition.

Figure S5. ERGIC-53 is Incorporated into Arenavirus Particles, Related to Figure
5D
JUNV C#1 particles generated in Vero E6 cells were adhered onto glass cover slips,
permeabilized, and screened for JUNV NP (green) and ERGIC-53 (red) via confocal
microscopy as described in the Extended Experimental Procedures. The data presented
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are representative of 2 independent experiments. The arrowheads highlight JUNV
particles that contain ERGIC-53. Scale bar, 5 µm.
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Figure S6. The C-Terminal Region of ERGIC-53’s CRD Is Required for the
ERGIC-53 - JUNV GP Interaction, Related to Figure 6
(A) Depiction of ERGIC-53 mutants used in this study. ERGIC-53 is a nonglycosylated,
type I transmembrane protein that forms homohexamers and consists of an ER-lumenal
domain, a transmembrane domain, and a cytoplasmic domain (for review see (Hauri et
al., 2000b)). The ER-lumenal portion of the protein contains a carbohydrate recognition
domain (CRD) that selectively binds high mannose glycans in a Ca2+- and pH-dependent
manner (Appenzeller-Herzog et al., 2004; C. Appenzeller et al., 1999b; Itin et al., 1996).
Lectin binding can be disrupted by deletion of the entire CRD ( CRD) (residues 44 147

269) or specific -strands within the CRD (e.g. strands 1 & 2 (
through 3 (

3) (residues 43 - 76), or 1 through 4 (

2) (residues 43-72), 1

4) (residues 43-83)) (Zheng, Liu,

Yuan, et al., 2010), or through mutation of individual amino acids (N156A or D181A)
(Itin et al., 1996; Velloso, Svensson, Pettersson, & Lindqvist, 2003a; Zheng, Liu, Yuan,
et al., 2010) within the CRD that are critically required for coordinating Ca2+-binding.
The ER-lumenal region of ERGIC-53 also encodes an alpha helical domain and two
cysteine residues (C466 & C475) that are all required for the formation of ERGIC-53
homohexamers. Deletion of the helical domain ( Helix) (residues 271 - 457) (E. P. Neve,
U. Lahtinen, & R. F. Pettersson, 2005) or mutation of the cysteine residues to alanine
(C466A/C475A) (Nufer et al., 2003) results in the loss of noncovalently-associated or
disulfide-linked homohexamers, respectively. Deletion of the helical domain combined
with mutation of C466 and C475 to alanine ( helix monomer ( HM)) (Zheng, Liu,
Yuan, et al., 2010) completely abolishes ERGIC-53 oligomerization and yields
monomeric ERGIC-53, which, like the DN mutant (KKAA) (Kappeler, Klopfenstein,
Foguet, Paccaud, & Hauri, 1997a), cannot traffic beyond the ER. Additionally, several of
these constructs ( CRD,

1,

2,

3,

4, and HM) abolish ERGIC-53’s ability to

interact with MCFD2 (Zheng, Liu, Yuan, et al., 2010). SS, signal sequence; F, Flag
epitope tag; TM, transmembrane.
(B) HEK 293T cells were co-transfected with the BirA plasmid, a plasmid encoding
JUNV C#1 GP with a C terminal HA tag and BAP, and a plasmid encoding the indicated
ERGIC-53 mutants with an N-terminal FLAG epitope tag. JUNV GP species (GPC and
GP2) were AP as bait from cell lysates. Input lysates and captured bead fractions were
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screened for ERGIC-53 (prey) and, as a control, CRT (prey) via Western blot. The data
are representative of 2 independent experiments.

Supplemental Experimental Procedures
Cells and Viruses
HEK 293T/17 cells (CRL-11268, American Type Culture Collection, Manassas, VA)
(referred to as HEK 293T cells in the manuscript) were grown in Dulbecco’s Modified
Eagle Medium (DMEM) (11965-118) supplemented with 10% fetal bovine serum, 1%
Penicillin-Streptomycin (15140-163), 1% MEM Non-Essential Amino Acids Solution
(11140-050), 1% HEPES Buffer Solution (15630-130), and 1% GlutaMAX (35050-061)
purchased from Invitrogen (Carlsbad, CA). Vero E6 cells were provided by J. L. Whitton
(The Scripps Research Institute, La Jolla) and grown in DMEM supplemented with 10%
FBS, 1% Penicillin-Streptomycin, and 1% HEPES Buffer Solution. The EBVimmortalized B lymphoblastoid cell lines derived from normal (LMAN1+/+; 2829-D) or
ERGIC-53 null (LMAN1-/-; CRC-78 and CRC-79) individuals have been described
previously (the null lines are described as A2 and A12, respectively, in (Neerman-Arbez
et al., 1999)) and were maintained in RPMI 1640 Medium (22400-105, Invitrogen)
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containing 10% FBS and 1% Penicillin-Streptomycin. The two LMAN1-/- individuals are
from different families but encode an identical null mutation (c.822-1G>A splice site
mutation) that completely abrogates expression of ERGIC-53. All cell lines were cultured
at 37°C in a humidified incubator containing 5% CO2. JUNV C#1 was provided by R.
Tesh (The University of Texas Medical Branch at Galveston) and M. J. Buchmeier
(University of California, Irvine) and DANV by W. I. Lipkin (Columbia University).
JUNV C#1, which is an attenuated vaccine strain, was originally derived from WT JUNV
strain XJ and differs by 12 amino acids (Chosewood, Wilson, Centers for Disease
Control and Prevention (U.S.), & National Institutes of Health (U.S.), 2009; Goni et al.,
2006). Working stocks of infectious JUNV C#1 and DANV were generated in Vero E6
cells. Infectious titers of these viruses were determined via plaque assay on Vero E6 cells.
VSV G encoding a GFP reporter has been described elsewhere (Takada et al., 1997) and
was provided by M. Whitt (The University of Tennessee Health Science Center,
Memphis, TN). An infectious stock of VSV G pseudotyped with VSV G was generated
by first transfecting HEK 293T cells with a pCAGGS plasmid encoding VSV G and then
24 hr later inoculating these cells with infectious VSV G (which had previously been
pseudotyped with VSV G) at a multiplicity of infection (MOI) of 3. Supernatants were
collected 24 hr following inoculation and infectious titer was determined by enumerating
green foci via focus assay in Vero E6 cells.

Plasmids and Transfections
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To identify and/or validate the interaction of human proteins, including ERGIC-53, with
various viral GPs in Figures 1, 3, 6, S1, and S6, we subcloned each respective viral GP
into our previously described pCAGGS expression vector (C. T. Cornillez-Ty, L. Liao, J.
R. Yates, 3rd, P. Kuhn, & M. J. Buchmeier, 2009). This vector expresses each GP as a
fusion protein containing 3 C-terminal elements: a hemaglutinin (HA) epitope tag
(YPYDVPDYA) followed by the tobacco etch virus (TEV) cleavage site (ENLYFQG)
followed

by

a

23

amino

acid

biotin

acceptor

peptide

(BAP)

(MASSLRQILDSQKMEWRSNAGGS). When co-transfected with a second plasmid that
encodes the bacterial biotin ligase BirA, the BAP can be biotinylated for affinity
purification with streptavidin beads. GPs were subcloned into this vector using Gateway
Technology (Invitrogen) following the manufacturer’s instructions. Briefly, each GP was
first amplified via PCR using forward and reverse primers containing attB1 and attB2
sequences, respectively. In each case, the stop codon was excluded. PCR products were
subcloned into pDONR221 via a BP recombination reaction. GP genes were then
subcloned from pDONR221 into the modified pCAGGS vector via an LR recombination
reaction. The nucleotide sequence of each GP clone was verified by DNA sequencing.
GPs were subcloned from the following viral strains (for each GP, an NCBI Gene
Identifier number and a Protein Locus number are listed to provide a link to the actual
nucleotide sequence cloned for that particular GP and the corresponding translated amino
acid sequence, respectively): ANDV strain CHI-7913 (30313864, AAO86638), SNV
NMR11 (999407 (note that there are two silent mutations in our clone: G changed to T
and A changed to C at positions 60 and 843, respectively, of referenced sequence),
AAC42202), LASV strain Josiah (23343509, NP_694870), LCMV strain Armstrong 53b
151

(61655715, AAX49341), JUNV strain XJ (also referred to as Parodi) (see (Reignier et al.,
2006) for description of the nucleotide sequence; the amino acid sequence of the cloned
gene matches JVU70799), JUNV strain C#1 (52222815, AAU34180), MACV strain
Carvallo (see (Reignier et al., 2006) for description of nucleotide sequence, the amino
acid sequence of the cloned gene matches AAN09942); GTOV strain INH-95551
(22901284, AAN09938), WWAV strain AV 9310135 (14333982, AAK60497), SARS
CoV S from strain Tor2 (JX163924, AFR58686), influenza HA from strain A/WSN/33
(CY010788, ABF47955), EBOV strain Zaire (EBORNA, AAB81004), and MARV strain
Musoke (DQ217792, ABA87127). Each of these GPs, with the exception of LCMV GP,
JUNV XJ GP, MACV GP, SARS CoV S, influenza virus A/WSN/33 HA, EBOV GP,
and MARV GP was synthesized by Bio Basic Inc. (Markhamm, ON). The LCMV strain
Armstrong GP gene was provided by J. C. de la Torre (The Scripps Research Institute, La
Jolla) while the JUNV strain XJ GP and MACV strain Carvallo GP were provided by P.
Cannon (University of Southern California, Los Angeles). The MARV GP in pCAGGS
and EBOV GP in pcDNA3.1 were obtained through BEI Resources, NIAID, NIH,
Manassas, VA (NR-19815 and NR-19814, respectively). The SARS CoV S was provided
by M. J. Buchmeier (University of California, Irvine) while the influenza virus
A/WSN/33 HA in pCAGGS was provided by M. Shaw and A. Garcia-Sastre (Mount
Sinai School of Medicine, New York). For the VSV pseudotyping experiments in Figures
3 and S3, we utilized standard pCAGGS vectors encoding VSV G (provided by J. C. de
la Torre (Lee, Perez, Pinschewer, & de la Torre, 2002)) or EBOV GP (NR-19814, BEI
Resources), our modified pCAGGS vector encoding SARS CoV S, and a pSA90 vector
encoding JUNV XJ GP provided by P. Cannon (Reignier et al., 2006). The pCAGGS
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VSV G plasmid was also used for the immunoprecipitation experiments to screen for an
interaction between VSV G and ERGIC-53 in Figures 3E and 3F. For the viral challenges
(Figures 2, 3, S2, and S3), GP interaction (Figures 3G-3J), GP trafficking (Figures 4A
and 4B), hTfR1 trafficking (Figure S4), and VLP experiments (Figure 4C) we utilized
pCDNA3 GM (which encodes WT ERGIC-53 with an N-terminal c-Myc tag) and/or
pECE KKAA (which encodes the DN ERGIC-53 with an N-terminal c-Myc tag; the 2 Cterminal phenylalanines of this ERGIC-53 gene have been replaced with alanines)
plasmids that were provided by H. P. Hauri (University of Basel, Basel, Switzerland)
(Itin, Schindler, & Hauri, 1995b). For the VLP experiments, we also utilized our
modified pCAGGS vector encoding JUNV strain XJ13 Z (this gene was synthesize by
Bio Basic Inc. and subcloned via Gateway Technology) (33868610, AAQ55249 as well
as JUNV XJ GP with a modified series of C-terminal epitope tags (HA followed by
FLAG). We have previously described the panel of ERGIC-53 plasmids that were
utilized to determine the molecular basis for the JUNV GP - ERGIC-53 association in
Figures 6 and S6 (Zheng, Liu, Yuan, et al., 2010). Briefly, the WT and ERGIC-53
mutants were cloned into the pED plasmid by replacing the ERGIC-53 signal sequence
with that of calreticulin (CRT) and introducing a FLAG epitope directly after the signal
sequence. The mutant plasmids used were

CRD (R44-E269),

Helix (G271-N457),

HM (G271-N457 and C466A/C475A), C466A/C475A, N156A, D181A, KKAA (the 2
C-terminal phenylalanines were replaced with alanines),
N72),

3 (H43-S76), and

1 (H43-Q59),

2 (H43-

4 (H43-A83) (a schematic of each mutant is shown in

Figures 6A and S6A; a detailed description of each mutant is provided in the Figure S6A
legend). All transfections were done using either Fugene HD (4709713001, Roche
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Applied Science, Indianapolis, IN) (3 µl Fugene HD per 1 µg DNA) or Polyethylenimine
(PEI) (23966, Polysciences, Inc., Warrington, PA) (5 µl PEI (from a 1 mg/ml solution in
PBS (10010049, Invitrogen)) per 1 µg DNA).

Affinity Purification of Viral GPs
To capture biotinylated viral GPs for the identification of human protein partners via
mass spectrometry (Figures 1A, 1B, S1B, and S1C) or validation of protein partners via
Western blot (Figures 1D, 1F, 1G, and S1E), HEK 293T cells were co-transfected with
our modified pCAGGS plasmid that encodes each respective viral GP with a C-terminal
HA epitope tag and a BAP, and a second plasmid that encodes BirA to facilitate
biotinylation of the viral GPs. As a control for the mass spectrometry studies and APs
done to validate an interaction between a given viral GP and endogenous ERGIC-53,
cells were co-transfected with the BirA plasmid and an empty pCAGGS plasmid. For the
experiments to screen for an association between ERGIC-53 and coronavirus,
orthomyxovirus, or filovirus GPs in Figures 3G and 3I, in addition to receiving the GP
and BirA plasmids, cells were also transfected with pCDNA3 GM plasmid encoding WT
ERGIC-53. For the experiments to map the molecular basis for the interaction between
JUNV GP and ERGIC-53 in Figures 6 and S6, in addition to receiving the GP and BirA
plasmids, cells were also transfected with a third plasmid encoding either the WT or one
of mutant FLAG-tagged, ERGIC-53 proteins. In each case, cells were scraped into the
media 48 hr following transfection, pelleted, washed with cold PBS, and then gently
lysed on ice in 25 mM Tris-HCL, pH 7.6 containing 1% Triton X-100 (T9284, Sigma154

Aldrich, St. Louis, MO), 0.5% Nonidet P-40 IGEPAL CA-630 (198596, MP
Biomedicals, Solon, OH), 140mM NaCl, 1 mM calcium chloride (21115, SigmaAldrich), and a Complete Mini EDTA-Free Protease Inhibitor Cocktail tablet
(04693159001, Roche Applied Science). Cell lysates were clarified of insoluble material
by centrifugation at 10,000 rpm at 4°C followed by incubation with magnetic streptavidin
beads (Dynabeads MyOne Streptavidin T1, 65602, Invitrogen) on a rotating platform for
2.5 hours at 4°C. Following 4 washes in ice cold lysis buffer to remove nonspecific
proteins, each captured viral GP and its associated cellular protein partners were stripped
from the streptavidin beads by boiling the beads in Laemmli buffer containing 5% mercaptoethanol and separated by size and charge on Novex 4-20% Tris-Glycine
polyacrylamide gels (EC60285BOX, Invitrogen) for either Western blot analysis to
confirm bait/prey purification or Coomassie staining for mass spectrometry analysis
(described in next section).

Mass Spectrometry
To identify human protein partners of LCMV GP or ANDV GP in Figures 1A, 1B, S1B,
and S1C, HEK 293T cells were co-transfected with our modified pCAGGS plasmid
encoding each respective viral GP with a C-terminal HA epitope tag and a biotin acceptor
peptide (BAP) and a second plasmid encoding BirA to ensure biotinylation of the viral
GPs. As a control, cells were co-transfected with the BirA plasmid and an empty vector.
Two days later, biotinylated GPs and associated host proteins were affinity purified (AP)
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from whole cell lysates as described above, run out on a Novex 4-20% Tris-Glycine
polyacrylamide gel, stained with Coomassie stain (0.1% Brilliant Blue R (B7920, SigmaAldrich) in 40% methanol with 20% acetic acid) diluted in 30% methanol with 10%
acetic acid solution to 20% v/v overnight at room temperature, and then destained for 4
to 6 hr in 30% methanol with 10% acetic acid solution. Each gel lane was cut into 15
(LCMV GP) or 14 (ANDV GP) sections (see Figures S1B and S1C for cut maps) for ingel digestion of captured proteins using Sequencing Grade Modified Trypsin (V5111,
Promega, Madison, WI 6 ng/ L) in 50 mM ammonium bicarbonate overnight at 37°C as
previously described (Ballif, Cao, Schwartz, Carraway, & Gygi, 2006). Peptides were
extracted from gel sections with 50% acetonitrile (MeCN) and 2.5% formic acid (FA)
and then dried. Peptides were then resuspended in 2.5% MeCN and 2.5% FA and loaded
onto a microcapillary column packed with 12 cm of reversed-phase Magic C18 material
(5 m, 200 Å, Michrom Bioresources, Inc., Auburn, CA) using a MicroAS autosampler
(Thermo Scientific, Pittsburgh, PA). Elution was performed with a 5 35% MeCN (0.15%
FA) gradient using a Surveyor Pump Plus HPLC (Thermo Scientific) over 40 min, after a
15 min isocratic loading at 2.5% MeCN and 0.15% FA. Mass spectra were acquired in an
LTQ-XL linear ion trap mass spectrometer (Thermo Scientific) over the entire run using
10 MS/MS scans following each survey scan. Raw data were searched against the human
IPI forward and reverse concatenated databases using SEQUEST software requiring
tryptic peptide matches with a 2 Da mass tolerance. Cysteine residues were required to
have a static increase in 71.0 Da for acrylamide adduction, and differential modification
of 16.0 Da on methionine residues was permitted. Host proteins were considered
legitimate GP protein partners if 2 or more unique tryptic peptides were detected from a
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host protein in samples transfected with a given GP plasmid but not the empty vector or,
alternatively, if there was a 5-fold higher quantity of total tryptic peptides detectable from
a given human protein in a GP sample compared to the empty vector sample. These
filters resulted in a false discovery peptide rate of less than 1%.
Immunoprecipitations
Whole cell protein lysates used for immunoprecipitation studies were generated as
described above in the “Affinity Purification of Viral GPs” section. Following
centrifugation at 10,000 rpm at 4°C to remove insoluble material, protein lysates were
pre-cleared by incubating them with magnetic Protein G beads (Dynabeads Protein G
beads, 10004D, Invitrogen) on a rotating platform for 15 minutes at 4°C. Each cleared
lysate was then incubated (on a rotating platform) with its respective antibody for 2 hr
followed by magnetic Protein G beads for 1 hr. The beads were then washed 4 times with
ice cold lysis buffer to remove nonspecific proteins and excess antibody. Captured bait
proteins and their associated protein partners (prey) were stripped from the beads by
boiling them in Laemmli buffer (with or without 5% -mercaptoethanol) and separated
by size and charge on gradient Novex 4-20% Tris-Glycine polyacrylamide gels for
Western blot analysis to confirm bait/prey purification. Immunoprecipitations from
cellular protein lysates were carried out using the following antibodies: ERGIC-53 was
immunoprecipated with either the mouse anti-ERGIC-53 G1/93 antibody (ALX-804-602C100, Enzo Life Sciences Farmingdale, NY) (Figures 1E, 1I-1K, 3F, 3H, 3J, S1G and
S1H) or a rabbit anti-ERGIC-53 antibody (sc-66880, Santa Cruz, Dallas, TX) (Figure
S1F and S1I); VSV G with the mouse anti-VSV G antibody (11 667 351 001, Roche
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Applied Science) (Figure 3E); JUNV GP with the mouse anti-GP1/GPC antibody GB03BE08 (NR-2564, BEI Resources) (Figure 1H); or, as a control, a species matched, nonimmune Mouse IgG1 Isotype (MAB002, R&D Systems Minneapolis, MN) (Figures 1K
and S1H).
To purify intact JUNV C#1 particles in Figure 5D, supernatant from JUNV C#1infected Vero E6 cells was collected 72 hr post-inoculation, cleared of cells by
centrifugation at 1400 RPM, then pre-cleared with magnetic Protein G beads, incubated
with the GP1-specific mouse monoclonal antibody QC03-BF11 (NR-2566, BEI
Resources) for 2 hr followed by magnetic Protein G beads for 1 hr. The beads were
washed 4 times with PBS containing 0.1% BSA and 1 mM calcium chloride and then
boiled in Laemmli buffer to elute/lyse the captured viral particles. The collected lysate
was then electrophoresed on a Novex 4-20% Tris-Glycine polyacrylamide gel for
Western blot analysis. Controls for this experiment included the use of the GP1-specific
antibody with supernatants from mock-infected cells as well as using the MAB002
Mouse IgG1 Isotype Control antibody for immunoprecipitation from the JUNV C#1infected supernatants.
SDS-PAGE and Western Blot
Protein lysates were separated by SDS-PAGE using Novex 4-20% Tris-Glycine
polyacrylamide gels. Protein transfer to nitrocellulose membranes was accomplished
using the iBlot Gel Transfer Device and iBlot Transfer Stack nitrocellulose membranes
(IB3010-01) from Invitrogen according to the manufacturer’s instructions. Following
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transfer, membranes were blocked by rocking in a solution of 5% milk in PBS for 1 hour
at room temperature followed by 3 washes with Western wash solution (PBS with 0.5%
Nonidet P-40 IGEPAL CA-630). Primary antibodies were diluted in antibody diluent
(PBS containing 5% milk, 3% FBS, and 0.05% Nonidet P-40 IGEPAL CA-630) and
incubated overnight at room temperature. Following 3 washes in Western wash,
membranes were incubated with secondary antibodies diluted in antibody diluent for 2 hr
at room temperature, followed by 3 final washes in Western wash. Membranes were then
developed using chemiluminescence (SuperSignal West Pico (34080) or Femto (34096)
Chemiluminescent Substrate, Thermo Scientific). The membranes that were visualized
via an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE) in Figures
6 and S6 were treated as described above with the following changes: the antibody
diluent for the primary antibodies was PBS containing 5% milk and 0.05% Nonidet P-40
IGEPAL CA-630, the antibody diluent for the secondary antibodies was PBS containing
5% milk, 0.02% SDS, and 0.05% Nonidet P-40 IGEPAL CA-630, while the final wash
was done using PBS.
Primary antibodies (and the dilutions they were used at) were: G1/93 mouse antiERGIC-53 (1:500), sc-66880 rabbit anti-ERGIC-53 (1:4,000), QC03-BF11 mouse antiJUNV GPC/GP1 (1:5,000), GB03-BE08 mouse anti-JUNV GPC/GP1 (1:500), 11 667
351 001 mouse anti-VSV G antibody (1:1,000), 9B11 mouse anti-Myc (2276, Cell
Signaling, Danvers, MA) (1:3,000), 71D10 rabbit anti-Myc

(2278, Cell Signaling)

(1:4,000), NA05-AG12 mouse anti-JUNV NP (NR-2582, BEI Resources) (1:200), clone
M2 mouse anti-FLAG (F1804, Sigma-Aldrich) (1:3,000), SPA-600 rabbit anti-CRT
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(Stressgen, Ann Arbor, MI) (1:4,000), Clone AC-15 mouse anti- -Actin (A5441, SigmaAldrich) (1:5,000), HA.11 Clone 16B12 mouse anti-HA (MMS-101P, Covance
Emeryville, CA) (1:4,000), and rabbit anti-JUNV Z (1:2,000) (provided by Sandra Goñi
and described in (Goni et al., 2010)). Detection of native JUNV C#1 GPC/GP1 using
GB03-BE08 or QC03-BF11 was done under non-reducing conditions.
Secondary antibodies used for chemiluminescence were: goat anti-mouse IgG
HRP conjugate (H+L) (71045, EMD Millipore, Billerica, MA) (1:10,000), goat antimouse light chain IgG HRP conjugate light chain specific (AP200P, EMD Millipore)
(1:50,000), Peroxidase-AffiniPure Goat Anti-Rabbit IgG (H+L) (111035045, Jackson,
West Grove, PA) (1:10,000), mouse anti-rabbit light chain IgG HRP (211032171,
Jackson) (1:50,000).
Secondary antibodies used for LI-COR were: IRDye 800CW Goat Anti-Rabbit
IgG (H+L) (926-32211, LI-COR) (1:20,000), IRDye 800CW Goat Anti-Rabbit IgG
(H+L) (926-32210, LI-COR) (1:20,000), and IRDye 680CW Goat Anti-Rabbit IgG
(H+L) (926-68070, LI-COR) (1:20,000).
Viral Challenge Assays
A series of viral challenge assays were conducted to determine how various
manipulations of ERGIC-53 (siRNA silencing of ERGIC-53, overexpression of WT
ERGIC-53, expression of DN ERGIC-53, or loss of ERGIC-53 expression due to null
mutation of LMAN1) would impact the ability of viruses (JUNV C#1, DANV, or VSV G
pseudotyped with VSV G, SARS CoV S, EBOV GP or JUNV XJ GP) to release
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infectious progeny. At each time point examined in the various assays, supernatants and
cells were collected (from each replicate well) to measure infectious virus or protein
expression levels, respectively. Supernatants were clarified via centrifugation at 2000
RPM for 5 minutes and then screened for infectious virus via plaque assay (JUNV C#1
and DANV) or focus forming assay (pseudotyped VSV G). To generate protein lysates,
cells were scraped into PBS, combined with any cells that pelleted while clarifying the
supernatants, pelleted by centrifugation at 2000 RPM, and then lysed on ice in 25 mM
Tris-HCL, pH 7.6 containing 1% Triton X-100, 0.5% Nonidet P-40 IGEPAL CA-630,
140 mM NaCl, and a Complete Mini EDTA-Free Protease Inhibitor Cocktail tablet.
Lysates were clarified of insoluble material by centrifugation at 10,000 rpm at 4°C and
run on Novex 4-20% Tris-Glycine polyacrylamide gels for Western blot analysis. For
selected challenge assays described below, we utilized the unpaired Student’s t test to
determine whether statistically significant differences existed between the quantities of
infectious virus released from control versus experimental groups as indicated in the
Figure legends.
For the siRNA challenge experiments shown in Figures 2A and S2A, HEK 293T
cells were plated in 6-well plates, reverse transfected with 25 nM of either an ERGIC-53specific

siRNA

(5’-GGACAGAAUCGUAUUCAUCdTdT-3’

as

sense

and

5’-

AUGAAUACGAUUCUGUCCdTdT-3’ as antisense) (B. Nyfeler et al., 2006) or a
scrambled, negative control siRNA (Allstars Negative Control siRNA, 1027280, Qiagen,
Valencia,
CA) using HiPerFect Transfection Reagent (301705, Qiagen) according to the
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manufacturer’s instructions. Cells were challenged 72 hr later with JUNV C#1 at an MOI
of 0.1. Supernatants and cell protein lysates were collected at 24, 48, and 72 hr postinoculation (96, 120, and 144 hr post-transfection with siRNA, respectively) and screened
for JUNV C#1 plaque forming units (PFU) via plaque assay or ERGIC-53 and CRT
(loading control) expression via Western blot. Prior to carrying out the viral challenge,
we determined, using the ERGIC-53-specific siRNA, the timeframe post-transfection that
would yield optimal ERGIC-53 knock-down. Using Western blot as a read out, we
observed silencing of ERGIC-53 in HEK 293T cells from 48 to 144 hr post-transfection
(data not shown).
For the overexpression challenge experiments shown in Figures 2B and S2B,
HEK 293T cells were plated in 6-well plates, transfected the next day with a plasmid
encoding Myc-tagged, WT ERGIC-53 or an empty vector, and challenged 1 day later
with JUNV C#1 at an MOI of 0.1. Supernatants and cell protein lysates were collected at
24, 48, and 72 hr post-inoculation and screened for JUNV C#1 PFU via plaque assay or
Myc-WT ERGIC-53 and CRT (loading control) expression via Western blot.
For the DN ERGIC-53 challenge assays shown in Figures 2C, 2D, S2C, and S2D,
HEK 293T cells were plated in 24-well plates, transfected the next day with a plasmid
encoding Myc-tagged, DN ERGIC-53 or an empty vector, and challenged 1 day later
with JUNV C#1 or DANV at an MOI of 0.1 or 0.001, respectively. Supernatants and cell
protein lysates were collected at 48 and 72 hr post-inoculation for JUNV C#1 or 48 hr
post-inoculation for DANV and screened for PFU via plaque assay or Myc-DN ERGIC53 and CRT (loading control) expression via Western blot.
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For the ERGIC-53 null cell line challenge assays shown in Figures 2E and S2E,
EBV-immortalized B lymphoblastoid cell lines derived from 1 normal (LMAN1+/+; 2829D) or 2 ERGIC-53 null (LMAN1-/-; CRC-78 and CRC-79) individuals were seeded in a
24-well plate and challenged with JUNV C#1 at an MOI of 1. Supernatants and cell
protein lysates were collected 72 hr post-inoculation and screened for PFU via plaque
assay or ERGIC-53 and actin (loading control) expression via Western blot.
For the VSV G pseudotyping challenge assays shown in Figures 3A-3D and S3,
HEK 293T cells were initially transfected with a plasmid encoding Myc-tagged WT or
DN ERGIC-53, then 24 hr later the WT and DN ERGIC-53 cells were transfected with a
plasmid encoding VSV G, JUNV XJ GP, SARS CoV S, or EBOV GP. Twenty-four hr
following the final transfection, cells were challenged with VSV G (that had been
previously pseudotyped with VSV G) at an MOI of 2. Supernatants and cell protein
lysates were collected 24 hr later and screened for infectious VSV G particles
pseudotyped with VSV G, JUNV XJ GP, SARS CoV S, or EBOV GP via focus assay
and Myc-ERGIC-53 (WT or DN) or CRT (loading control) via Western blot,
respectively.
For the ERGIC-53 null cell line challenge assays shown in Figures 4D-4G, EBVimmortalized B lymphoblastoid cell lines derived from a normal (LMAN1+/+; 2829-D) or
ERGIC-53 null (LMAN1-/-; CRC-78) individual were seeded in T-75 flasks and
challenged or not (mock) with JUNV C#1 at an MOI of 0.1. Supernatants were collected
96 hr post-inoculation, concentrated via ultracentrifugation as described below, and
screened for PFU via plaque assay, JUNV proteins (GP1, NP, and Z) or cellular proteins
(ERGIC-53 and actin (loading control)) via Western blot, and viral S segment genomic
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RNA via quantitative RT-PCR (as described below). RNA was extracted from each viral
preparation using the QIAamp Viral RNA Mini Kit (52906, Qiagen) according to the
manufacturer instructions. Virion preparations were also screened for their ability to bind
host cells in a virus-cell binding assay (described below).
Virus-Cell Binding Assay
To determine whether the viral particles produced in EBV-immortalized B
lymphoblastoid cell lines derived from a normal (LMAN1+/+; 2829-D) or ERGIC-53 null
(LMAN1-/-; CRC-78) individual had differing capacities to bind host cells in Figure 4G,
we chilled Vero E6 cells grown in 48-well plates to 4°C, washed them twice with PBS,
and then incubated duplicate wells with each viral preparation for 1.5 hrs at 4°C.
Unbound virus was then aspirated and each well was washed 3 times in PBS. Following
the final wash, total RNA was extracted from each monolayer using the RNeasy Mini Kit
(74106, Qiagen) according to the manufacturer instructions. RNA samples were then
subjected to quantitative RT-PCR, as described below, to determine the copies of JUNV
C#1 S segment genomic RNA.
Quantitative RT-PCR
To enumerate quantities of JUNV C#1 viral S segment genomic RNA, cDNA was
generated using 200 nM of primer 5’-AAGGGTTTAAAAATGGTAGCAGAC-3’, which
is specific for the NP region of the S segment genomic (negative-sense) RNA, with
Multiscribe-RT (4311235, Life Technologies, Carlsbad, CA). Reaction conditions were
25oC for 10 min, 48oC for 30 min, and 95oC for 5 min. Quantitative PCR was then
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performed using a primer-probe set originally described in (Trombley et al., 2010).
Specifically, we used forward primer (900 nM) 5’-CATGGAGGTCAAACAACTTCCT3’, reverse primer (900 nM) 5’-GCCTCCAGACATGGTTGTGA-3’, and probe (200 nM)
5’-6FAM-ATGTCATCGGATCCTT-MGBNFQ-3’. Note that the forward primer differs
by 1 nt from the originally reported sequence. Reactions were carried out using Taqman
Universal PCR Master Mix (4326614, Life Technologies). Reaction conditions were
95oC for 10 min and 45 cycles of 95oC for 15 sec and 60oC for 1 min. Absolute copy
numbers of JUNV C#1 S segment genomic RNA were determined by comparison with a
series of standard dilutions of the our modified pCAGGS plasmid encoding the JUNV
C#1 NP gene. Data was acquired using an Applied Biosystems StepOnePlus Real-Time
PCR System and analyzed with the provided StepOne software.
Virus-Like Particle (VLP) Assay
For the VLP assays shown in Figure 4C, HEK 293T cells were initially transfected with a
plasmid expressing Myc-tagged WT or DN ERGIC-53, then 24 hr later with a cocktail of
2 plasmids encoding the JUNV Z and XJ GPC proteins, respectively, to permit the
formation and release of VLPs. Cells and supernatants were collected 72 hr later and
screened for the presence of various GP species (the C-terminally FLAG-tagged
precursor GPC or proteolytically processed GP2) or actin (to serve as a loading control)
via Western blot. Cells were collected as described above in the “Viral Challenge Assay”
section. VLPs were concentrated from supernatants via ultracentrifugation through
sucrose (as described below) prior to Western blot analysis.
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Ultracentrifugation of VLPs and Authentic JUNV C#1 Particles
The JUNV VLPs in Figure 4C and JUNV C#1 particles in Figure 4D were concentrated
via ultracentrifugation through sucrose as previously described (Neuman, Adair, Yeager,
& Buchmeier, 2008). Briefly, supernatants were clarified of cellular debris via 2 rounds
of centrifugation at 1500 rpm and 2500 rpm, respectively. VLPs/particles were then
precipitated by dissolving polyethylene glycol MW 8,000 (81268, Sigma-Aldrich) into
clarified supernatants (10% weight/volume) at 4oC. Supernatants were then centrifuged at
10,000 RPM for 30 minutes at 4oC to pellet VLPs/particles. Pellets were gently
resuspended in HEPES buffered saline, pH 7.4, layered onto 20% sucrose, and
centrifuged at 100,000 x g in a T-865 Rotor (Thermo Scientific) for 2.5 hr at 4oC.
Pelleted virus was gently resuspended in HEPES buffered saline, pH 7.4 for use in plaque
and/or Western blot assays.

Confocal Microscopy
Confocal microscopy was used to visualize the localization of JUNV C#1 GP and
ERGIC-53 in HEK 293T cells (either internally, at the plasma membrane, or a
combination of internal/surface staining) or JUNV C#1 NP and ERGIC-53 in virions. For
the internal staining of JUNV C#1 GP and endogenous ERGIC-53 shown in Figure 1L,
HEK 293T cells were seeded onto 22 mm glass cover slips (12-541-B, Thermo
Scientific) within 6-well dishes, inoculated or not (mock) the next day with JUNV C#1 at
an MOI of 0.1, then 72 hr later washed with PBS, fixed with Z-FIX (174, ANATECH,
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Battle Creek, MI), permeabilized in PBS with 0.1% Triton X-100 and 1% BSA, then
blocked in PBS containing 3% FBS and 10% normal goat serum (005-000-121, Jackson)
for 30 minutes at room temperature. Cells were then incubated with a 1:500 dilution of
the G1/93 mouse anti-ERGIC-53 antibody in PBS containing 1% BSA and 0.1% Triton
X-100 overnight at 4oC. Cells were then washed 3 times with PBS containing 0.1% BSA
and incubated with Alexa Fluor 647-conjugated goat anti-mouse IgG (H+L) (A-21236,
Invitrogen). After 3 washes in PBS containing 0.1% BSA, cells were incubated with a
1:50 dilution of the GB03-BE08 mouse anti-JUNV GP1/GPC antibody that had been
directly conjugated to Alexa Fluor 488. Cover slips were washed 3 times with PBS,
stained with 4’, 6-diamidino-2-phenylindole hydrochloride (DAPI) (D9542, Sigma
Aldrich), washed 3 times with PBS, and then mounted onto glass slides using ProLong
Gold Antifade Reagent (P36934, Invitrogen).
The intracellular and surface staining of JUNV C#1 GP and endogenous ERGIC53 shown in Figures 5A and 5B, respectively, was accomplished by seeding HEK 293T
cells in T-75 flasks and then inoculating them or not (mock) the next day with JUNV C#1
at an MOI of 0.1. Cells were trypsinized 2 days later (at 48 hr post-inoculation), reseeded
onto 22 mm glass cover slips within 6-well dishes, and at 72 hr post-inoculation either a)
fixed, permeabilized, and blocked in an identical manner described above for internal
staining or b) incubated at 4oC for surface staining. Following blocking, internal staining
was done by incubating cells with a 1:500 dilution of the GB03-BE08 mouse anti-JUNV
GP1/GPC antibody and a 1:200 dilution of the sc-66880 rabbit anti-ERGIC-53 antibody
in PBS with 1% BSA overnight at 4oC. After 3 washes in PBS with 0.1% BSA, cells
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were incubated with a 1:800 dilution of both the Alexa Fluor 488-conjugated Goat AntiMouse IgG (H+L) (A-11029, Invitrogen) and Alexa Fluor 647-conjugated Goat AntiRabbit IgG (H+L) (A-21245, Invitrogen) antibodies. For the live-cell surface staining,
cells were incubated with a 1:50 dilution of the GB03-BE08 mouse anti-JUNV GP1/GPC
antibody and a 1:50 dilution of the sc-66880 rabbit anti-ERGIC-53 antibody in PBS with
3% FBS and 10% normal goat serum for 20 minutes at 4oC. After 3 washes in PBS with
3% FBS, cells were incubated with a 1:200 dilution of both the Alexa Fluor 488conjugated Goat Anti-Mouse IgG (H+L) and Alexa Fluor 647-conjugated Goat AntiRabbit IgG (H+L) antibodies. In both staining protocols, cells were washed 3 times
following incubation with the secondary antibodies, stained with DAPI, washed 3 times
with PBS, and then mounted onto glass slides using ProLong Gold Antifade Reagent. As
a control, cells were surface stained for JUNV C#1 GP and CRT using a 1:50 dilution of
the SPA-600 rabbit anti-CRT antibody (Figure 5C). The protocol was the same with the
exception of replacing the ERGIC-53-specific antibody with the CRT-specific antibody.
The surface staining of JUNV C#1 GP and intracellular staining of either Myctagged WT or DN ERGIC-53 shown in Figure 4A was accomplished by seeding HEK
293T cells in T-75 flasks, transfecting them with plasmids encoding either Myc-tagged
WT or DN ERGIC-53, then 1 day later inoculating them with JUNV C#1 at an MOI of
0.1. Cells were trypsinized 2 days later (at 48 hr post-inoculation) and reseeded onto 22
mm glass cover slips within 6-well dishes. At 72 hr post-inoculation cells were washed
in PBS and then surface stained for JUNV GP1/GPC via incubation with a 1:50 dilution
of the GB03-BE08 mouse anti-JUNV GP1/GPC antibody directly conjugated to Alexa
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Fluor 488 in PBS containing 3% FBS for 20 minutes at 4oC. Cells were then washed 3
times in PBS and fixed using Z-FIX. Following fixation, cells were washed 2 times with
PBS, permeabilized via incubation with PBS containing 0.1% Triton X-100 and 1% BSA
for 10 minutes, washed 3 times with PBS containing 0.1% BSA, blocked for 30 minutes
at room temperature with PBS containing 1% BSA and 10% normal goat serum, then
stained for Myc-tagged WT or DN ERGIC-53 via overnight incubation at 4oC with a
1:200 dilution of the 71D10 rabbit anti-Myc antibody in PBS containing 0.1% BSA.
Cells were washed 3 times in PBS containing 0.1% BSA, then incubated with a 1:800
dilution of the Alexa Fluor 647-conjugated goat anti-rabbit antibody in PBS containing
0.1% BSA for 2 hr, washed 3 times in PBS, stained with DAPI, washed 3 times in PBS,
then mounted on glass slides using ProLong Gold Antifade Reagent.
Detection of ERGIC-53 in JUNV C#1 particles shown in Figure S5 was
accomplished by incubating clarified media from either mock- or JUNV C#1-infected
cells for 2 hr at 37°C in 35 mm glass bottom culture dishes (P356-1.5-10-C, MatTek
Corporation, Ashland, MA) that had been coated with 0.01% Poly-L-Lysine (3438-10001, Trevigen, Gaithersburg, MD). The JUNV C#1-containing media had a titer of ~1 x
107 PFU/ml. Viral particles were subsequently fixed by incubation in 4%
paraformaldehyde for 30 minutes at room temperature, washed three times with 1X PBS,
permeabilized in PBS containing 1% BSA and 0.1% Triton X-100 for 10 minutes at room
temperature, and then blocked in PBS containing 1% BSA and 10% normal goat serum
for 30 minutes at room temperature. Staining for JUNV NP and ERGIC-53 was done via
incubation with a 1:200 dilution of the mouse anti-JUNV NP antibody NA05-AG12 (NR169

2582, BEI Resources) and a 1:100 dilution of a rabbit anti-ERGIC-53 antibody (raised by
B.Z.) in PBS containing 1% BSA for 2 hours at room temperature. Following 3 washes in
PBS with 0.1% BSA, the dishes were incubated with a 1:200 dilution of both the Alexa
Fluor 488-conjugated Goat Anti-Mouse IgG (H+L) and Alexa Fluor 647-conjugated Goat
Anti-Rabbit IgG (H+L) antibodies. The stained dishes were then washed 3 times in PBS
and stored at 4°C prior to imaging in PBS.
Images for all confocal experiments were obtained using a Zeiss LSM 510 Laser
Scanning Confocal Microscope. Images were captured using either a 63X or 100X
objective lens with a numerical aperture of 1.4. Optical zoom was set to 1.5X and images
were obtained at 1.0 Airy unit. The colocalization analysis shown in Figure 1L was
performed with the colocalization analysis module contained in the Zeiss Aim software
on images that were captured using the 63X objective lens. To determine background
gating thresholds for colocalization analysis, we averaged the background signal from
triplicate images of either mock-infected cells stained using the GB03-BE08 mouse antiJUNV GP1/GPC antibody directly conjugated to Alexa Fluor 488 or JUNV C#1-infected
cells stained with the Alexa Fluor 647-conjugated goat anti-mouse secondary antibody
(gates are shown as white lines in the histogram in Figure 1L).

Flow Cytometry
Flow cytometry was utilized to screen, in cells expressing either WT or DN ERGIC-53,
whether JUNV C#1 GP (Figure 4B) or hTfR1 (Figure S4) was detectable at the plasma
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membrane and, if so, the median fluorescence intensity (MFI) of these respective signals.
In both cases, HEK 293T cells were seeded in 6-well dishes and transfected the next day
with plasmids encoding either Myc-tagged WT or DN ERGIC-53. To screen for surface
expression of JUNV C#1 GP, cells were inoculated the next day with JUNV C#1 at an
MOI of 1.0. At 72 hr post-inoculation the media was aspirated and cells detached from
the plates by incubating them with Versene (2 mM EDTA in PBS) for 15 minutes at
37oC. Cell pellets were washed 2 times with PBS and then surface stained for JUNV
GP1/GPC via incubation with a 1:100 dilution of the GB03-BE08 mouse anti-JUNV
GP1/GPC antibody directly conjugated to Alexa Fluor 488 in FACS buffer (PBS
containing 2% fetal bovine serum and 0.2% sodium azide) for 20 minutes at 4oC. Cells
were then washed 3 times in FACS buffer, fixed/permeabilized in BD Cytofix/Cytoperm
solution (554722, BD Biosciences, San Jose, CA) for 20 minutes at room temperature,
washed 2 times in BD Perm/Wash buffer (554723, BD Biosciences), then stained for
Myc-tagged WT or DN ERGIC-53 via a 20 minute incubation at 4oC with a mouse antiMyc antibody directly conjugated to Alexa Fluor 647 (2233, Cell Signaling) diluted
1:100 in Perm/Wash buffer. For the experiments looking at surface expression of hTfR1,
72 hr following transfection of the WT or DN ERGIC-53 plasmids, cells were collected
and stained as described for JUNV C#1 GP with the exception of replacing the mouseanti JUNV C#1 GP Alexa Fluor 488 antibody with a primary/secondary antibody
combination consisting of a 1:100 dilution of an unlabeled A4A6 mouse monoclonal antihTfR1antibody provided by J. Cook (University of Kansas Medical Center, Kansas City,
KS) and a 1:200 dilution of a goat anti-mouse antibody directly conjugated to R-
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Phycoerythrin (P852, Invitrogen). Data was acquired on an LSR II (BD Biosciences) and
analysis was done using FlowJo software (v9.6.2, TreeStar, Inc., Ashland, OR).
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3.1. Abstract
The Arenaviridae are a family of zoonotic viruses able to cause a severe and often
fatal disease in humans. Despite the morbidity and mortality caused by these pathogens,
no FDA approved vaccines or effective antivirals exist. The simplicity of the viral
proteome (4 ORFs from 2 RNA segments) suggests an extensive interplay between the
viral and host proteomes. Identifying these host proteins and understanding their roles in
viral replication and disease progression is a promising strategy to develop therapeutic
interventions for arenavirus disease. Accordingly, we demonstrate a three-part
macromolecular complex is formed by arenavirus envelope glycoproteins (GPs) and the
Endoplasmic Reticulum (ER)- Golgi Intermediate Compartment 53 kilo-Dalton protein/
Multiple Coagulation Factor Deficiency Protein 2 (ERGIC-53/MCFD2) intracellular
cargo receptor complex, which is involved in trafficking of a restricted number of
cellular glycoproteins in the early secretory pathway, including coagulation factors V and
VIII. Loss of MCFD2, or changing of its protein levels, though not affecting GP binding,
potently regulates the ERGIC-53-dependent function of the intracellular cargo receptor in
the production of infectious arenavirus, coronavirus, filovirus, and hantavirus particles.
We show that MCFD2 expression is upregulated during arenavirus infection; addition of
an O-glycosylated purified MCFD2 restricts virus propagation, and thereby represents a
novel candidate for antiviral development. Collectively, these findings provide insight
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into the biology of the ERGIC-53/MCFD2 axis in the extracellular space, and provide
additional functionality to the cargo receptor complex.
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3.2. Introduction
The Arenaviridae are a family of enveloped RNA viruses comprised of a number
of human pathogens found within rodent populations in a variety of global settings (1).
The zoonotic nature of the viruses, and the biology of their reservoir rodents (2, 3), has
resulted in the emergence of new and re-emergence of existing human pathogens (4).
Increased surveillance and detection capabilities have facilitated the detection of new
arenavirus species approximately every 2-3 years (5). As such, there is a clear need to
develop antiviral treatments for this family of viruses that cause significant morbidity and
mortality annually (6). The Arenaviridae is comprised of a single genus that is subdivided
into Old and New World groupings based on location, serological reactivity, and genome
similarity (7). Pathogens in the Old World arenavirus grouping include Lassa virus
(LASV), which is the predominant cause of human disease in the family (8, 9), and
Lymphocytic choriomeningitis virus (LCMV), an under-reported pathogen able to cause
aseptic meningitis as well as severe neurological abnormalities in a developing fetus (10,
11). Dandenong virus (DANV), an LCMV-like virus, along with LCMV, has been
associated with severe and highly fatal outcomes in cases of organ transplantation (1214). Pathogenic arenaviruses in the New World grouping include Junín, Chapare,
Guanarito, Machupo, and White Water Arroyo viruses, which cause a severe
hemorrhagic fever syndrome (1). Junín virus is unique amongst the Arenaviridae in that
an attenuated vaccine strain has been developed, JUNV Candid1 (15), which currently
has FDA investigational new drug (IND) status (16).
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The limited arenavirus proteome consists of: an RNA-dependent RNA
polymerase (L polymerase) responsible for viral genome transcription and replication, a
viral nucleoprotein (NP) which encapsidates the RNA genome, a small zinc-binding
matrix protein (Z) that drives budding and, along with NP, has been proposed to interfere
with cellular immune responses (17-19), and lastly a tripartite envelope glycoprotein
complex (SSP-GP1-GP2) formed from a precursor molecule (GPC) that is proteolyzed by
the host signal peptidase (SPase) (20, 21), and site-1 protease (S1P) (22) to form the
functional spike complex required for attachment and entry (17, 23). The simplicity of
the arenavirus proteome suggests that these viruses have evolved highly multifunctional
proteins that are able to effectively utilize a network of host-derived macromolecular
complexes to accomplish their entry (24-26), biosynthesis (21, 22), and exit strategies
(27) encoded for in such limited viral genomic space. We have recently utilized a
proteomics screen to identify human proteins in complex with a prototypic arenavirus GP
molecule. In doing so we uncovered a novel role for ERGIC-53 in the production of
infectious arenaviruses, coronaviruses, and filoviruses. We found that ERGIC-53, during
infection with an arenavirus, is relieved of its normal ER-ERGIC recycling program and
gets packaged into arenavirus particles. Viral particles lacking ERGIC-53 were found to
be non-infectious, in part, because of their inability to attach to host cells (28).
Given the importance of these findings for ERGIC-53 in viral propagation, and
knowing that the protein forms a receptor complex, we wished to further investigate the
function of the primary macromolecular complex formed by ERGIC-53 and MCFD2.
ERGIC-53 is a type 1 transmembrane protein that cycles continuously between the ER
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and ERGIC (29-31), under normal conditions, where it functions as an intracellular cargo
receptor. ERGIC-53 can require a soluble cofactor, MCFD2, for binding to and moving a
discreet subset of cellular glycoproteins via its calcium-sensitive lectin activity (32, 33).
The cellular ligands dependent upon the complete complex are the coagulation factors V
and VIII. Loss of ERGIC-53 in humans results in combined deficiencies of factor V and
VIII (OMIM 2273000), a rare and often mild hemophilia which results in low serum
concentration and activity of FV and FVIII (34, 35). A second genetic impairment
causing F5F8D has been identified in the MCFD2 locus (36). The resulting genetic
lesions result in either a loss of protein, or code for a protein no longer able to interact
with ERGIC-53 (37). The ERGIC-53 cargo receptor complex is maintained in a calciumdependent fashion via several intramolecular contact sites, and both Ca2+ and ligand
binding cause conformational changes in its structure (38, 39). ERGIC-53 is able to bind
to high mannose N-linked glycans in the absence of MCFD2 (40-42), however upon
MCFD2 binding, it has been reported that ERGIC-53 has a higher affinity for its cognate
glycans (43).
The precise molecular mechanisms involved in ERGIC-53’s role in arenavirus
attachment and entry are currently unknown. In the current study we have extended our
analysis of ERGIC-53’s function in arenavirus propagation to include the soluble
cofactor MCFD2, and show that a three-part complex is formed between the GP, ERGIC53 and MCFD2, that only occurs in the presence of ERGIC-53. We show that binding of
MCFD2, minimally, to ERGIC-53 regulates the function of the complex in arenavirus
propagation, and that MCFD2’s antiviral function is conserved across not only
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arenaviruses, but also coronavirus, filovirus, and hantavirus particles in a GP restricted
fashion. We demonstrate that the addition of exogenous MCFD2 neutralizes cell-free
arenaviruses, and also provide mechanistic insight into the orientation of the cargo
receptor complex on arenavirus particles through the use of super resolution imaging.
3.3. Methods
3.3.1. Antibodies, Cells, Viruses and Plasmids
The following antibodies were used: HA.11 Clone 16B12 mouse anti-HA (MMS101P, Covance Emeryville, CA) (1:4,000) was used to detect recombinant viral
glycoproteins in Western Blot assays. Mouse anti MCFD2 and rabbit anti ERGIC-53,
used in microscopic examination of endogenous MCFD2 and ERGIC-53 by confocal and
STORM applications respectively, were the generous gift of Bin Zhang and have been
previously described (28, 44). 9B11 mouse anti-Myc (2276, Cell Signaling, Danvers,
MA) (1:3000) was used to detect myc-MCFD2 in Western Blot assays. Calreticulin was
used as a calcium-sensitive lectin prey-control in Western blots and was detected using
rabbit anti (CRT) SPA-600 (Stressgen, Ann Arbor, MI) at 1:4,000. Mouse monoclonal
anti JUNV GP-1 QC03-BF11 and NP NA05-AG12 (NR-2566 and NR-2582, BEI
resources) were used to detect intracellular GP (confocal analysis) and C#1 particles (NP
dSTORM analysis). Recombinant ERGIC-53 was detected in Western blots using clone
M2 mouse anti-FLAG (1:3,000) (F1804, Sigma-Aldrich), and rabbit anti-ERGIC-53
antibody (sc-66880, Santa Cruz, Dallas, TX) (1:4,000) was used to detect endogenous
ERGIC-53 in Western blot assays. For a thorough description of each viral GP used :
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JUNV XJ GP, JUNV C#1 GP, LASV GP, SARS S, ANDV GP, EBOV GP, MARV GP,
FLUAV WSN33A HA, and VN HA, see the extended supplemental section of ref (28).

(28). JUNV C#1 was provided by R. Tesh (The University of Texas Medical Branch at
Galveston) and M. J. Buchmeier (University of California, Irvine) and DANV by W. I.
Lipkin (Columbia University).
Protein (GFP) in lieu of its own native G protein was provided by M. Whitt (The
University of Tennessee Health Science Center, Memphis TN).
All transfections were carried out using low-passage HEK293T/17 cells (CRL11268, American Type Culture Collection, Manassas, VA). HEK293T cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10%
fetal bovine serum, 1% Penicillin-Streptomycin, 1% MEM Non-Essential Amino Acids
solution, 1% GlutaMax, and buffered with 1% Hepes. All cell culture reagents were
purchased from Invitrogen (Carlsbad, CA). Vero cells were provided by J. Lindsay
Whitton (The Scripps Research Institute, La Jolla, CA) were cultivated in DMEM
supplemented with 10% FBS, 1% Penicillin-Streptomycin, and 1% Hepes. B-cells from
either a healthy donor (MCFD2

+/+

) (2829D) or from F5F8D patients with MCFD2

mutations CRC80 (c.149+5G>A (family A32)) and 1258 ( c.103delC (family A21)) have
been previously described (36) and were cultured in RPMI 1640 containing 10% FBS,
1% Penicillin-Streptomycin, and 1% Hepes.
3.3.2. Transfections
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All transfections were carried out using Polyethylenimine (PEI) (23966,
Polysciences,

3.3.3. Affinity Purifications
To determine the molecular basis for arenavirus glycoproteins binding to ERGIC53 and MCFD2 we transfected into sub-confluent HEK293T/17 cells a PCAGGS
expression plasmid previously described by Cornillez-Ty et al., into which we subcloned
JUNV C#1 GP [synthesized via Bio Basic Inc (Markhamm, ON)] along with a plasmid
encoding the bacterial biotin ligase BirA to ensure biotinylation of target GP molecules
within cells. ERGICet al., 2010 and Klaus et al., 2013); FLAG-ERGIC-

-

MCFD2 WT, D89A, and D129E were the generous gift of Bin Zhang (Cleveland Clinic,
Cleveland, OH) and have been previously described (Zheng et al., 2008) and (Klaus et
al., 2013), and were cotransfection, cultures were incubated for 48 hours at which point the cells were harvested
as previously described (28). Clarified lysates were incubated with streptavidin-coated
magnetic beads (Dynabeads MyOne Streptavidin T1, 65602, Invitrogen) at 4°C on a
rotating platform for 2.5 hr to allow binding of biotinylated bait-prey protein complexes.
The bead fractions were extensively washed with cold lysis buffer to remove unbound
proteins, and proteins were eluted via boiling in Lammli buffer supplemented with fresh
-mercaptoethanol to 5%. Captured proteins were then analyzed by SDS PAGE on
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Novex Tris-Glycine 4-20% precast gels (Invitrogen) and Western blot by probing for the
different bait-prey combinations.
Co-immunoprecipitations in which exogenously added sMCFD2 was used as bait
to examine its potential for binding ERGIC-53 released from cells, were carried out by
first collecting supernatant from JUNV C#1, or mock, infected HEK cells cultured in
Pro293 (protein free) medium (Lonza), and clarifying the supernatant of cellular debris
by two centrifugation steps each 15 minutes at 1500 rpm in a refrigerated centrifuge.
Following clarification, samples were pre-cleared of immunoglobulin binding proteins by
incubation with Protein G beads (Dynabeads Protein G beads, 1004D, Invitrogen).
n in a buffer containing PBS
supplemented with 0.05% BSA , 2.5 mM calcium chloride, and a Complete Mini EDTAFree Protease Inhibitor Cocktail tablet (04693159001 Roche Applied Science), buffered
with 1% Hepes pH 7.2. The supernatants were incubated for 2.5 hr on a rotating platform
in the cold. To immunoprecipitate sMCFD2-ERGIC-53 protein complexes, mouse anti
MYC mAb was added to each sample, and incubated for an additional 2 hr. Following
the antibody incubation, Protein G magnetic beads were added to each condition and
incubated for an additional 2 hr. Following extensive washing with cold wash buffer to
remove non-specific bound proteins, the sMCFD2 captured complexes were concentrated
on a magnetic column and then eluted by boiling in Lammeli buffer wit

-Me.

Samples were then analyzed by SDS PAGE and Western blot for myc-MCFD2 (bait) and
ERGIC-53 (prey).
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3.3.4. SDS PAGE and Immunoblotting
SDS PAGE and Immunoblot analysis was performed as described by Klaus et al., 2013.

3.3.5. Production of sMCFD2
Purification of secreted human MCFD2 was accomplished by transfecting into a
T-75 flask of sub-confluent HEKs, a modified PCAGGS plasmid encoding human
MCFD2 containing a 6X His tag and MYC tag (sub-cloned from pcDNA3.1 MCFD2
Zhang et al., 2008). Cells were allowed to recover for 2 days, were then trypsinized and
re-seeded into 2 T-150 flasks. After 1 day of recovery the medium was removed, cells
were washed once with PBS, and then replenished with Pro293 medium (Lonza) and
incubated for 2 days prior to harvesting. Following 2 centrifugation steps, to remove any
cellular debris (6000 g for 15 min), 5X Qiagen start buffer was added to the collected
production medium, containing the secreted MCFD2, to yield a final concentration of 1X
Qiagen start buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 20 mM imidazole, 10%
glycerol and 0.05% sodium azide). The His tagged sMCFD2 was then captured by
passage over a Qiagen Ni-NTA column (8 mL of resin, 2 mL/min). The column was
attached to a BioCad Sprint system (Applied Biosystems) allowing for continuous
monitoring of the absorbance at 280 nm, the conductivity, and the pH. Following sample
loading, the column was washed with start buffer until the baseline returned to the
background level (< 0.1 A280 units).

The sMCFD2 was eluted with start buffer

containing 250 mM imidazole and 3 mL fractions were collected. The absorbance of each
fraction at 280 nm was determined on a Cary 100 spectrophotometer. Fractions were
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screened via Western blot to identify samples containing myc-MCFD2 which were
subsequently pooled. Pooled fractions were then concentrated using 10 kDa MWCO
Ultracel microconcentrators to a concentration of 1 mg/mL, stored in Hepes-buffered
PBS supplemented with 1 mM calcium chloride, and stored at 4° until use.
3.3.6. Microscopy
2-color confocal microscopy analysis was completed as previously described (28).
Briefly, for analysis of intracellular JUNV C#1 GP and MCFD2, HEK293T cells were
seeded onto 12 mm glass coverslips (Thermo Scientific), and infected the following day
with JUNV C#1 at a multiplicity of infection of 0.1. At 72 hours post-infection cells were
washed with PBS, and fixed using 4% paraformaldehyde (PFA) for 30 minutes at room
temperature followed by extensive washing with PBS to remove excess PFA. Cells were
permeabilized in a buffer containing 0.1% Triton-X 100 and 0.1% bovine serum albumin
(BSA). A blocking step was carried out for 30 minutes at room temperature in a buffer
containing 1% BSA and 10% normal goat serum (NGS). Mouse anti MCFD2 mAb was
used at a dilution of 1:2000, incubated overnight at 4°, and then antibody binding
revealed with Alexa Fluor 647-conjugated goat anti-mouse IgG (H+L) (A-21236,
Invitrogen) at a dilution of 1:800. JUNV GP was stained using mouse monoclonal anti
JUNV GP-1 QC03-BF11 directly conjugated to Alexa Fluor 488 (Invitrogen) at a dilution
of 1:50. Nuclei were visualized via 4’, 6-diamidino-2-phenylindole hydrochloride (DAPI)
(D9542, Sigma Aldrich) staining, and slides were mounted using ProLong Gold Antifade
Reagent (P36934, Invitrogen). Cells were imaged using a Zeiss LSM 510 META Laser
Scanning Confocal Microscope housed in the UVM Microscopy Imaging Center. Images
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were acquired using a 63X lens with a numerical aperature of 1.4 with the optical zoom
set to 1.5X. Using the AIM software suite images were captured at 1 airy unit, with gain
settings for 488 and 647 signals balanced based on either mock infected controls (GP488) or secondary only controls (MCFD2-647).
For visualizing JUNV C#1 virions containing three fluorophores

using 2-

dimensional (2D) and 3-dimernsional (3D) direct stochastic optical reconstruction
microscopy (2D and 3D 3dSTORM), clarified supernatant from JUNV C#1 (containing
1.0 x 107 PFU/mL virus), or mock infected cells was incubated for 2 hr at 37° in 35 mm
glass bottom culture dishes (P356-1.5-10-C, MatTek Corporation, Ashland, MA)
pretreated with 0.01% Poly-L-Lysine (3438-100-01, Trevigen, Gaithersburg, MD).
Following adsorption, the dishes were fixed using 4% PFA for 30 minutes at room
temperature and then washed extensively to remove excess PFA. The virions were then
permeabilized in a buffer containing 0.1% Triton-X100 with 0.1% BSA for 10 minutes at
room temperature and washed 3x in buffer containing PBS with 0.1% BSA. A blocking
step was carried out with PBS containing 1% BSA and 10% NGS for 30 minutes at room
temperature.
Staining of virions was accomplished by first bathing the dishes with sMCFD2
2,

for 4 hours at 4° C. Dishes were then washed with buffer AB 3-times, before incubation
with a mouse anti myc mAb, recognizing sMCFD2, at 1:50, and a rabbit polyclonal
antibody recognizing ERGIC-53, at 1:50 for 2 hours at 4°C. The dishes were then washed
3-times in buffer AB, and incubated with Alexa Fluor 647-conjugated goat anti-rabbit
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IgG (H+L) (Invitrogen) to reveal ERGIC-53 staining, and Alexa Fluor 568-conjugated
goat anti-mouse IgG (H+L) (Invitrogen) to reveal sMCFD2, at 1:100, respectively for 2
hr 4° C. Following 3 additional washes in Buffer AB, JUNV NP staining was
accomplished by incubating dishes with a biotin-conjugated mAb NA05-AG12
recognizing JUNV NP at a dilution of 1:50 for 2 hours at 4 degrees. Dishes were washed
3 additional times in buffer AB before NP was counter-stained with Alexa Fluor 488
conjugated streptavidin (Invitrogen) at a dilution of 1:100 in buffer AB for 2 hr at 4° C.
Plates were then washed 3-times with PBS and stored at 4°C prior to imaging.
We have developed a method for the visualization of three fluorophores all using
direct STORM (dSTORM) methodology. The Nikon N-STORM super-resolution
microscope system consists of a Nikon Eclipse Ti-E TIRF inverted microscope base with
laser modules delivering excitation at 405 nm, 488 nm, 561 nm, and 647 nm, and a high
sensitivity Andor iXON3 DU897 EMCCD camera. Theoretically, this instrument
provides resolution in the fluorescence mode of 20 nm lateral dimension and 50 nm axial
dimensions. For the triple dSTORM protocol, the following parameters were chosen:
100X, 1.45 NA objective lens; 64 X 64 pixel frame size; EM gain 10MHz at 14 bit, EM
gain multiplier 300, and 1X conversion gain; auto exposure 1 frame, and no binning.
TIRF setting of illumination was determined to be 4100 using 647 nm laser excitation.
Images were acquired using N-STORM “normal mode” setting with 0 activation cycles
and 2 reporter cycles. A STORM quad cube (Nikon part # 260319) was inserted into the
microscope turret to separate the three fluorescence signals. Sequential order of activation
was 488 nm (62 mWatts), followed by 647 nm (33 mWatts), and finally 561 nm (59
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mWatts). Following acquisition of 15,000-30,000 frames, the data were rendered into a
super-resolution image using a Gaussian distribution function. For three-dimensional
image acquisition, an astigmatic lens was inserted into the microscope beam path. Image
processing and display were accomplished with NIS Elements software.
All images were acquired in an oxygen scavenging buffer system containing
glucose oxidase (G2133, Sigma) and catalase (C30, Sigma) in 50mM Tris-HCl, with 10%
glucose, and 0.1M cysteamine (30070, Sigma) that was prepared fresh prior to each
imaging session.

3.3.7. Viral challenge assays
Viral challenge assays to assess the role of MCFD2 were conducted as previously
described (28). Briefly, to assess the consequences of plasmid over expression of MCFD2
(figure 1), HEK293T cells were seeded in 24 well plates (Fisher) and allowed to adhere
for 24 hr at which time they were transfected with a plasmid encoding WT MCFD2, or
with an empty plasmid, and incubated overnight. The following day monolayers were
infected with JUNV C#1 at a multiplicity of infection of 0.1, or with DANV at a
multiplicity of infection of 0.001, and the viruses were allowed to adsorb for 1 hour at
37° C. Following viral adsorption, monolayers were washed extensively with
maintenance medium and returned to the incubator. At 48 and 72 hours post-infection,
the supernatant was harvested, clarified by centrifugation for 5 minutes at 1500 rpm,
transferred to a fresh Eppendorf tube, and stored for determination of PFU by standard
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plaque assay on Vero E6 cells. Results were tested for statistical significance using the
Student’s unpaired t-test where p values < .05 were considered significant.
Viral challenge assays to determine the respective contributions of ERGIC-53’s
CRD features were carried out as described above with minor modifications.
Combinations of plasmids that were transfected were balanced with an equal
concentration of an empty vector where indicated (figure 3).
Viral challenge assays to assess the ability of EBV-transformed B cells from a
healthy donor (2829D) or 2 MCFD2 null F5F8D patients (CRC-79 and 1258) to produce
infectious arenavirus were conducted by infecting equal numbers of cells with JUNV C#1
in a low volume at a multiplicity of infection of 1. Viral adsorption was carried out at 37°
C for 2 hours at which time the cells were gently pelleted and inoculums were removed.
The cells were then washed 3-times with PBS with each wash being followed by a low
speed centrifugation step (1200 rpm for 5 minutes). Infected cells were then plated in a
24 well culture dish in complete RPMI medium, and returned to the incubator. After 72
hours the post infection supernatants were harvested via centrifugation (1200 rpm for
minutes), and the clarified supernatants stored at -80° C until determination of PFU
content by standard plaque assay on Vero E6 cells.

3.4. Results
3.4.1. MCFD2 is a negative regulator of arenavirus propagation
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It is well established that ERGIC-53 plays a critical role in production of
infectious arenavirus particles: since it forms a complex, we wanted to explore the role of
the macromolecular cargo receptor complex formed between ERGIC-53 and MCFD2.
We hypothesized that by increasing MCFD2 expression levels, an enhancement in viral
propagation, similar to one observed following ERGIC-53 overexpression, would occur.
We transiently overexpressed WT MCFD2 in HEK293T cells, and tested the impact of its
expression on a representative New and Old world arenavirus (Junín virus Candid1 (C#1)
and Dandenong virus (DANV)). In striking contrast to the effect of overexpressed
ERGIC-53, increased expression of MCFD2 led to a potent decrease in the generation of
infectious C#1 at 48 and 72 hours post infection (75.22% p = 0.001 and 48.7%
reduction p = 0.0116, respectively) as well as DANV at 48 hpi (83.7% reduction p =
0.0001), strongly suggesting a conserved and restrictive effect in both Old and New
World arenavirus propagation (Fig 1C-D). Thus, MCFD2 and ERGIC-53 have a
divergent contribution to arenavirus propagation.
3.4.2. JUNV C#1 propagation is enhanced in cells from F5F8D patients who are
MCFD2 null
We have previously reported that the production of infectious C#1 particles is
impaired in B cells derived from ERGIC-53 null F5F8D patients (28). Given the
divergent influence of MCFD2 overexpression in arenavirus propagation compared to
ERGIC-53’s, we next wanted to examine the effect on arenavirus replication in B cells
derived from two unrelated F5F8D patients who had WT ERGIC-53, but were null for
MCFD2 (1258 and CRC80 – family A21 and A32 (36)). A healthy MCFD2 WT (2829D)
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donor served as a neccesary control. Cells from each donor were challenged with C#1 to
determine whether loss of MCFD2 would affect the production of infectious virus.
Surprisingly, loss of MFD2 in these cells resulted in an increase in the release of
infectious virus at 72 hpi (141.2% and 988.3% increase CRC80 and 1258 p < 0.0001 and
p = 0.049, respectively) (figure 1D), thereby adding support to the antiviral role of the
molecule.
3.4.3. MCFD2 forms a tripartite complex with ERGIC-53 and viral glycoproteins
We have previously reported the conserved association of ERGIC-53 with envelope GPs
encoded by arenaviruses, coronaviruses, filoviruses, hantaviruses, and orthomyxoviruses (28).
MCFD2 has likewise been reported to associate with ERGIC-53, and is required for efficient
secretion of blood coagulation factors (F)V and FVIII (32, 39, 45). Using a biotin-streptavidin
affinity purification technique (46), we therefore wanted to test whether MCFD2 would associate
with an arenavirus glycoprotein, or if the viral GP by interacting with ERGIC-53, precluded its
binding to MCFD2. HEK 293T cells were co-transfected with plasmids encoding the JUNV C#1
GP and the bacterial biotin ligase BirA to ensure in-situ biotinylation of the GP, along with either
WT ERGIC-53, WT MCFD2, or CRD mutants of ERGIC-MCFD2 binding)) and as an internal control ERGICMCFD2 (D89A and D129E) unable to bind ERGIC-53 (37) because of changes in tertiary
structure (38), which are sufficient to cause F5F8D (36). Biotinylated C#1 GP efficiently
precipitated WT MCFD2 in the presence of WT ERGIC-53, but not ERGIC-

which lacks

the ability to bind MCFD2 (37) (Fig 1F), suggesting that ERGIC-53 links MCFD2 to C#1 GP
indirectly.
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In validation of the requirement of ERGIC-53 to form the three-part complex, when
ERGIC-

-expressed in cells, which is unable to interact with JUNV GP, WT

MCFD2 did not precipitate with C#1 GP (Fig 1F). MCFD2 binding was then restored following
expression of ERGIC(aa 47-60) for the formation of the complex. Conversely, when JUNV GP precipitated WT
ERGIC-53 in cells also expressing either of the two inactivating MCFD2 mutants (D89A and
D129E), no MCFD2 was detected in the complex. These data indicate that MCFD2 forms an
ERGIC-53 dependent complex with C#1 GP that minimally requires MCFD2 EF-hand residues
D89 and D129 as well as ERGIC-53 CRD residues 47-60.

3.4.4. MCFD2 trafficking during infection with an arenavirus
To confirm the biochemical data suggesting a multi-protein complex between JUNV C#1
GP and MCFD2, and to visualize the intracellular distribution of these proteins, we performed 2color confocal microscopy analysis on cells infected, or not, with Candid1 72 hr post-infection
(hpi). At 72 hpi, infected cells demonstrated a profound shift in the intracellular concentration and
localization of MCFD2 compared to uninfected cells (Figure 1F). The intracellular pool of
MCFD2 was found to concentrate with JUNV GP, within the structure we have putatively
identified as the ERGIC (figure 1F and data not shown). Compared to the mock-infected control
cells, a marked increase in MCFD2 was observed primarily within the ERGIC and punctate
transport vesicles. These data demonstrate a virus-specific upregulation of MCFD2 expression
and coordinated trafficking of MCFD2 to sites of GP concentration.

3.4.5. ERGIC-53/MCFD2 receptor complex has a conserved interaction with viral
GPs
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Given the broad extent of ERGIC-53’s association with viral envelope glycoproteins, we
next examined whether MCFD2 could also form a complex with additional envelope
glycoproteins from arenaviruses (JUNV XJ and Lassa Virus (LASV) GP), hantaviruses (ANDV
GP), as well as severe acute respiratory syndrome coronavirus (SARS CoV S), orthomyxoviruses
(HA proteins from FLUAV WSN and VN (H1 & H5)), filoviruses (Ebola virus and Marburg
virus (EBOV & MARV)), and finally a rhabdovirus envelope from vesicular stomatitis virus
(VSV G) (figure 2A). All envelope glycoproteins tested, with the exception of VSV G , were
found to complex with both ERGIC-53 and MCFD2 clearly showing that the ERGIC-53 :
MCFD2 molecular complex has a highly conserved but specific biochemical affinity for viral
glycoproteins (Fig 2A).

3.4.6. MCFD2’s antiviral action is highly conserved and restricted by the GP
To assess the conservation of MCFD2’s regulation of viral propagation, and to
determine whether the molecular activity of MCFD2 can be restricted to the envelope
glycoprotein : ERGIC-53 complex, we employed a vesicular stomatitis virus (VSV)
pseudotyping approach whereby cells overexpressing MCFD2, or not, were transfected
with plasmids encoding GPs representing a subset of those able to form a complex with
ERGIC-53 and MCFD2 (Figure 2A). Specifically, GPs from JUNV, SARS, ANDV,
MARV, EBOV, and as a control VSV. Cells were infected a day later with pre-made
VSV pseudo-particles

(47). The resulting pseudotyped
or ANDV GP)

generated from cells overexpressing MCFD2 (75.68 % p = 0.005; 71.01% p = .0152;
55.26 % p = 0.0238; 56.61 % p = 0.0277; 68.18% p = 0.0142 reduction, respectively), but
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not the empty control plasmid, were similarly restricted as with bona fide New and Old
W

was unaffected by MCFD2

(Figure 2B). The pseudo-particle experiments indicate a highly conserved antiviral
mechanism of action of MCFD2 across arenavirus, coronavirus, filovirus, and hantavirus
particles that can be restricted to the presence of their respective envelope glycoproteins.
3.4.7. MCFD2 controls ERGIC-53 function in arenavirus propagation
Because MCFD2 associates with arenavirus GPs in an ERGIC-53 dependent
fashion (Figure 1F), and ERGIC-53 interacts with the arenavirus GP via its carbohydrate
recognition domain (28), we designed a series of challenge experiments to tease apart the
relative contributions of the molecular complex. We first wished to assess the role of
ERGIC-53’s entire CRD, which contains 3 non-overlapping regions: the GP binding
region (Figure 1F), the MCFD2 binding site (45), and the sugar binding cleft (48), in
arenavirus propagation. We therefore transfected cells with either: (i) a plasmid in which
the CRD has been entirely deleted

CRD), or as a control, plasmids encoding either (ii)

WT ERGIC-53 (known to enhance C#1 replication), (iii) WT MCFD2, (iv) or an empty
plasmid, and infected the cells a day later with JUNV C#1. At 48 hpi, in cells making an
ERGIC-53 which can no longer bind to GP, sugar, or MCFD2

CRD), there was a

reduction in the amount of infectious virus produced (61.95% reduction p = 0.0002)
(Figure 3A). Likewise, when MCFD2 is in excess, there is a net reduction in the release
of infectious virus (Figures 1A-C, and Figure 3A).
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We next wished to test the individual contributions of ERGIC-53’s binding
partners (e.g. MCFD2 and carbohydrate) to the ERGIC-53 mechanism of action on
arenavirus replication. Given the CRD requirement for binding to GP, MCFD2, and
carbohydrates, we designed an experiment in which we infected HEK293T cells that had
been co-transfected with either an empty plasmid, or plasmids making WT ERGIC-53,
ERGIC-53

(non-MCFD2 binding), ERGIC-53

(non-MCFD2 and non-sugar

binding), or N156A (non-sugar binding), in tandem with WT MCFD2 (to ensure the
opportunity for the cargo receptor complex to form). Association of MCFD2 with
ERGIC-53 is known to increase its ability to bind to N-linked glycans (43). Accordingly,
expression of ERGIC-53

cannot bind to carbohydrate or MCFD2,

diminished the replication of JUNV C#1 (figure 3A). ERGIC-53 lacking MCFD2
was unable to inhibit viral propagation (28.26% reduction, p = 0.09 (ns)), or MCFD2 and
carbohydrate b

less efficient at inhibiting viral propagation

(61.96% reduction, p = 0.0067), respectively. Therefore, these results suggest that an
MCFD2-dependent allosteric regulation of ERGIC-53’s lectin activity could be
contributing to diminished viral propagation. Finally, ERGIC-53 N156A, unable to bind
carbohydrate, but able to bind MCFD2, was also able to diminish viral propagation
(84.89% reduction, p = 0.0012). Collectively these data suggest a potent negative
regulatory role for MCFD2 in the propagation of arenaviruses that is exerting its effect
via an association with ERGIC-53 (potentially by altering its lectin activities).
3.4.8. Secretory MCFD2 can interact with ERGIC-53 in the extracellular space
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It has been suggested that ERGIC-53 plays a role in the attachment of arenavirus
particles to the surface of permissive cells. We were then interested in determining
whether we could utilize the binding of MCFD2 to secreted ERGIC-53 to alter the entry
of an arenavirus. In doing so we could more precisely establish the properties of an
ERGIC-53-dependent antiviral mechanism of action by MCFD2 in arenavirus
propagation. Specifically, we wanted to first test if a purified recombinant MCFD2
secreted from HEK cells (Fig S1A-B) would interact with ERGIC-53 in the extracellular
space. The secreted form of MCFD2 (sMCFD2), in mammalian cells, is heavily Oglycosylated (49). Our purified protein migrated at approximately 28 kDa, consistent
with the multiple additions of O-linked glycans in accordance with previous reports. To
test whether sMCFD2 was capable of directly binding to ERGIC-53 we utilized a coimmunoprecipitation (Co-IP) technique whereby sMCFD2 was used to co-purify ERGIC53 secreted from JUNV C#1 infected or mock infected cells (virus and exosome or
exosome only). Culture fluid from infected and mock infected cultures was sequentially
incubated with soluble recombinant MCFD2 (sMCFD2), followed by an antibody
recognizing the C-terminal Myc tag of recombinant protein, and Protein-G coated
magnetic beads. Recombinant sMCFD2 was able to co-purify ERGIC-53 from the
supernatant under both conditions, indicating that the complex was stable outside of the
secretory pathway, and that the post-translational modification of MCFD2 (O-linked
glycosylation) did not prevent the formation of the cargo receptor complex (Figure 4A).
3.4.9. MCFD2 neutralizes arenavirus particles
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Having demonstrated that sMCFD2 could interact with ERGIC-53 released from
cells, and knowing that ERGIC-53 affects the attachment and entry of arenaviruses, we
next wanted to determine if sMCFD2 could exert an effect on arenavirus entry via its
association with ERGIC-53. To test this we pre-incubated C#1 and or DANV with
purified sMCFD2, or a vehicle control, to allow for the formation of protein complexes.
Following addition of pre-complexed sMCFD2 – virions to cells, we then tested for an
impact on virus production at 72 (C#1) and 48 (DANV) hpi. In both cases there was a
potent inhibitory effect on the production of infectious virus; JUNV C#1 ( 90.32%
reduction, p = 0.0223) and DANV (94.88% reduction, p = 0.0038) (Fig 4 C-D).
To confirm whether sMCFD2 was capable of directly binding to an arenavirus we
utilized a 2D and 3D, triple color, direct stochastic optical reconstruction microscopy
(2D and 3D 3dSTORM) approach to visualize, at a sub-diffraction level, the spatial
arrangement of purified sMCFD2 pre-complexed with arenavirus virions (C#1) adhered
to Poly-L-Lysine-treated matTek dishes. The virions, visualized via nucleoprotein (NP)
staining, revealed sMCFD2 arranged in clusters of ~ 200-500 nm rings, along with
ERGIC-53, that were surrounding the densely packed arenavirus NP core (Fig 4 C-D).
3.5. Discussion
The ERGIC-53-MCFD2 receptor complex consists of equal molar ratios of the
type I transmembrane sorting lectin, as well as the soluble EF-hand containing molecule
MCFD2 (32, 38). We have previously shown that ERGIC-53’s ability to bind to viral
glycoproteins occurs in the C-terminus of the carbohydrate recognition domain (CRD)
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independently of MCFD2 (28). In the current study, we refined and extended those
findings to include the greater macromolecular cargo receptor complex, and found that a
tripartite complex was formed between ERGIC-53, MCFD2 and the GPs of arenaviruses,
coronaviruses, filoviruses, hantaviruses, and orthomyxoviruses, and that MCFD2’s
interaction was contingent upon ERGIC-53 binding to the GPs (Figure 1F and 2B). The
formation of the complex was also found to require functional EF-hand domains of
MCFD2 (Figure 1F), which supports the existing model of ERGIC-53-MCFD2
interactions (37, 38).
The unexpected antiviral activity of MCFD2 was demonstrated to occur via
several lines of evidence. First, cells from MCFD2 null F5F8D patients (50) were more
adept at producing infectious JUNV (Figure 1D), in contrast to our previous studies on
ERGIC-53 null cells (28). Second, plasmid-driven overexpression of MCFD2 was able to
inhibit the production of bonafide NW and OW arenavirus particles (Figure 1A-C), and
we were able to restrict the impact of MCFD2 overexpression on viral propagation to the
arenavirus GP independent of the remaining arenavirus core (Figure 2 A-B). VSV
pseudoparticles bearing not only arenavirus, but also coronavirus, filovirus, and
hantavirus GPs were likewise inhibited by the increased expression of MCFD2 in a GP
specific manner which indicates a basic and highly conserved mechanism of action
(Figure 2A-B). Third, infection with an arenavirus greatly enhanced the expression of
MCFD2, and concentrated it in the structure we and others have identified as the ERGIC
(Figure 1F) (51). These data are in agreement with previous studies of an arenavirus
infected non-human primate where MCFD2 was shown to be transcriptionally
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upregulated nearly 15-fold in the liver (52) which surpasses the transcriptional
upregulation of ERGIC-53 in the same study. Lastly, exogenously supplied soluble
MCFD2 was able to interact with individual arenavirus particles, visualized at subdiffraction limited resolution, and pre-complexed virus was deficient in its ability to
successfully initiate a new round of propagation (Figure 4A).
How is MCFD2 regulated intracellularly, and how does this affect arenavirus
propagation? We and others have observed that MCFD2, following escape from a
presumed ERGIC-53 retention system (MCFD2 lacks a known ER retention signal), can
become O-glycosylated, and is secreted into the extracellular space (32, 49, 53). In
accordance with this, following expression of mutants of ERGIC-53 unable to retain
MCFD2 within cells, (Fig1A and data not shown) depletion in the intercellular MCFD2
pool was observed. The increased expression of MCFD2 leads to the efficient secretion
of the molecule (Figure S1). Based on this we suggest that an upregulated and secreted
MCFD2 may be able to allosterically regulate ERGIC-53’s lectin activity, and that
changes in ERGIC-53’s lectin activity could regulate the infectivity of viral particles
(Figure 3A-B and 4A-C). Interestingly, it has been reported that MCFD2 interacts with
ERGIC-53 via 2 separate sites (38), which could imply alternative functions of ERGIC53 based on MCFD2 site usage. However, several other possibilities exist, including
MCFD2 regulating a crucial intracellular GP maturation event that requires the ERGIC53-MCFD2 complex. Alternatively, MCFD2 may be ligating an, as of yet unknown,
surface receptor with antiviral potential. The presence and structure of O-linked glycans
on sMCFD2 may also contribute to the structure-function relationship of the two
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molecules in the complex, however, to date, most biochemical and structural analyses
have utilized the de-glycosylated form of MCFD2.
The intracellular regulation thus far reported for MCFD2 is largely dependent
upon ERGIC-53 (54), its expression levels, and intracellular location (in terms of
binding, the compartment its located in, and calcium levels) (32). The unique
upregulation seen during arenavirus infection suggests that the transcriptional or
translation regulation for MCFD2 is likely to possess elements distinct from the ER stress
response element within ERGIC-53’s promoter region (55). In support of this notion,
Toda and colleagues noticed an upregulation of MCFD2 (which they refer to as Stem
Cell-derived Neural Stem/Progenitor Cell Supporting Factor (SDNSF)) following
ischemic treatment and FGF-2 withdrawal of primary rat hippocampal cultures (53). The
increased expression of both ERGIC-53 and MCFD2 seen during heat shock (54), also
could have implications in protein folding and secretion during the insidious febrile phase
of an arenavirus infection (or other viral infections). Additionally, the stimulation of the
ATF-6 branch of the unfolded protein response is known to be selectively initiated via
LCMV GP (56), and also upregulates both ERGIC-53 and MCFD2 (55). Lastly, during
Juinn virus infection, it has been reported that levels of nitric oxide are increased (57)
which are also known to upregulate both ERGIC-53 and MCFD2 (58). The consequence
of these combined stimuli on MCFD2 transcriptional control, and its regulation of viral
propagation, however, remains unsolved.
The binding of an arenavirus GP to a site within the CRD that is distinct from the
sugar-binding region, preserves the lectin function of ERGIC-53, presumably to the
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benefit of the virus. Accordingly, when the CRD was removed from ERGIC-53
expressed in a viral challenge assay, a concomitant reduction in arenavirus propagation

expressed in addition to MCFD2 overexpression, a dampening in the MCFD2-mediated
regulation occurred (Figure 3A-B), suggesting MCFD2 acts through the CRD to alter
arenavirus propagation. The strategy of utilization of host-machinery, particularly in NW
arenavirus entry, by engaging in non-essential areas of the host-molecule, has been
elegantly shown for the transferrin receptor 1 (59, 60). NW arenaviruses GPs have
evolved to utilize this highly expressed surface receptor at a site distinct from its ligand
binding site. The interaction of arenavirus GPs with ERGIC-53 and MCFD2 may follow
a similar strategy.
Our findings provide a proof of principle that targeting ERGIC-53’s lectin
activity, via its known cofactor MCFD2, is an attractive therapeutic approach for treating
arenavirus infections (Figure 4A-C). Given the conservation of the MCFD2-dependent
antiviral activity with not only arenaviruses, but also coronaviruses, filoviruses, and
hantaviruses (Figure 2A-B), the molecule may represent a valuable broad-spectrum
antiviral target. Further, the enhanced expression of MCFD2 during arenavirus infection
(Figure 1E) (52) may suggest that MCFD2 is acting as an antiviral signaling molecule
following its upregulation, if it is indeed secreted under these circumstances. MCFD2,
when added to neuron slice cultures, has been recently reported to cause a signaling event
contributing to the maintenance of adult neuronal stem ccll populations (53, 61)
suggesting it may have inherent signaling capabilities. It is of interest to determine if
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sMCFD2 can be detected in the serum of VHF patients during the acute phase of
infection, which would support a cytokine-like signaling potential.
The presence of ERGIC-53 in the extracellular space, in the context of both virus
(28) and exosomes (62, 63), and MCFD2s ability to engage and interact with ERGIC-53
there (Figure 4A), could alter the activity of the cargo receptor complex via its binding to
the blood coagulation factors FV or FVIII. Although this process is poorly understood,
FV after it is secreted, is endocytosed and stored within alpha granules in
megakaryocytes (64), which is interestingly a site of JUNV replication (65). Our current
understanding of the role of ERGIC-53 and MCFD2 in clotting factor biogenesis and
activity has been limited to their interactions in the early secretory pathway. One
potential role of the ERGIC-53-MCFD2 complex in the extracellular space could be to
assist in the targeting or endocytosis of the clotting factors. Accordingly, the C-terminus
of ERGIC-53 contains a signal involved in endocytic uptake, as well as targeting (66,
67), and F5F8D patients have been demonstrated with deficiencies not only in circulating
levels of FV and FVIII, but in the endocytosed fraction found in platelets (68).
Alternatively, during virion biogenesis and budding, disruption of the complex biogenic
process of FV and FVIII, by direct GP competition for ERGIC-53/MCFD2, could also
contribute to the bleeding abnormalities observed during infection with an arenavirus; a
process that is likewise poorly characterized and understood (69, 70).
Last, the paradoxical and diametrically opposed phenotypes driven by loss of
ERGIC-53 versus MCFD2 may suggest opposing evolutionary selective pressures from
the side of host (MCFD2) versus virus (ERGIC-53). Interestingly, the prevalence of
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MCFD2 genetic abnormalities in F5F8D is substantially less than those caused by
ERGIC-53 lesions (70% vs 30%) (34, 50). Since loss of MCFD2 could lead to
individuals within the human population being more susceptible to infection (Figure 1D),
this could select against maintenance of diseased alleles within the human genome.
Interestingly, F5F8D caused by disruptions in MCFD2 have also been shown to have a
modest, but significant, increase in phenotypic severity (e.g. lower levels of FV and
FVIII in the plasma) (68). Epidemiological studies of F5F8D, as well as immunological
assessment of the different F5F8D populations will be required, however, before a firm
understanding of the evolutionary forces at work on the ERGIC-53 macromolecular
receptor complex can be assessed.
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3.7. Figure legends
Figure 3.1 MCFD2 is an arenavirus restriction factor that forms a tripartite
complex with ERGIC-53 and JUNV GP:
(A-C) Overexpression of WT MCFD2 leads to impairment in production of infectious
JUNV C#1 and DANV. HEK293T cells were transfected with a plasmid encoding
MCFD2 or an empty plasmid. 24 hr. following transfection, cells were infected with
JUNV C#1 at an MOI of 0.1, or DANV at an MOI of 0.001, and after 48 or 72 hour post208

infection (hpi) supernatants were screened for number of plaque forming units (PFU) by
a standard plaque assay on Vero E6 cells. Data are from replicate experiments (n=6, 48
hpi C#1 and n= 3 DANV, n=6 72 hpi C#1) and are presented as mean PFU ± SEM
relative to the cells receiving the empty vector.
(D) Production of infectious JUNV C#1 is enhanced in MCFD2 null cells. EBV
transformed lymphoblastoid cells from a healthy MCFD2 +/+ donor (2829D) and MCFD2
-/-

individuals with F5F8D (CRC-80 and 1258) were challenged with JUNV C#1 at an

MOI of 1.0 and 72 hpi supernatants were screened for PFU via plaque assay. Data are
presented as mean PFU ± SEM relative to the MCFD2 +/+ cells. Data are representative of
two independent experiments (n=6 per condition per experiment).
(E) MCFD2 expression and trafficking during infection with an arenavirus. HEK293T
infected cells infected with JUNV C#1 were fixed 72 hpi and stained internally for JUNV
GP (green) and MCFD2 (red) and visualized by confocal microscopy. The image is
representative of a minimum of 10 fields of view. Background signal was subtracted via
gain reduction based on values obtained from secondary antibody alone (MCFD2) or
mock infected cells (GP).
(F). MCFD2 forms an ERGIC-53 dependent tripartite complex with JUNV C#1 GP that
requires MCFD2 EF-hand residues 89 and 129. HEK293T cells were co-transfected with
a modified PCAGGS vector (pCC384) encoding JUNV C#1 GP with a carboxy-terminal
biotin acceptor peptide (BAP), for efficient streptavidin based purification, and an HA
epitope used for detection of GPC and GP2 by Western blot; a bacterial biotin ligase,
BirA, to ensure in-situ biotinylation, and plasmids encoding the indicated versions of
ERGIC-53 and MCFD2. Biotinylated proteins were isolated using streptavidin coated
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beads, and purified complexes were eluted and analyzed by SDS PAGE and Western blot
detection of GPC/GP2 (bait), FLAG-ERGIC-53 (prey), MYC-MCFD2 (prey), and CRT
as a control.

Figure 3.2 MCFD2 antiviral action is conserved across multiple pathogenic RNA
viruses and is specific to the viral GP.
(A) MCFD2 forms a tripartite complex with arenavirus, coronavirus, filovirus,
hantavirus, and orthomyxovirus envelope glycoproteins. HEK293T cells were cotransfected with modified PCAGSS vectors (pCC384) with carboxy terminal BAP and
HA features for purification and detection procedures encoding the respective viral GPs:
LASV GP, JUNV XJ GP, ANDV GP, EBOV GP, MARV GP, SARS S, VN HA (H5),
WSN HA (H1), and VSV G, along with WT ERGIC-53 and MCFD2, as well as BirA to
ensure in-situ biotinylation. Streptavidin precipitated GP-cellular protein complexes were
analyzed via SDS PAGE and Western blot for GP (bait) content, ERGIC-53, and MCFD2
(prey) content along with CRT as a control.(B) MCFD2 has a highly conserved antiviral
function that can be restricted to the viral glycoprotein. HEK293T cells were first
transfected with either an empty plasmid, or one encoding WT MCFD2. The following
day cells were transfected with each of the respective viral glycoproteins: VSV G, JUNV
XJ GP, SARS S, MARV GP, EBOV GP, and ANDV GP. 24 hr following the final
-GFP pseudoparticles decorated with
VSV G. Supernatants were harvested 24 hpi to assay for focus forming units (FFU) on
fresh Vero monolayers. Data are presented as mean FFU ± SEM relative to the cells
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receiving an empty vector. Data are representative of two independent experiments (n=3
per condition per experiment).

Figure 3.3 MCFD2 regulates ERGIC-53’s lectin activity to inhibit arenavirus
replication.
(A) ERGIC-53’s CRD is critical for production of infectious JUNV C#1. HEK 293T cells
were transfected with either an empty plasmid, or one containing WT ERGIC-53,
ERGIC-

or WT MCFD2. Monolayers were infected 24 hpi with JUNV C#1 at

an MOI or 0.1, virus containing supernatants were harvested at 48 hpi and assayed for
PFU content via standard plaque assay. Data are represented as mean PFU ± SEM
relative to the cells receiving an empty vector.
(B) Interactions of ERGIC-53’s CRD regulate arenavirus production. HEK 293T cells
were co-transfected with either an empty plasmid, or one containing WT MCFD2 in
tandem with WT and functional mutants of ERGIC-53 to test for their relative
contributions to the ERGIC-

N156A (unable to bind sugar). Monolayers were infected 24 hpi with JUNV C#1 at an
MOI or 0.1, virus containing supernatants were harvested at 72 hpi and assayed for PFU
content via standard plaque assay. Data are represented as PFU ± SEM relative to the
cells receiving

empty vector.

Figure 3.4 sMCFD2 interacts with extracellular ERGIC-53 and arenaviruses to
inhibit infectivity.
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(A) Purified MCFD2 interacts with ERGIC-53 secreted from infected and mock infected
cells. MCFD2 purified from HEK293T cells (see methods section for details on
purification) was added to clarified supernatant from JUNV C#1 and mock infected
cultures. Recombinant MCFD2 in complex with ERGIC-53 was immunoprecipitated
using an anti-myc antibody that recognizes the recombinant MCFD2 molecule.
Precipitated fractions were separated via SDS PAGE and analyzed by Western blot for
the presence of myc-MCFD2 (bait) and endogenous ERGIC-53 (prey).
(B) Purified MCFD2 is able to inhibit the entry of Old and New World arenaviruses.
Purified MCFD2 or vehicle was added to supernatant containing 200 PFU of JUNV C#1
or DANV derived from Vero E6 cells. The supernatant was incubated with purified
protein for 2 hr at 4° C before being overlaid onto monolayers of HEK293T cells.
Following a 2 hr adsorption at 37° C the cells were washed extensively and fresh medium
was added. At 48 (DANV) and (72) hpi, supernatants were harvested and assayed for
PFU content by standard plaque assay. Data are represented as mean PFU ± SEM relative
to the supernatant treated with vehicle.
(C-D) 2D and 3D 3dSTORM imaging reveals organization of sMCFD2 and ERGIC-53
on arenavirus particles. JUNV C#1 containing particles generated in Vero E6 cells were
fixed onto poly-L-Lysine treated MatTek dishes. Following fixation with PFA, adsorbed
virions were permeablized and incubated with purified sMCFD2 from HEK293T cells
prior to staining for myc-MCFD2(blue), JUNV NP (green), and endogenous ERGIC-53
(red). Images are representative from a minimum of 10 acquisitions of 15,000 to 30,000
frames. Scale bars are indicated for each image. Signal versus noise values were assessed
by imaging single fluorophores in their respective channels, as well as in all 3 channels to
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ensure localizations from each respective fluorophore were distinct. The 2 panels in (C)
are of a 1,000 nm view of a series of JUNV C#1 particles, and then a single particle
magnified. The image in panel (D) is a 3D rendering of an individual JUNV C#1 virion
identified via NP staining (green) containing a ring of ERGIC-53 (red) and MCFD2
(blue). The model presented in panel (E) illustrates the arenavirus lifecycle and specific
stages where MCFD2 can exert an effect. The bottom WT cell (red shaded) represents a
scenario where MCFD2 is present in abundance. The interaction between ERGIC53/MCFD2 and GP is likely to occur early during synthesis in the ER/ERGIC (1) where
the proteins are concentrated. Binding of MCFD2 to the complex may alter an
intracellular maturation event leading up (folding, proteolysis, glycan maturation) to
budding and release (2). MCFD2 interacts with ERGIC-53 in the context of viral particles
(3) when added exogenously, and presumably during endogenous secretion, where it
interferes with steps of arenavirus entry. MCFD2 binding may act at the level of receptor
binding (4) either through blocking of arenavirus receptors, by changing ERGIC-53’s
sugar preference, or by ligation of an unknown MCFD2-specific receptor. If the entry
defect is post-attachment, the targeting and trafficking (5), and fusion cascade (6) may
also be disrupted.
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Figure 3.1 MCFD2 is an arenavirus restriction factor that forms a tripartite
complex with ERGIC-53 and JUNV GP
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Figure 3.2 MCFD2 antiviral action is conserved across multiple pathogenic RNA
viruses and is specific the viral GP.
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Figure 3.3 MCFD2 regulates ERGIC-53’s lectin activity to inhibit arenavirus
replication.
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4.

SUMMARY OF RESULTS, DISCUSSION, AND FUTURE DIRECTIONS
Summary of aims

The body of this dissertation has been put forth to discuss, at length, four specific aims
that, following their completion, would advance the field’s current understanding of the
cellular biological framework of arenavirus biogenesis and pathogenesis. The focus of the
dissertation was directed primarily on the arenavirus envelope glycoprotein complex, but
also incorporated hantavirus GPs. The first aim was to establish a comprehensive
interactome of an arenavirus GP with the human proteome. The inclusion of a prototypic
hantavirus GP served both as a control for this venture, as well as a scientific
advancement in its own right. The hantavirus glycoproteins, much like their arenavirus
counterparts, have a dearth of information regarding their interactions (and subsequent
biological consequences) with human cellular proteins. Following the characterization of
these interactomes, the second aim of these studies was to identify cellular targets from
the interactomes that were biologically relevant to either the propagation of viruses, or
the progression of disease caused by each virus. This aim focused on two specific host
proteins; ERGIC-53 and MCFD2. The third aim, which became the bulk of the studies,
was to identify and characterize the mechanism of action of the biologically relevant
cellular targets identified in aim 2 (ERGIC-53 and MCFD2). The fourth aim was to
characterize the molecular nature of the interaction between the viral and host molecules
(e.g. map domains and residues supporting the interaction). These four aims will be
summarized and explored individually where possible; however given the interesting and
occasionally circuitous route the data led us on, some sections are not mutually exclusive.
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4.1. Summary of GP interactome studies and future directions (aim 1)
The first aim of this dissertation was to generate an arenavirus and hantavirus GP
– human protein interactome. Accordingly, data presented here provides a primary and
comprehensive identification of human proteins involved in the biogenesis of arenavirus
and hantavirus glycoproteins. Our collective understanding of specific proteins involved
in their biogenesis has been limited thus far to the proteases involved in maturation
cleavage of the arenavirus (SPase and S1P) and hantavirus GPs (SPase). The new
collection of interacting proteins identified here will be of use to researchers interested in
dissecting the molecular machinery involved in the chaperone-assisted folding,
glycosylation, isomerization, and transport of the glycoprotein complex. The proteomics
screen revealed molecules with associated functions in each of these categories. It should
be noted, however, that there was a caveat to the approach detailed in chapter 2 in the use
of HEK293T cells to generate the interactomes. The cells were selected based on both the
ability of these viruses to productively infect them, as well as for their permissiveness to
transfection for the production of recombinant proteins. Future studies to confirm these
interactions within tissue relevant cell types will likely provide additional interactions,
some of which may be tissue specific.
Chapter 1 summarizes the different approaches to understanding the imperative
nature of the N-linked glycosylation additions to arenavirus glycoprotein structure and
function. It will be of particular interest to investigate more fully the glycosylation
machinery involved. Despite several elegant studies, the exact make-up of the glycan
additions remain unknown and the enzymes involved in shaping them are likewise
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murky. We identified several sugar processing (adding and trimming) enzymes as well as
lectins and lectin binding proteins in this study including ERGIC-53, calreticulin,
calnexin, Golgi apparatus protein 1, LMAN2, and LMAN2L. Given the importance of
ERGIC-53 and its lectin function in the production of infectious virus, characterizing the
role of each of these lectins may also shed insight into the intracellular trafficking and
glycosylation content of the GP, as well as reveal other unknown lectin-mediated
activities for both virus and cell.
Chapter 2 describes the cluster analysis of the individual versus the conserved GP
interactomes. While this type of primary analysis is insightful, a more thorough
investigation will be required to cross-reference the interactomes with existing databases
for human viral pathogens (i.e. influenza and HIV) for which similar proteomics or RNAi
based studies have been carried out. In addition to an in-depth bioinformatics analysis,
functional studies carried out via forward or reverse genetics approaches (genetic deletion
vs over expression) will be needed to characterize the significance of the remainder of the
interactome. Since there are several enzymes also listed, specifically those involved in the
proteasome function, small molecules targeting their enzymatic activity should also be
utilized where feasible. This type of approach has gained traction recently. Specifically,
treatment of cells with Bortezomib, a clinically approved proteasome inhibitor, as well as
MG12, has been demonstrated to result in the impaired propagation of orthomyxoviruses
and paramyxoviruses, respectively (Dudek, Luig, Pauli, Schubert, & Ludwig, 2010;
Watanabe et al., 2005). During the preparation of this dissertation, Jager et al. identified
ERGIC-53 as an interacting protein of HIV-1 GP in a proteomics screen characterizing
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the HIV-interactome (Jager et al., 2012), however it has not yet been revealed whether
ERGIC-53 will likewise be important for retrovirus propagation. Given the phenotypes
presented thus far for the arenavirus, coronavirus, filoviruses, and hantaviruses, and
ERGIC-53’s interaction with them, it is plausible that HIV may also utilize ERGIC-53’s
pro-viral function.
While these studies were underway, Panda et al. performed a genome-wide
siRNA screen searching for proteins involved in rhabdovirus (VSV), arenavirus (LCMV),
and human parainfluenza virus (HPIV) replication (D. Panda et al., 2011). Several GP
partners identified in our studies were found to be deleterious to viral replication when
silenced. Specifically coatomer (COPA), archain 1 (ARCN), stromal cell derived factor 4
(SDF4), and Renin Receptor (ATP6AP2), when silenced, restricted replication. In light of
our findings, it is likely that the mechanism by which these proteins restrict replication
occurs via their interaction with the arenavirus glycoprotein. A recent study by Iwasaki
and colleagues, after mining the Panda data set, extended their findings for sodium
hydrogen exchanging 3 (NHE3), by demonstrating that loss of NHE3 resulted in an entry
defect involving the macropinocytosis pathway that was conserved across OW and NW
arenaviruses. Further, the authors were able to utilize zoniporide, a drug used in clinical
trials for preventing myocardial ischemia, to inhibit arenavirus entry (Iwasaki, Ngo, & de
la Torre, 2014). This study is an excellent example of how the sharing of large data sets
encourages cooperation amongst labs in the field to understand more in detail the cellular
biology of these viruses, and how therapeutic targets can be identified through basic
science.
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In addition to the study by Panda and colleagues, an arenavirus entry screen into
human cells has recently been carried out using a gene-trap viral vector, bearing LASV
GP, as a platform to select for genes allowing survival in a population of virally disrupted
haploid cells (L. T. Jae et al., 2013). Disruption of both ERGIC-53 and MCFD2 genes
showed signs of inactivating insertions within the genes, but were below the threshold of
statistical significance, suggesting that there may be either tissue specificity in the
ERGIC-53/MCFD2 phenotype, or different sensitivities between screening techniques.
Further, a recent genome-wide siRNA screen was also carried out using VSV decorated
with JUNV C#1 GP, which yielded little to no overlap amongst the validated protein
targets with the data presented in this dissertation (M. Lavanya, C. D. Cuevas, M.
Thomas, S. Cherry, & S. R. Ross, 2013). A thorough pathway analysis may provide
clues as to the incongruence of overlap amongst the varying screens which has thus far
been minimal. Specifically, it will be important to determine if the conserved protein
complexes, rather than specific proteins, are similarly impacted. This criterion may then
re-connect the disparate data sets. However, similar discrepancies in host-protein
significance have been reported in the HIV literature, and so does not come as a surprise
that following genome-scale screens specific proteins are not found to be functionally
relevant across studies (Brass et al., 2008; Zhou et al., 2008). In summary, the proteomics
data generated in these studies provide a starting point for a more detailed and
comprehensive testing of the cellular mechanisms involved with individual proteins, and
may be carried out by the arenavirus and hantavirus community at large. The remainder
of the discussion will emphasize the results obtained regarding ERGIC-53, MCFD2, and
the ERGIC-53-MCFD2 receptor complex.
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4.1.1. ERGIC-53 interacting proteins and future directions
Several interesting hypotheses can be made regarding the GP proteomics data
presented in these studies, that though not specifically tested, may provide additional
insight into the mechanisms at play regarding ERGIC-53’s presence and purpose in a
multi-protein complex with the GPs. Accordingly, multiple ERGIC-53 interacting
proteins were also identified in the GP interactome data sets including several COP
proteins (including alpha and gamma) (Haines et al., 2012; Itin, Foguet, et al., 1995; Itin,
Schindler, et al., 1995a; Kappeler et al., 1994b), and several tubulin proteins (Haines et
al., 2012) (TUBB), ERP44 (Margherita Cortini & Roberto Sitia, 2010), valosincontaining protein (VCP) (Haines et al., 2012), nicastrin (NCSTN) (Morais et al., 2006),
and sulfatase modifying factor 1 (SUMF1) (Fraldi et al., 2008) which binds indirectly
through SUMF2 heterodimer formation (Zito et al., 2005). Interrogating the contribution
of these proteins, individually and synergistically, to viral propagation may greatly
increase our understanding of ERGIC-53’s regulation and function in the secretory
pathway and beyond. Several of these proteins have a variety of documented roles
involved in viral replication including coatomer protein’s pro-viral role with VSV,
LCMV, HPIV (D. Panda et al., 2011), as well as FLUAV (Sun, He, & Zhuang, 2013)).
VCP/p97 has also been shown to be critical for entry of an alphavirus, Sinbis virus
(SINV), (Panda et al., 2013) and is involved in a human adenovirus (AdV) TRIM21mediated neutralization process (Hauler, Mallery, McEwan, Bidgood, & James, 2012), as
well as an enterovirus (polio virus (PV)) RNA replication (Arita, Wakita, & Shimizu,
2012). Examining how ERGIC-53 associates with its other known interacting proteins
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may reveal additional functionality to the molecule and/or molecular complex, as well as
illustrate the exact role it is playing during the production of infectious virus.
It is interesting to note that despite the large complex of ERGIC-53 interacting
proteins identified in our proteomics screen, several of its known interacting partners
-1 antitrypsin (Nyfeler, Reiterer, et al., 2008a), fibroblast growth factor
receptor 3 (Lievens et al., 2008), as well as the cathepsins C and Z (Christian Appenzeller
et al., 1999; Vollenweider et al., 1998a)). This may suggest that there are separate pools
of ERGIC-53 within the early secretory pathway, each with their own repertoire of
regulatory proteins purposed to unique tasks. Alternatively, binding of ERGIC53/MCFD2 to the viral GPs may impair its ability to interact with the remaining proteins
mentioned above. In addition, the sensitivity of our assay may be insufficient to isolate
macromolecular complexes past the second layer of proteins involved (e.g. GP to
ERGIC-53 (1st) and GP-ERGIC-53 to COP (2nd)). The lack of MCFD2 identification
within the interactomes suggests that the sensitivity may indeed be insufficient to detect
low abundance proteins, or protein complexes that may only be formed transiently.
However, the exact ordering of the interactions is not currently known based on our
biochemical interrogations. There may in fact be additional proteins bridging the GPs to
ERGIC-53. Given the discovery of ERGIC-53 outside of the confines of the cell (e.g.
within exosomes and virions), it will be important to extend the search for its
cargo/ligands to the extracellular milieu (i.e. exosomes), cell surface proteins, as well as
within the endocytic pathway.
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4.1.2. Summary of the ERGIC-53-GP interaction

In chapters 2 and 3 we demonstrated ERGIC-53’s conserved binding to several
viral GPs. The structural significance of the conservation of ERGIC-53’s interaction with
GPs encoded by arenaviruses, coronaviruses, filoviruses, hantaviruses, orthomyxoviruses,
and retroviruses remains to be determined. However, these data strongly suggest that
these viral envelopes share some structural homology to an ancestral viral GP. The
conservation of the cargo-receptor complex formed with MCFD2 and the listed GPs
reinforces this idea. The large degree of primary amino acid separation amongst the GPs
further suggests that the specific recruitment is based on a conserved fold or domain,
rather than a specific amino acid sequence (or the presence of glycans). High-resolution
structural data exist for several of the viral GPs listed including SARS S1 (receptor
binding domain) and S2 (fusion subunit) (Deng, Liu, Zheng, Yong, & Lu, 2006; Li, Li,
Farzan, & Harrison, 2005), EBOV GP1/GP2 (J. E. Lee et al., 2008; Weissenhorn, Carfi,
Lee, Skehel, & Wiley, 1998), HIV Env (reviewed in (Merk & Subramaniam, 2013), as
well as both OW and NW arenavirus GP-1/GP-2 (Abraham et al., 2010; Igonet et al.,
2011; Parsy et al., 2013) . Comparisons of the individual subunits, and their respective
domains, may yield vital information regarding how ERGIC-53 recognizes and binds to a
viral GP. The ERGIC-53 CRD and MCFD2 complex, likewise, has been crystallized
(Nishio et al., 2010). Fitting of the known GP subunits with the reported structures may
reveal how the overall complex is formed. It has been reported that upon binding to
MCFD2, carbohydrate, or calcium, that some refolding occurs amongst the ERGIC-53 MCFD2 complex (Guy, Wigren, Svard, Hard, & Lindqvist, 2008; Nishio et al., 2010;
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Wigren et al., 2010). It will therefore be imperative to analyze these proteins as a
complex. The envelope glycoproteins have, however, produced several barriers to
crystallization in a native state as glycosylated, full length, or intact GPs are notoriously
challenging to crystallize (Lee et al., 2009).
The biochemical studies presented in chapters 2 and 3 demonstrate that GP’s are
all recognized by ERGIC-53 early in the secretory pathway based on its selective binding
to full-length GPs (with the exception of hantavirus GPs). This was further supported by
the finding that intracellular C#1 GP, ERGIC-53 (Chapter 2) and MCFD2 (Chapter 3), all
selectively concentrate within the ERGIC during infection. Also, the ERGIC-53 domain
mapping experiments in chapter 2, which demonstrated that the ER-restricted ERGIC-53
(KKAA) binds to GP, confirms a pre-ERGIC association. The consequence, if any, of the
intracellular concentration, and how it relates to the proteolytic and/or maturation status
of the glycoproteins also remains to be determined. One potential explanation is that a
conserved glycan array on the viral GPs could be selectively modified within the ERGIC.
In support of this notion, a specific endomannosidase has been reported to colocalize with
ERGIC-53 and the intermediate compartment (Zuber, Spiro, Guhl, Spiro, & Roth, 2000).
This glycan modification could in turn target the GPs to a specific subdomain or
compartment, much like the mannose-6-phospate receptor (a P-type lectin) lysosomal
targeting mechanism (reviewed in (Kim, Olson, & Dahms, 2009)), for later modification
or secretion. However, in our studies, we were unable to detect changes in the release of
GP, or in their migration via SDS PAGE in cells lacking ERGIC-53 that would be
indicative of changes in glycosylation. The limit of resolution in our SDS-PAGE –
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Western blot assay, may however, be insufficient to detect minor alterations in glycan
composition. A mass spectroscopy-based approach to analyze the glycan composition
with substantially greater mass-resolution would answer this question, much like what
has been proposed by Krudysz-Amblo and colleagues for human tissue factor (KrudyszAmblo, Jennings, Matthews, Mann, & Butenas, 2011).
4.2. Summary of findings for ERGIC-53 and MCFD2 functional studies and future
directions (aim 2)
4.2.1.

Summary of findings for ERGIC-53 functional studies and future directions
(aim 2)
The discovery of an important role for ERGIC-53 in the propagation of

arenaviruses fulfilled the goal of aim 2, and in doing so, catalyzed several additional
important biological findings for not only ERGIC-53, but also for its soluble cofactor
MCFD2. This significance was extended to several additional families of enveloped RNA
viruses, all of which represent human pathogens in need of antiviral treatments. Briefly,
following the biochemical identification of a novel class of pathogen-derived ligands for
ERGIC-53, we used several complimentary techniques to determine that ERGIC-53 plays
a critical role in the generation of infectious virions. First, RNAi knockdown of ERGIC53 in cells resulted in JUNV C#1 propagation being reduced. Second, overexpression of
ERGIC-53 in cells resulted in an enhancement in production of JUNV C#1. Third, human
B cells naturally lacking ERGIC-53 were defective in their ability to produce infectious
arenavirus particles. Lastly, expression of an ER-restricted mutant of ERGIC-53 potently
inhibited the production of infectious C#1 and DANV particles, as well as
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pseudoparticles of VSV decorated with SARS S and EBOV GP. This last piece of data
suggested specifically that either the post-ER trafficking of ERGIC-53 was important for
the production of infectious virus, or that its C-terminal targeting domain was required
for viral propagation. These two concepts are not mutually exclusive, and so can be
challenging to separate. Creating an ERGIC-53 tail chimera on a related lectin (VIP-36)
could assist in discriminating between these two potential contributors.
ERGIC-53 expression has also been found to be upregulated in several types of
mouse-derived cells (ANA-1 macrophages, MEFs, or embryonic endothelial progenitor
cells) following infection with murine gammaherpes virus 68 (MHV68). Following
ERGIC-53 siRNA knockdown there was a reduction in virus yield (Mages et al., 2008).
Interestingly, the authors also pre-treated NIH3T3 cells with a phospholipase A2 inhibitor
(ONO-RS-082), known to inhibit retrograde trafficking of ERGIC-53 (de Figueiredo et
al., 2000), and found that treatment also inhibited viral yield. These data, together with
ours, indicates that the intact recycling pathway of ERGIC-53 is of critical importance for
the generation of infectious virions, and is important in the propagation of multiple
families of enveloped RNA viruses, and at least one DNA virus. Screening for an
ERGIC-53 - dependent phenotype for additional pathogenic viruses including OW and
NW hantaviruses, flaviviruses, and paramyxoviruses will be of interest to the virology
community at large.
4.2.2.

Summary of findings for MCFD2 functional studies and future directions
(aim 2)
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The investigation into the role of MCFD2 in viral propagation was initiated
(unlike ERGIC-53, which began from an unbiased screen) as an interesting control
because of its known role in forming a complex with ERGIC-53. The protective role of
overexpressed MCFD2 during JUNV C#1 and DANV propagation (chapter 3) led us to
hypothesize that MCFD2 may be acting as a viral restriction factor. The unexpected
discovery of its antiviral role following overexpression, led us to investigate whether
cells from MCFD2 null F5F8D patients would support infectious virus production. The
enhanced production of infectious virus from MCFD2 null cells further supports the
notion that this protein is acting as a restriction factor for arenaviruses. Overexpression of
MCFD2 was also shown to inhibit the propagation of VSV bearing coronavirus, filovirus,
and hantavirus GPs suggesting that, like ERGIC-53, its impact is highly conserved, and
can be restricted to the presence of the respective viral GPs. The difference, however,
was in the respective direction of regulation (i.e ERGIC-53 is pro-viral and MCFD2 is
anti-viral).
4.3. Summary of findings for ERGIC-53’s mechanism of action and future
directions (aim 3)
Using several techniques we tested how ERGIC-53 and MCFD2 were impacting
the production of infectious arenavirus particles. In chapter 2 we relied upon the DN
ERGIC-53 to show that trafficking of ERGIC-53, despite being critical for generating
infectious virus, was not required for the proteolytic processing, trafficking of GP, or its
assembly and release in viral particles. During these studies we also discovered that
ERGIC-53 would traffic to the plasma membrane along with the GP, and be packaged
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into viral particles. Further, we were able to minimally map the stage of the defect in viral
propagation to cell surface attachment. Specifically, virus from ERGIC-53 null cells was
defective, in part, in its ability to attach to a permissive cell. These data are supported by
the fact that DN ERGIC-53 cannot traffic beyond the ER (Andersson et al., 1999; Felix
Kappeler & Hauri, 1997), and so would be prevented from entering into viral particles
and thus influencing attachment. Collectively, these data suggest that ERGIC-53 may be
acting as a host-derived attachment factor that is incorporated into virions.
The presence of ERGIC-53 in the extracellular space in both infected and
uninfected preparations suggested that it was also found in cellular exosomes. This
finding was corroborated by 2 additional studies which identified ERGIC-53 in human
and rat derived exosomes (Conde-Vancells et al., 2008; Gonzalez-Begne et al., 2009).
Moreover, it has been demonstrated that d,l-threo-1-phenyl-2-decanoylamino-3morpholino-1-propanol (PDMP), a sphingolipid synthesis inhibitor known to interfere
with the production of glycosylceramide and sphingomyelin, ER calcium homeostasis,
and interfere with ERGIC-53’s recycling (Maceyka & Machamer, 1997; Sprocati,
Ronchi, Raimondi, Francolini, & Borgese, 2006), causes a reduction in the uptake of
HIV-1 particles, produced in PDMP treated cells, by dendritic cells (Hatch, Archer, &
Gummuluru, 2009). Further, this mechanism was later refined to include the requirement
of CD169 (a SigLec) on the surface of dendritic cells recognizing the glycosphingolipid
GM3 (for capture and trans-infection of HIV (Puryear et al., 2013). The same surface

acid, specifically within the marginal zone of the spleen (Saunderson, Dunn, Crocker, &
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McLellan, 2014), a prominent site involved in LCMV infection (Macal et al., 2012). If
ERGIC-53, or its recycling, is required for biosynthesis of this class of specialized lipid,
restriction of ERGIC-53 to the ER could disrupt the lipid content of viruses, as well as
exosomes, and could therefore be expected to interfere with both capture of virus, as well
as exosomes. Given our findings on the presence of ERGIC-53 in both virus and
exosomes, we can further postulate that ERGIC-53 is involved directly in targeting or
maintaining of the GPs in specific microdomains enriched in these lipids. Interestingly,

addition of PDMP (Stuart & Brown, 2007). We provide evidence in chapters 2 and 3 that
additional FLUAV HA’s from WSN and VN (H1 and H5) also interact with ERGIC-53.
The effect of PDMP and ERGIC-53 on the uptake of these respective HA-bearing viruses
will be important to determine experimentally. Further, dissecting a potential role of
ERGIC-53 in the cellular biology of CD169 as well as glycosphingolipid biogenesis may
shed light on the exact nature of this otherwise complicated interaction.
Another potential connection to lipid metabolism can be inferred by the
interaction of both LCMV and ANDV GPs with molecules associated with sphingolipid
biosynthesis; serine palmitoyltransferase long chain base subunit 1 and 2 (SPTLC1 and 2)
which are involved in ER synthesis of sphingolipids (Gault, Obeid, & Hannun, 2010),
and UDP-glucose ceramide glucosyltransferase-like 1 and 2 (UGCGL1 and UGCGL2).
Given the number of other ERGIC-53 interacting proteins found within the proteomics
list, some of these enzymes may have been found in complex with the glycoproteins via
their association with ERGIC-53. In support of this notion, Haines and colleagues, while
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mapping binding partners of UBDX1 and ERGIC-53, identified UGCGL1 (Haines et al.,
2012).
Several additional hypotheses can be made regarding the role that ERGIC-53 is
asserting during its control of arenavirus particle infectivity. Chapter 2 describes the
mapping of the interaction between C#1 GP and ERGIC-53, minimally, to the C-terminal
portion of ERGIC-53’s CRD (in completion of aim 4). Further, chapter 3 demonstrates
that expression of ERGICrequirement of ERGIC-53’s CRD both for binding to the GP and coordinating its
function in the production of infectious virus could indicate that ERGIC-53 (without its
CRD) is not packaged in virions due to lack of GP binding and/or that the CRD is
controlling the infectivity of the particles directly. The major biological role of the CRD
is binding to N-linked sugars (and the proteins to which they are attached) (AppenzellerHerzog et al., 2004; Christian Appenzeller et al., 1999; Kawasaki et al., 2008; Moussalli
et al., 1999b). ERGICwhich could indicate that ERGIC-53 controls viral infectivity, in part, via binding of its
CRD to N-linked glycans on the surface of cells. This idea is supported by data
illustrating that infection by an arenavirus could be blocked via addition of mannan
(Goncalves et al., 2013; Martinez et al., 2013). The authors in these studies were
investigating C-type lectin attachment factors (DC-SIGN and L-Sign) which are also
known to bind mannosylated glycoproteins. Collectively these data may suggest a
cooperative lectin-mediated attachment mechanism between virion associated ERGIC-53
and host cell-displayed DC-SIGN.
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Alternatively, Velloso and colleagues, while examining the structure of ERGIC53’s CRD, reported on the structural similarity between the CRD and neurexins (Velloso,
Svensson, Schneider, Pettersson, & Lindqvist, 2002). Neurexins are also known ligands
-DG, and occupy a similar site on the receptor as OW arenavirus GPs (Rojek,
Campbell, et al., 2007). These data could indicate that ERGIC-53, contained in OW
-DG along with the GP to increase binding avidity
of virions to cells. Furthermore, ERGIC-53 has also been reported to show structural
homology to galectins (Arar et al., 1995). Galectin-3 has been demonstrated to be
upregulated following infection with JUNV C#1 (Giusti et al., 2011), and has been shown
also to bind to Mac-2BP (Inohara, Akahani, Koths, & Raz, 1996). Mac-2BP which also
interacts with ERGIC-53’s CRD (Chen et al., 2013), in a carbohydrate-dependent
fashion. Therefore, Mac-2BP could bridge ERGIC-53 embedded in virions to Galectin-3
on the surface of cells. In addition, Mac-2BP has also been demonstrated to be
upregulated during hantavirus infection, and binds to Tula virus, an OW hantavirus
(Vaheri et al., 2013), suggesting a similar mechanism could be involved in hantavirus
entry.
The presence of ERGIC-53 within arenavirus virions was an unexpected finding.
The mechanism(s) involved in its recruitment to sites of arenavirus assembly and budding
are currently unclear. Of relevance, ERGIC-53’s expression levels are upregulated 2.5
fold during LCMV WE infection in primate liver cells (Djavani et al., 2009). Therefore it
could be postulated that this upregulation allows ERGIC-53 to saturate its COPI retention
(Kappeler et al., 1997b; Ellen J. Tisdale, Helen Plutner, Jeanne Matteson, & William E.
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Balch, 1997) and traffic to the surface of cells. LCMV GP has also been reported to
selectively induce the ATF6 branch of the unfolded protein response (Pasqual, Burri, et
al., 2011b), which has been shown to upregulate ERGIC-53 (Nyfeler et al., 2003a),
further supporting the hypothesis of its role in causing post-ERGIC movement of
ERGIC-53. Heat-shock (Spatuzza et al., 2004) as well as the presence of NO (Renna et
al., 2006) also upregulate ERGIC-53, and are known consequences of arenavirus
infection (Brocato & Voss, 2009) and would likewise support this proposed mechanism
of viral GP induced alterations in ERGIC-53’s trafficking.

4.3.1.

Summary of findings for the mechanism of action of ERGIC-53 and MCFD2
in viral propagation and future directions
An outstanding question remains: how does MCFD2 regulate viral propagation?

Several lines of evidence support its role as a restriction factor. First, MCFD2 following
arenavirus infection, is highly upregulated (Chapter 3) and (Djavani et al., 2009)).
Second, plasmid overexpression inhibits propagation of multiple enveloped RNA viruses
in a GP-restricted fashion. Third, cells lacking MCFD2 are more susceptible to infection.
Importantly, VSV is neither impacted by MCFD2, nor is its GP able to form a complex
with ERGIC-53 and MCFD2. This evidence indicates that the MCFD2 contains
specificity in its antiviral action, and that its action is restricted by specific viral GPs. The
data presented in Chapter 3 also indicate that MCFD2 may be acting as a restriction
factor through its interaction with ERGIC-53 by regulating ERGIC-53’s ability to control
viral infectivity. We have not, however, conclusively ruled out the possibility that the two
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proteins may be acting independently of one another. MCFD2 may bind to a separate
receptor on the surface of cells that, following binding, initiates an antiviral cascade. In
order to test for this possibility, several methodologies could be employed. To identify a
cell surface receptor of MCFD2, cell surface proteins could be biotinylated and isolated
via streptavidin beads, and the captured proteins subjected to a Far-Western blot analysis
where soluble MCFD2 was used as a probe. MCFD2 positive proteins bands could then
be excised and identified via mass spectroscopy. Alternatively, cell membrane
preparations could be isolated via gradient ultracentrifugation, and incubated with
immobilized MCFD2. Captured proteins could then be eluted, and identified via mass
spectroscopy. These two approaches would require additional studies targeting the
expression and function of the putative receptor to then formally test its sufficiency for
antiviral signaling.
The triple dSTORM analysis of sMCFD2, ERGIC-53, and C#1 NP, as well as the
pre-complexed sMCFD2-virus addition assays lend support to a model where the
antiviral activity of MCFD2 is taking place directly via neutralization of the virus. Using
the highly sensitive qPCR-based attachment assay outlined in chapter 2, it could be tested
whether the defect is taking place solely at the level of attachment, or if MCFD2, when
pre-complexed to virions, is impeding its intracellular trafficking, disrupting the fusion
capabilities of the GP, or interfering with the transcription or replication of the RNA
through an unknown mechanism. In order to examine potential alterations in either fusion
potential or trafficking of the pre-complexed virions, Alexa Fluor 647 conjugated virus
(highly concentrated) could be used to study the trafficking of virus through the
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endosomal system (Lozach et al., 2011; Pasqual, Rojek, et al., 2011). A similar approach,
but with dual fluorescently labeled virus (DioC and R18) has been successfully used to
quantitate influenza virus fusion in real-time based on fluorescent shifts following fusion
of virus within endosomes (Sakai et al., 2006). A similar approach would be feasible with
arenaviruses, and would facilitate the quantitative assessment of fusion alterations
following addition of MCFD2, if that is indeed the case. A pitfall to both of these
approaches is the high multiplicity of infection required to gain adequate signal to noise
ratios. However, the ERGIC-53 dependent phenotype could likewise be altered during
these steps of the viral life cycle, and thus could benefit from a quantitative assessment.
Collectively, the identification of a proviral and antiviral role for the ERGIC53/MCFD2 cargo receptor complex strongly suggests that this cellular machinery is of
critical importance to the outcome of infection with multiple viruses that are pathogenic
for humans. Selectively targeting the CRD of ERGIC-53 via a library of small molecules
would likely yield valuable lead compounds for drug development, based on the critical
role demonstrated in chapter 2 for binding to GP, and chapter 3 for controlling viral
infectivity. Interestingly, in support of this notion, a recent study by Lu and colleagues
demonstrated that a small molecule interfering with the interaction of JUNV C#1 Z and
TSG101 resulted in a pronounced reduction in viral release (Lu et al., 2014). Further,
given the small size and solubility of MCFD2, its potent role in the neutralization of viral
infectivity, and the advanced structural data on the molecule, a small molecule could be
rationally designed to mimic MCFD2’s ERGIC-53 interacting residues.
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4.4. Summary of findings for the molecular arrangement of the ERGIC-53/MCFD2
complex binding to glycoproteins.
The details of the domain residues required for ERGIC-53 to interact with JUNV
C#1 GP were discussed in chapter 2, and have been mentioned in section 4.2.2. Briefly,
we tested a comprehensive panel of plasmids encoding deletions and mutations in each of
the known functional regions of ERGIC-53 (excluding the transmembrane domain) and
found that the CRD alone was responsible for binding to an arenavirus GP. This finding
was in agreement with our original hypothesis, as the glycoproteins are heavily
mannosylated (Buchmeier et al., 2007; Wright et al., 1990a) and ERGIC-53 is a
mannose-specific lectin (C. Appenzeller et al., 1999b; Kamiya et al., 2008; Moussalli et
al., 1999b). Interestingly, the sugar, calcium, and MCFD2 binding properties of ERGIC53 along with its oligomerization, and forward trafficking, were all found to be unrelated
to the interaction with C#1 GP. These data demonstrate a novel lectin-independent
mechanism of cargo binding. As has been discussed above, there is a plausible benefit to
the virus to maintain its interaction with ERGIC-53 from a site distinct from its normal
ligand binding: maintenance of ERGIC-53’s normal cellular functions. This strategy has
also been employed by New World arenaviruses interacting with TfR1 and may then
represent a common mechanism by which the viruses engage passively with a host
molecule (Abraham et al., 2010; Radoshitzky et al., 2007).
4.5. Summary of findings, biological and evolutionary significance, and closing
remarks
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It is feasible that the interaction of viral GPs with the ERGIC-53/MCFD2 cargo
receptor complex is not entirely harmless to the host. While loss of ERGIC-53 and
MCFD2 is well tolerated by humans (Khoriaty et al., 2012), it does, however, result in a
specific deficiency in FV and FVIII (F5F8D) (Nichols et al., 1998; Bin Zhang et al.,
2003). Accordingly, deficiencies in circulating FV and FVIII cause bleeding
abnormalities following trauma such as surgery or child birth (Spreafico & Peyvandi,
2008; Zhang, 2009). Loss of ERGIC-53 or MCFD2, though able to cause disease, is a
manageable syndrome with little to no long term consequences. Loss of ERGIC-53 or
MCFD2 allows the cellular architecture to remain intact and the host secretome is largely
unmodified (Mitrovic et al., 2008; Vollenweider et al., 1998a; Zhang et al., 2011). This
information was the primary impetus for this in-depth study of ERGIC-53 and
specifically its selection as an antiviral target. Arenaviruses, hantaviruses, and notably the
filoviruses, each can cause a hemorrhagic fever syndrome, where specific deficiencies in
clotting factors have been reported (Lee, 1987; Lee et al., 1989; Felisa C. Molinas et al.,
1981; Schwarz et al., 1972).

However, given the logistical problems involved in

obtaining and testing serum samples from infected patients, much of what is currently
understood about coagulation abnormalities caused by these viruses is the result of
animal models of infection (Molinas et al., 1978; Xiao, Zhang, Yang, & Tesh, 2001). We
provide several lines of evidence that support the notion that the ERGIC-53/MCFD2
cargo receptor may no longer be able to support the secretion of coagulation factors
during an infection. First, the binding of the trimeric GP complex to the ERGIC53/MCFD2 complex, specifically within the CRD, may impede the binding of the large
FV and FVIII molecules. Second, the re-routing of ERGIC-53, along with the viral GP, to
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the plasma membrane, as well as to the surface of virions, removes the potential for those
ERGIC-53 molecules to shuttle FV and FVIII forward. Given the recycling nature of the
ERGIC-53/MCFD2 complex, removal of a fraction of the pool is likely to have a
compounding effect over time.
The first explanation mentioned in the preceding paragraph, inhibition of
FV/FVIII binding caused by GP-mediated steric hindrance, can be experimentally tested
using a well-established co-immunoprecipitation technique (Cunningham et al., 2003;
Zheng, Liu, Yuan, et al., 2010; Zheng, Liu, Zhou, et al., 2010). Expression of the
glycoprotein in cells also expressing the clotting factors should, if this hypothesis is
correct, show a reduced co-immunoprecipitation of each factor with ERGIC-53 and
MCFD2. There are notable caveats to this approach, however, first in the cost reagents to
identify FV and FVIII directly, and secondly, the need to express the clotting factors in
trans. To date, most biochemical evaluations of the ERGIC-53/MCFD2 complex and
FV/FVIII binding have relied upon transient transfections to express FV and FVIII. The
second proposed mechanism, inefficient secretion due to lack of available ERGIC53/MCFD2, can be tested indirectly through a coagulation activity assay (Tilley, Levit, &
Samis, 2012; Zhang et al., 2008). Similar caveats exist for this approach as well.
A thorough understanding the molecular mechanisms behind the bleeding
abnormalities observed during infection with VHFs will likely reveal a multifactorial
cause. Platelet abnormalities, specific factor deficiencies, as well as endothelial barrier
dysfunction may all contribute to the hemorrhaging. However, removal of either ERGIC53 or MCFD2 is sufficient to cause a coagulopathy. Through the biochemical interaction
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and the trafficking alterations, it would seem that the arenavirus GPs are likely sufficient
to disrupt the efficient secretion of these molecules, and therefore provide a direct
molecular mechanism explaining the bleeding abnormalities that have mystified scientists
and clinicians for half of a century.
Last, and perhaps most importantly, given the potent role of ERGIC-53 and
MCFD2 in dictating the infectivity of arenavirus, coronavirus, filovirus, and hantavirus
particles, there may be sufficient selective pressure to preserve (ERGIC-53) or discourage
(MCFD2) the maintenance of diseased alleles in the human population. Several lines of
evidence support of this idea. Firstly, genetic lesions in the MCFD2 gene occur much less
frequently in the human population relative to ERGIC-53 (30% vs 70 %). The disease
caused by loss of MCFD2 is also somewhat more profound in the impairment of FV and
FVIII secretion (Zhang et al., 2008). We demonstrate that cells from people lacking
ERGIC-53 produce less infectious virus, whereas cells from people lacking MCFD2
produce more infectious virus. People lacking MCFD2, if this cellular phenotype holds
true, would produce more virus. Viral titer is a strong predictor of disease severity
(Richmond & Baglole, 2003). Further, in areas of Africa where Lassa virus is endemic, it
has been hypothesized that the virus may provide a selective pressure on certain SNPs
-DG (Oldstone &
Campbell, 2011; Sabeti et al., 2007). The receptor for pathogenic NW arenaviruses has
also been hypothesized to be under positive selection (Demogines et al., 2013). Inherent
human disease providing protection from acquired disease has been proposed for a
number of circumstances. The earliest, and perhaps, most well-known example of this
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would be the proposal of Allison in 1954, who, based on Raper and Lehman’s 1949
observations of high frequencies of sickle cell anemia in Ugandans (Lehmann & Raper,
1949), suggested that the abundance of the disease could be a result of the protection it
afforded from malaria (Allison, 1954), the disease cause by the plasmodium falciparum
parasite. Therefore, in our studies, exposure to rodents and the viruses they harbored may
have provided a similar protection to an archetype arenavirus.
In conclusion, the identification of conserved biosynthetic machinery utilized by
multiple families of enveloped RNA viruses has revealed a wealth of information about
not only the evolution of these viruses, but also the co-evolution of virus and host. From
these studies, a clearer picture of the underlying cellular biology and cause of arenavirus
propagation and disease has been obtained, a novel molecular machine to interfere with
therapeutically has been identified, and insight into the selective pressures that have
shaped the modern human have been gained.
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Appendix

Table S1A, Related to Figures 1A-1C. Intersect of Identified Proteins Interacting with GP
Proteins of ANDV and LCMV. The number of total peptides identified is listed. *Indicates non-GP
control contained peptides from this protein but at levels at least five times less.
Proteins Identified Interacting with GP proteins of both
ANDV and LCMV
Gene symbol
Description
B3GALT6

UDP-Gal:betaGal beta 1,3galactosyltransferase polypeptide 6
BAG2
BCL2-associated athanogene 2
CALR
calreticulin
CALU
calumenin
CANX
calnexin
CPNE3
copine III
DDOST
dolichyl-diphosphooligosaccharideprotein glycosyltransferase
DHX30
DEAH (Asp-Glu-Ala-His) box
polypeptide 30
DNAJA1
DnaJ (Hsp40) homolog, subfamily A,
member 1
DNAJB11
DnaJ (Hsp40) homolog, subfamily B,
member 11
DNAJC10
DnaJ (Hsp40) homolog, subfamily C,
member 10
DNAJC7
DnaJ (Hsp40) homolog, subfamily C,
member 7
EMD
emerin (Emery-Dreifuss muscular
dystrophy)
ERLIN1
SPFH domain family, member 1
ERLIN2
SPFH domain family, member 2
G3BP1
Ras-GTPase-activating protein SH3domain-binding protein
GANAB
glucosidase, alpha; neutral AB
GPX8
similar to RIKEN cDNA 2310016C16
HSP90B1
heat shock protein 90kDa beta
(Grp94), member 1
HSPA5
heat shock 70kDa protein 5 (glucoseregulated protein, 78kDa)
KPNA2;LOC728860 karyopherin alpha 2 (RAG cohort 1,
importin alpha 1)
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ANDV

LCMV

IPI id

#
#
Peptides Peptides
IPI00064848
2
2
IPI00000643
IPI00020599
IPI00045396
IPI00020984
IPI00024403
IPI00297084

3
9
8
53*
2
6

16*
24
36
75
3
10*

IPI00164906

29*

2

IPI00012535

2

7*

IPI00008454

5

11

IPI00293260

4

4

IPI00329629

6

12

IPI00032003

6

20*

IPI00007940
IPI00026942
IPI00012442

2
6*
8

15
19
4

IPI00011454
IPI00291695
IPI00027230

19*
2
18*

16
4
22*

IPI00003362

481*

144*

IPI00002214

2

4

LMAN1 (ERGIC53)
LYAR
MYBBP1A
MYO1B
MYO1C
MYO6
P4HB

PDIA6
PSMB6
PSMD2
RCN1
RPL22
RPL28
RPLP2
RPN1
RPS24
RPS9
RRBP1
RRP1
SDF2L1
SDF4
SEP15
SIL1
SLC25A13
SMC2
TOR3A
TUBB2A
UBC;RPS27A;UBB
UGCGL1
VCP

lectin, mannose-binding, 1 (ERGIC53)
hypothetical protein FLJ20425
MYB binding protein (P160) 1a
myosin IB
myosin IC
myosin VI
procollagen-proline, 2-oxoglutarate
4-dioxygenase (proline 4hydroxylase), beta polypeptide
protein disulfide isomerase family A,
member 6
proteasome (prosome, macropain)
subunit, beta type, 6
proteasome (prosome, macropain)
26S subunit, non-ATPase, 2
reticulocalbin 1, EF-hand calcium
binding domain
ribosomal protein L22
ribosomal protein L28
ribosomal protein, large, P2
ribophorin I
ribosomal protein S24
ribosomal protein S9
ribosome binding protein 1 homolog
180kDa (dog)
DNA segment on chromosome 21
(unique) 2056 expressed sequence
stromal cell-derived factor 2-like 1
stromal cell derived factor 4
15 kDa selenoprotein
SIL1 homolog, endoplasmic reticulum
chaperone (S. cerevisiae)
solute carrier family 25, member 13
(citrin)
SMC2 structural maintenance of
chromosomes 2-like 1 (yeast)
torsin family 3, member A
tubulin, beta 2A
ribosomal protein S27a
UDP-glucose ceramide
glucosyltransferase-like 1
valosin-containing protein
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IPI00026530
IPI00015838
IPI00005024
IPI00376344
IPI00010418
IPI00008455
IPI00010796

12
3
9
3
10
21
14

15
6
18*
2
9*
2
10

IPI00299571

27*

17*

IPI00000811

3

4

IPI00012268

3

6

IPI00015842

9

50

IPI00219153
IPI00182533
IPI00008529
IPI00025874
IPI00029750
IPI00221088
IPI00215743

2
7
7
9
3
11
11

5*
10*
3
13
3
10*
3

IPI00550766

2

3

IPI00106642
IPI00009794
IPI00030877
IPI00296197

2
2
4
3

3
12
3
5

IPI00007084

2

8

IPI00007927

2

9

IPI00301631
IPI00013475
IPI00179330
IPI00024466

3
5
50*
51

5
27*
88*
58

IPI00022774

15

21

Table S1B, Related to Figures 1A-1C. Proteins Identified Interacting with LCMV GP and Not ANDV
GP. The number of total peptides identified is listed. *Indicates non-GP control contained peptides from
this protein but at levels at least five times less.
Gene symbol

Description

ABCD3

ATP-binding cassette, sub-family D (ALD),
member 3
acyl-Coenzyme A dehydrogenase family,
member 9
acyl-CoA thioesterase 8
acid phosphatase 1, soluble
programmed cell death 8 (apoptosis-inducing
factor)
A kinase (PRKA) anchor protein 8-like
aldehyde dehydrogenase 1 family, member
B1
archain 1
ADP-ribosylation factor 1
ADP-ribosylation factor 4
armadillo repeat containing, X-linked 3
ATPase family, AAA domain containing 3B

ACAD9
ACOT8
ACP1
AIFM1
AKAP8L
ALDH1B1
ARCN1
ARF1
ARF4
ARMCX3
ATAD3B
ATP2A1
ATP2A2
ATP5A1
ATP6AP2
ATXN10
AURKB
BCAP31
BZW2
C14orf21
C19orf10
C22orf28
C8orf41
C8orf55
C9orf89
CAND1
CAND2

IPI id

ATPase, Ca++ transporting, cardiac muscle,
fast twitch 1
ATPase, Ca++ transporting, cardiac muscle,
slow twitch 2
ATP synthase, H+ transporting,
mitochondrial F1 complex, alpha subunit 1
ATPase, H+ transporting, lysosomal
accessory protein 2
ataxin 10
aurora kinase B
B-cell receptor-associated protein 31
basic leucine zipper and W2 domains 2
chromosome 14 open reading frame 21
chromosome 19 open reading frame 10
hypothetical protein HSPC117
chromosome 8 open reading frame 41
chromosome 8 open reading frame 55
chromosome 9 open reading frame 89
cullin-associated and neddylation-dissociated
1
cullin-associated and neddylation-dissociated
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IPI00002372

#
Peptides
2

IPI00152981

2

IPI00298202
IPI00218847
IPI00000690

3
3
12

IPI00297455
IPI00103467

2
3

IPI00298520
IPI00215914
IPI00215918
IPI00009906
IPI00045921;
IPI00178879
IPI00024804

5
2
5*
2
40*

IPI00177817

8

IPI00440493

19*

IPI00168884

4

IPI00001636
IPI00176642
IPI00218200
IPI00022305
IPI00216999
IPI00056357
IPI00550689
IPI00306207
IPI00171421
IPI00177808
IPI00100160

7
2
8
3
8
2
2
2
2
2
8

IPI00374208

4

5

CCDC3
CCDC47
CDC2
CDKN2A
CHST14
CLTC
CNPY2
COPA
COPG2
CPE
CSE1L
CYC1
DHCR24
DHCR7
DHRS7B
DNAJA2
DNAJB1
DNAJB4
DNAJB6
DNAJC11
DSG2
EARS2
EIF2B1
EIF2B2
EIF2B4
ERP44
FAF2
FAM3C
FANCD2
FANCI
FAR1
FSTL1
FUCA2
GALK1
GALNT2

2
coiled-coil domain-containing protein 3
coiled-coil domain containing 47
cell division cycle 2, G1 to S and G2 to M
cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
dermatan 4 sulfotransferase 1
clathrin, heavy polypeptide (Hc)
transmembrane protein 4
coatomer protein complex, subunit alpha
coatomer protein complex, subunit gamma 2
carboxypeptidase E
CSE1 chromosome segregation 1-like (yeast)
cytochrome c-1
24-dehydrocholesterol reductase
7-dehydrocholesterol reductase
dehydrogenase/reductase (SDR family)
member 7B
DnaJ (Hsp40) homolog, subfamily A,
member 2
DnaJ (Hsp40) homolog, subfamily B,
member 1
DnaJ (Hsp40) homolog, subfamily B,
member 4
DnaJ (Hsp40) homolog, subfamily B,
member 6
DnaJ (Hsp40) homolog, subfamily C,
member 11
desmoglein 2
KIAA1970 protein
eukaryotic translation initiation factor 2B,
subunit 1 alpha, 26kDa
eukaryotic translation initiation factor 2B,
subunit 2 beta, 39kDa
eukaryotic translation initiation factor 2B,
subunit 4 delta, 67kDa
thioredoxin domain containing 4
(endoplasmic reticulum)
UBX domain containing 8
family with sequence similarity 3, member C
Fanconi anemia, complementation group D2
KIAA1794
male sterility domain containing 2
follistatin-like 1
fucosidase, alpha-L- 2, plasma
galactokinase 1
UDP-N-acetyl-alpha-Dgalactosamine:polypeptide N-
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IPI00385079
IPI00024642
IPI00026689
IPI00001560

2
2
2
3

IPI00044326
IPI00024067
IPI00443909
IPI00295857
IPI00002557
IPI00031121
IPI00022744
IPI00029264
IPI00016703
IPI00294501
IPI00550165

2
2
3
2
2
2
6
2
3
2
2

IPI00032406

9

IPI00015947

3

IPI00003848

3

IPI00024523

6*

IPI00333016

3

IPI00028931
IPI00384503
IPI00221300

3
4
2

IPI00028083

6

IPI00005979

6

IPI00401264

5

IPI00172656
IPI00334282
IPI00075081
IPI00019447
IPI00386139
IPI00029723
IPI00012440
IPI00019383
IPI00004669

6
3
4
5
7
2
2
3
3

GBAS
GCN1L1
GEMIN4
GEMIN6
GLA
GLG1
GLMN
GLT8D1
GPC4
HADHA
HAX1
HEATR2
HEATR3
HEXA
HLA-A
HLA-B;HLA-C
HS2ST1
HSD17B12
HSPB1
HSPBP1
HSPD1
IARS2
IDH3A
IKIP
ILK-2;CCT4
IMMT
IPO11
IPO4
IPO5
IPO7
IPO8
IPO9
IQGAP2
KIAA0368
KIAA0913
KIAA1524

acetylgalactosaminyltransferase 2
glioblastoma amplified sequence
GCN1 general control of amino-acid
synthesis 1-like 1 (yeast)
gem (nuclear organelle) associated protein 4
gem (nuclear organelle) associated protein 6
galactosidase, alpha
golgi apparatus protein 1
glomulin, FKBP associated protein
glycosyltransferase 8 domain containing 1
glypican 4
hydroxyacyl-Coenzyme A dehydrogenase
alpha subunit
HCLS1 associated protein X-1
hypothetical protein FLJ20397
hypothetical protein FLJ20718
hexosaminidase A (alpha polypeptide)
major histocompatibility complex, class I, A
major histocompatibility complex, class I, B
heparan sulfate 2-O-sulfotransferase 1
hydroxysteroid (17-beta) dehydrogenase 12
heat shock 27kDa protein 1
hsp70-interacting protein
heat shock 60kD protein 1
isoleucine-tRNA synthetase 2, mitochondrial
isocitrate dehydrogenase 3 (NAD+) alpha
IKK interacting protein
chaperonin containing TCP1, subunit 4
(delta)
inner membrane protein, mitochondrial
(mitofilin)
importin 11
importin 4
importin 5
importin 7
importin 8
importin 9
IQ motif containing GTPase activating
protein 2
proteasome-associated protein ECM29
homolog
zinc finger SWIM domain-containing protein
KIAA0913
cancerous inhibitor of PP2A
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IPI00016077
IPI00001159

5
20

IPI00027717
IPI00103087
IPI00025869
IPI00414717
IPI00074604
IPI00020470
IPI00232571
IPI00031522

4
3
2
2
3
2
2
8*

IPI00010440
IPI00242630
IPI00100984
IPI00027851
IPI00472013
IPI00004657
IPI00040900
IPI00007676
IPI00025512
IPI00100748
IPI00784154
IPI00017283
IPI00030702
IPI00043598
IPI00302927

8
2
4
2
3
3
7
3
2
7
9
2
2
2
5

IPI00009960

16

IPI00301107
IPI00156374
IPI00793443;
IPI00514205;
IPI00639960
IPI00007402
IPI00007401
IPI00185146
IPI00299048

2
6
41

IPI00157790

2

IPI00166606

2

IPI00154283

2

15
4
10
2

KPNB1
LAP3
LEPRE1
LMAN2
LMNB1
LOC442497;SLC3A2
LPCAT1
LRPAP1
LRRC59
MAGED1
MAGT1
MARS
MCM3AP
MDN1
MIA3
MLF2
MSH6
MTCH1
MTCH2
MTHFD1
MTX2
MYH15
NCLN
NCSTN
NDUFS1
NDUFS3
NDUFS7
NDUFV1
NDUFV2
NGDN
NOMO1;NOMO3
NRM
NUCB1
NUCB2

karyopherin (importin) beta 1
leucine aminopeptidase 3
leucine proline-enriched proteoglycan
(leprecan) 1
lectin, mannose-binding 2
lamin B1
solute carrier family 3 (activators of dibasic
and neutral amino acid transport), member 2
acyltransferase like 2
low density lipoprotein receptor-related
protein associated protein 1
leucine rich repeat containing 59
melanoma antigen family D, 1
implantation-associated protein
methionine-tRNA synthetase
MCM3 minichromosome maintenance
deficient 3 (S. cerevisiae) associated protein
MDN1, midasin homolog (yeast)
melanoma inhibitory activity family, member
3
myeloid leukemia factor 2
mutS homolog 6 (E. coli)
mitochondrial carrier homolog 1 (C. elegans)
mitochondrial carrier homolog 2 (C. elegans)
methylenetetrahydrofolate dehydrogenase
(NADP+ dependent) 1
metaxin 2
myosin, heavy chain 15
nicalin homolog (zebrafish)
nicastrin
NADH dehydrogenase (ubiquinone) Fe-S
protein 1, 75kDa (NADH-coenzyme Q
reductase)
NADH dehydrogenase (ubiquinone) Fe-S
protein 3, 30kDa (NADH-coenzyme Q
reductase)
NADH dehydrogenase (ubiquinone) Fe-S
protein 7, 20kDa (NADH-coenzyme Q
reductase)
NADH dehydrogenase (ubiquinone)
flavoprotein 1, 51kDa
NADH dehydrogenase (ubiquinone)
flavoprotein 2, 24kDa
neuroguidin, EIF4E binding protein
NODAL modulator 1
nurim (nuclear envelope membrane protein)
nucleobindin 1
nucleobindin 2
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IPI00001639
IPI00419237
IPI00045839

15*
6
4

IPI00009950
IPI00217975
IPI00027493

3
2
6

IPI00171626
IPI00026848

4
5

IPI00396321
IPI00328354
IPI00301202
IPI00008240
IPI00028954

3
3
4
6*
2

IPI00167941
IPI00455473

11
17

IPI00023095
IPI00106847
IPI00386258
IPI00003833
IPI00218342

3
2
3
3
2

IPI00025717
IPI00180408
IPI00470649
IPI00021983
IPI00604664

4
2
3
2
6

IPI00025796

2

IPI00307749

2

IPI00028520

4

IPI00291328

4

IPI00000162
IPI00329352
IPI00217557
IPI00295542
IPI00009123

2
4
3
9
5

NUP205
NUP210
NUP93
ORC4L
OS9
OXA1L
P4HA1
P4HA2
PCYT1A
PCYT1B
PDIA3
PEX11B
PHB
PHB2
PHGDH
PIGK
PIGS
PIK3CG
PLOD1
PPFIBP1
PPP2R1A
PREB
PRKDC
PSMA1
PSMA3
PSMA4
PSMA5
PSMA6
PSMA7
PSMB1
PSMB2

nucleoporin 205kDa
nucleoporin 210kDa
nucleoporin 93kDa
origin recognition complex, subunit 4-like
amplified in osteosarcoma
oxidase (cytochrome c) assembly 1-like
procollagen-proline, 2-oxoglutarate 4dioxygenase (proline 4-hydroxylase), alpha
polypeptide I
procollagen-proline, 2-oxoglutarate 4dioxygenase (proline 4-hydroxylase), alpha
polypeptide II
phosphate cytidylyltransferase 1, choline,
alpha
phosphate cytidylyltransferase 1, choline,
beta
protein disulfide isomerase family A,
member 3
peroxisomal biogenesis factor 11B
prohibitin
prohibitin 2
phosphoglycerate dehydrogenase
phosphatidylinositol glycan, class K
phosphatidylinositol glycan, class S
phosphoinositide-3-kinase, catalytic, gamma
polypeptide
procollagen-lysine 1, 2-oxoglutarate 5dioxygenase 1
PTPRF interacting protein, binding protein 1
(liprin beta 1)
protein phosphatase 2 (formerly 2A),
regulatory subunit A (PR 65), alpha isoform
prolactin regulatory element binding
protein kinase, DNA-activated, catalytic
polypeptide
proteasome (prosome, macropain) subunit,
alpha type, 1
proteasome (prosome, macropain) subunit,
alpha type, 3
proteasome (prosome, macropain) subunit,
alpha type, 4
proteasome (prosome, macropain) subunit,
alpha type, 5
proteasome (prosome, macropain) subunit,
alpha type, 6
proteasome (prosome, macropain) subunit,
alpha type, 7
proteasome (prosome, macropain) subunit,
beta type, 1
proteasome (prosome, macropain) subunit,
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IPI00783781
IPI00291755
IPI00397904
IPI00015164
IPI00186581
IPI00014301
IPI00009923

19
3
9*
2
3
2
3

IPI00003128

2

IPI00329338

8

IPI00001562

3

IPI00025252

25

IPI00021978
IPI00017334
IPI00027252
IPI00011200
IPI00022543
IPI00465308
IPI00292690

6
5
8
7*
2
2
2

IPI00027192

3

IPI00179172

17

IPI00168184

3

IPI00033349
IPI00296337

2
135*

IPI00016832

8

IPI00171199

4

IPI00299155

3

IPI00291922

7

IPI00029623

4

IPI00024175

6

IPI00025019

4

IPI00028006

3

PSMB4
PSMB5
PSMB7
PSMC1
PSMC2
PSMC3
PSMC4
PSMC5
PSMC6
PSMD1
PSMD11
PSMD12
PSMD13
PSMD14
PSMD3
PSMD4
PSMD6
PSMD7
PSMD8
PTPLAD1
RAD23B
RCN2
RPL35
RPL36
RPN2
RPS10
RPS13
RPS15
RPS17

beta type, 2
proteasome (prosome, macropain) subunit,
beta type, 4
proteasome (prosome, macropain) subunit,
beta type, 5
proteasome (prosome, macropain) subunit,
beta type, 7
proteasome (prosome, macropain) 26S
subunit, ATPase, 1
proteasome (prosome, macropain) 26S
subunit, ATPase, 2
proteasome (prosome, macropain) 26S
subunit, ATPase, 3
proteasome (prosome, macropain) 26S
subunit, ATPase, 4
proteasome (prosome, macropain) 26S
subunit, ATPase, 5
proteasome (prosome, macropain) 26S
subunit, ATPase, 6
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 1
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 11
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 12
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 13
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 14
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 3
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 4
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 6
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 7 (Mov34 homolog)
proteasome (prosome, macropain) 26S
subunit, non-ATPase, 8
protein tyrosine phosphatase-like A domain
containing 1
RAD23 homolog B (S. cerevisiae)
reticulocalbin 2, EF-hand calcium binding
domain
ribosomal protein L35
ribosomal protein L36
ribophorin II
ribosomal protein S10
ribosomal protein S13
ribosomal protein S15
ribosomal protein S17
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IPI00555956

4

IPI00383971;
IPI00479306
IPI00003217

9*

IPI00011126

5

IPI00021435

18*

IPI00018398

18*

IPI00020042

10

IPI00023919

16

IPI00021926

12

IPI00299608

5*

IPI00105598

17

IPI00185374

9

IPI00375380

10

IPI00024821

2

IPI00011603

11

IPI00022694

4

IPI00014151

7

IPI00019927

4

IPI00010201

2

IPI00008998

3

IPI00008223
IPI00029628

2
19

IPI00412607
IPI00216237
IPI00028635
IPI00008438
IPI00221089
IPI00479058
IPI00221093

5*
3
4*
7*
14
2
6*

6

SAAL1
SAPS3
SDF4
SEC11A
SEC16A
SEC22B
SFXN4
SGPL1
SIRT1
SLC16A1
SLC25A12
SLC25A22
SLC25A24
SLC25A3
SLC25A5
SMC4
SMPD4
SNX3
SPTLC1
SPTLC2
SRPRB
SSR4
STT3B
STUB1
SUMF2
TBRG4
TELO2
TFB2M
TIMELESS
TMED1
TMED10

serum amyloid A-like 1
SAPS domain family, member 3
stromal cell derived factor 4
SEC11-like 1 (S. cerevisiae)
SEC16-like 1 (S. cerevisiae)
SEC22 vesicle trafficking protein-like 1 (S.
cerevisiae)
sideroflexin 4
sphingosine-1-phosphate lyase 1
sirtuin (silent mating type information
regulation 2 homolog) 1 (S. cerevisiae)
solute carrier family 16 (monocarboxylic
acid transporters), member 1
solute carrier family 25 (mitochondrial
carrier, Aralar), member 12
solute carrier family 25 (mitochondrial
carrier: glutamate), member 22
solute carrier family 25 (mitochondrial
carrier; phosphate carrier), member 24
solute carrier family 25 (mitochondrial
carrier; phosphate carrier), member 3
solute carrier family 25 (mitochondrial
carrier; adenine nucleotide translocator),
member 5
SMC4 structural maintenance of
chromosomes 4-like 1 (yeast)
sphingomyelin phosphodiesterase 4, neutral
membrane (neutral sphingomyelinase-3)
sorting nexin 3
serine palmitoyltransferase, long chain base
subunit 1
serine palmitoyltransferase, long chain base
subunit 2
signal recognition particle receptor, B
subunit
signal sequence receptor, delta (transloconassociated protein delta)
STT3, subunit of the
oligosaccharyltransferase complex, homolog
B (S. cerevisiae)
STIP1 homology and U-box containing
protein 1
sulfatase modifying factor 2
transforming growth factor beta regulator 4
KIAA0683 gene product
transcription factor B2, mitochondrial
timeless homolog (Drosophila)
transmembrane emp24 protein transport
domain containing 1
transmembrane emp24-like trafficking
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IPI00304935
IPI00019540
IPI00106646
IPI00104128
IPI00031242
IPI00006865

5
2
2
4
2
2

IPI00412741
IPI00099463
IPI00016802

2
4
5

IPI00024650

4

IPI00386271

2

IPI00003004

4

IPI00337494

6*

IPI00022202

8*

IPI00007188

94*

IPI00328298

7

IPI00743121

2

IPI00216508
IPI00005745

3
7

IPI00005751

3

IPI00295098

2

IPI00019385

11*

IPI00152377

5

IPI00025156

5

IPI00171412
IPI00329625
IPI00016868
IPI00034069
IPI00335541
IPI00009976

4
3
2
2
2
3

IPI00028055

8

TMED2
TMED4
TMED9
TMEM109
TMEM33
TMEM43
TMEM59
TMX1
TNPO1
TOMM40
TOR1AIP2
TROVE2
TTC13
TUBA4A
TUBB
TUBB2C
TUBB3
TUBB4
TUBB6
TUBG1
UBAC2
UBE3C
UFD1L
UGCGL2
UNC45A
UQCRC2
USP9X
VDAC3
XPO1
XPO5
XPO6
XPOT
YME1L1
YWHAH

protein 10 (yeast)
transmembrane emp24 domain trafficking
protein 2
transmembrane emp24 protein transport
domain containing 4
transmembrane emp24 protein transport
domain containing 9
transmembrane protein 109
transmembrane protein 33
transmembrane protein 43
transmembrane protein 59
thioredoxin domain containing
transportin 1
translocase of outer mitochondrial membrane
40 homolog (yeast)
torsin A interacting protein 2
TROVE domain family, member 2
tetratricopeptide repeat domain 13
tubulin, alpha 1 (testis specific)
tubulin, beta
tubulin, beta 2C
tubulin, beta 3
tubulin, beta 4
tubulin, beta 6
tubulin, gamma 1
phosphoglycerate dehydrogenase like 1
ubiquitin protein ligase E3C
ubiquitin fusion degradation 1 like (yeast)
UDP-glucose ceramide glucosyltransferaselike 2
unc-45 homolog A (C. elegans)
ubiquinol-cytochrome c reductase core
protein II
ubiquitin specific peptidase 9, X-linked
voltage-dependent anion channel 3
exportin 1 (CRM1 homolog, yeast)
exportin 5
exportin 6
exportin, tRNA (nuclear export receptor for
tRNAs)
YME1-like 1 (S. cerevisiae)
tyrosine 3-monooxygenase/tryptophan 5monooxygenase activation protein, eta
polypeptide
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IPI00016608

7

IPI00296259

3

IPI00023542

6

IPI00031697
IPI00299084
IPI00301280
IPI00399320
IPI00395887
IPI00024364
IPI00014053

2
21*
10
6
2
9
2

IPI00168878
IPI00019450
IPI00301227
IPI00007750
IPI00011654
IPI00007752
IPI00013683
IPI00023598
IPI00646779
IPI00295081
IPI00007034
IPI00472810;
IPI00604464
IPI00218292
IPI00024467

7
2
2
45*
40*
150*
3
3
4
2
3
7

IPI00072534
IPI00305383

4
16*

IPI00003964
IPI00031804
IPI00298961
IPI00549861;
IPI00640703
IPI00465296
IPI00306290

5*
2
27
10

IPI00045946
IPI00216319

3
2

4
3

2
7

Table S1C, Related to Figures 1A-1C. Proteins Identified Interacting with ANDV GP and Not
LCMV GP. The number of total peptides identified is listed. *Indicates non-GP control contained
peptides from this protein but at levels at least five times less.
Gene
symbol
AMOT
ANXA6
ATAD3A
CAPRIN1
CHMP4B
CLGN
CSDA
DARS
DDX21
DHX29
DIMT1L
DNAJB12
DNAJC3
ERGIC1
EXT2
FLOT2
FMR1
G3BP2
GNB2
HSPA7
IGF2BP3
LACTB
LARS

Description

IPI id

angiomotin
annexin A6
ATPase family, AAA domain containing 3A
cell cycle associated protein 1
chromatin modifying protein 4B
calmegin
cold shock domain protein A
aspartyl-tRNA synthetase
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21
DEAH (Asp-Glu-Ala-His) box polypeptide 29
dimethyladenosine transferase
DnaJ (Hsp40) homolog, subfamily B, member 12
DnaJ (Hsp40) homolog, subfamily C, member 3
endoplasmic reticulum-golgi intermediate compartment
(ERGIC) 1
exostoses (multiple) 2
flotillin 2
fragile X mental retardation 1
Ras-GTPase activating protein SH3 domain-binding
protein 2
guanine nucleotide binding protein (G protein), beta
polypeptide 2
heat shock 70kDa protein 7 (HSP70B)
insulin-like growth factor 2 mRNA binding protein 3
lactamase, beta
leucyl-tRNA synthetase
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IPI00163085
IPI00002459
IPI00295992
IPI00783872
IPI00025974
IPI00024776
IPI00031801
IPI00216951
IPI00015953
IPI00217413
IPI00004459
IPI00014400
IPI00006713
IPI00003635

#
Peptides
5
5
6
12
2
3
4
2
7
3
4
2
8
2

IPI00004047
IPI00789008
IPI00215720
IPI00009057

2
2
2
6

IPI00003348

2

IPI00011134
IPI00165467
IPI00294186
IPI00103994

13*
4
2
3

LIMA1
LMAN2L
MOGS
MYO1D
NACA
NCL
NDUFA9
NOP2
NPM1
NUFIP2
PABPC4
PCBP2
PCNA
PLOD2
PURA
PXDN
QARS
RAB11B
RARS
RFC2
RFC3
ROD1
RPL11
RPL13A
RPL14
RPL17
RPL18
RPL18A
RPL19
RPL23A
RPL24
RPL26
RPL26L1
RPL3
RPL30
RPL35A
RPL37A
RPL5
RPL6
RPL7;

LIM domain and actin binding 1
lectin, mannose-binding 2-like
glucosidase I
myosin ID
nascent-polypeptide-associated complex alpha
polypeptide
nucleolin
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,
9, 39kDa
nucleolar protein 1, 120kDa
anaplastic lymphoma kinase (Ki-1)
nuclear fragile X mental retardation protein interacting
protein 2
poly(A) binding protein, cytoplasmic 4 (inducible form)
poly(rC) binding protein 2
proliferating cell nuclear antigen
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
purine-rich element binding protein A
peroxidasin homolog (Drosophila)
glutaminyl-tRNA synthetase
RAB11B, member RAS oncogene family
arginyl-tRNA synthetase
replication factor C (activator 1) 2, 40kDa
replication factor C (activator 1) 3, 38kDa
ROD1 regulator of differentiation 1 (S. pombe)
ribosomal protein L11
ribosomal protein L13a
ribosomal protein L14 variant
ribosomal protein L17
ribosomal protein L18
ribosomal protein L18a
ribosomal protein L19
ribosomal protein L23a
ribosomal protein L24
ribosomal protein L26
ribosomal protein L26-like 1
ribosomal protein L3
ribosomal protein L30
ribosomal protein L35a
ribosomal protein L37a
ribosomal protein L5
ribosomal protein L6
ribosomal protein L7; ribosomal protein L7 pseudogene
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IPI00008918
IPI00218337
IPI00328170
IPI00329719
IPI00023748

4
2
3
2
3

IPI00183526
IPI00003968

4
2

IPI00294891
IPI00220740
IPI00002349

2
11*
2

IPI00012726
IPI00012066
IPI00021700
IPI00337495
IPI00023591
IPI00016112
IPI00026665
IPI00020436
IPI00004860
IPI00017412
IPI00031521
IPI00159072
IPI00376798
IPI00304612
IPI00069693
IPI00413324
IPI00215719
IPI00026202
IPI00025329
IPI00021266
IPI00306332
IPI00027270
IPI00007144
IPI00550021
IPI00219156
IPI00029731
IPI00414860
IPI00000494
IPI00329389
IPI00796861

3
3
2
2
3
2
2
2
2
2
3
3
7*
11*
7*
2
20*
5
5*
6
8*
3
5
6
5
5
3
17*
3
2

RPL7P32
RPL7A
RPL7A;
RPL7AP27
RPLP0
RPS12
RPS16
RPS19
RPS27
RPS3A
RPS5
RPS6
RPS8
RRP1B
SND1
STAU1
TEX10
TMPO
TP53
USP10
WRNIP1
XRN2

32
ribosomal protein L7a
ribosomal protein L7; ribosomal protein L7a pseudogene
27
ribosomal protein, large, P0
ribosomal protein S12
ribosomal protein S16
ribosomal protein S19
ribosomal protein S27
ribosomal protein S3A
ribosomal protein S5
ribosomal protein S6
ribosomal protein S8
ribosomal RNA processing 1 homolog B (S. cerevisiae)
staphylococcal nuclease domain containing 1
staufen, RNA binding protein, homolog 1 (Drosophila)
testis expressed sequence 10
thymopoietin
tumor protein p53 (Li-Fraumeni syndrome)
ubiquitin specific peptidase 10
Werner helicase interacting protein 1
5'-3' exoribonuclease 2

IPI00299573
IPI00075558

9
11*

IPI00008530
IPI00013917
IPI00221092
IPI00215780
IPI00397358
IPI00419880
IPI00008433
IPI00021840
IPI00216587
IPI00032374
IPI00140420
IPI00000001
IPI00549664
IPI00030131
IPI00025087
IPI00291946
IPI00102997
IPI00100151

22*
3
7*
21*
2
16*
9*
9*
2
2
4
2
2
2
2
5
3
2

Table S1D, Related to Figures 1A-1C, S1D, and Tables S1-S3. NIH DAVID Functional Annotation
Clustering of Proteomic Data. Gene symbols from proteins identified interacting with LCMV
GPC, ANDV GPC, or those interacting with both (intersect) were analyzed by NIH DAVID using
medium stringency and with Homo sapiens as background. Data for the clusters below all show
enrichments of four-fold over background. Sub-categories are provided and the numbers of
proteins identified in each sub-category and their corresponding P value and percent of total
proteins. These data are tabulated at the end of this table and were used to generate Figure
S1D.

LCMV and ANDV
Intersect
Annotation Cluster
1
(Endoplasmic
Reticulum A)

Sub-category
endoplasmic reticulum lumen

308

Count

P Value

Percent

12

4.20E-15

24

Enrichment Score:
8.9

Annotation Cluster
2
(Endoplasmic
Reticulum B)
Enrichment Score:
8.49

intracellular organelle lumen

23

5.70E-08

46

organelle lumen
membrane-enclosed lumen

23
23

8.60E-08
1.20E-07

46
46

Average

20

Sub-category

41

Count

P Value

Percent

endoplasmic reticulum

21

1.80E-16

42

endoplasmic reticulum part

18

2.10E-15

36

endoplasmic reticulum lumen
endoplasmic reticulum
short sequence motif:Prevents secretion
from ER
signal
signal peptide
glycosylation site:N-linked (GlcNAc...)
glycoprotein

12
23
9

4.20E-15
3.50E-13
2.10E-12

24
46
18

19
19
14
14

6.80E-04
7.30E-04
2.50E-01
3.00E-01

38
38
28
28

Average

17

Annotation Cluster
3
(Protein Folding)

Sub-category

Enrichment Score:
7.44

33

Count

P Value

Percent

protein folding

13

1.40E-13

26

unfolded protein binding

9

2.70E-09

18

Chaperone
disulfide bond

9
7

5.90E-09
7.80E-01

18
14

Average

10

19

Annotation Cluster
4
(Vesicles)

Sub-category

Count

P Value

Percent

melanosome

8

3.10E-08

16

Enrichment Score:
4.39

pigment granule

8

3.10E-08

16

cytoplasmic membrane-bounded vesicle
membrane-bounded vesicle
cytoplasmic vesicle
vesicle

9
9
9
9

8.00E-04
9.80E-04
2.10E-03
2.80E-03

18
18
18
18

Average

9

17

LCMV_NOT_ANDV
Annotation Cluster
5

Sub-category

Count

309

P Value

Percent

(Proteasome A)

proteasome

30

3.30E-40

12

Enrichment Score:
19.93

proteasome complex

31

1.20E-36

12

Proteasome
negative regulation of ubiquitin-protein
ligase activity
negative regulation of ligase activity
negative regulation of ubiquitin-protein
ligase activity during mitotic cell cycle
anaphase-promoting complex-dependent
proteasomal ubiquitin-dependent protein
catabolic process
proteasomal protein catabolic process
proteasomal ubiquitin-dependent protein
catabolic process
negative regulation of protein
ubiquitination
positive regulation of ubiquitin-protein
ligase activity during mitotic cell cycle
regulation of ubiquitin-protein ligase
activity
positive regulation of ubiquitin-protein
ligase activity
regulation of ubiquitin-protein ligase
activity during mitotic cell cycle
regulation of ligase activity
positive regulation of ligase activity
positive regulation of protein
ubiquitination
regulation of protein ubiquitination
negative regulation of protein modification
process
negative regulation of cellular protein
metabolic process
negative regulation of protein metabolic
process
negative regulation of catalytic activity
ubiquitin-dependent protein catabolic
process
negative regulation of molecular function
positive regulation of protein modification
process
mitotic cell cycle
regulation of protein modification process
positive regulation of cellular protein
310

27
28

4.30E-32
1.00E-31

10
11

28
27

1.00E-31
1.80E-30

11
10

27

1.80E-30

10

31
31

2.50E-30
2.50E-30

12
12

28

2.70E-30

11

27

7.70E-30

10

28

1.50E-29

11

27

1.90E-29

10

27

3.00E-29

10

28
27
28

4.80E-29
7.00E-29
1.50E-28

11
10
11

29
29

1.10E-27
2.30E-25

11
11

31

1.90E-22

12

31

6.10E-22

12

35
33

6.50E-21
1.00E-20

14
13

36
28

3.00E-19
1.30E-18

14
11

35
31
28

5.90E-17
3.00E-16
3.90E-16

14
12
11

metabolic process
positive regulation of protein metabolic
process
regulation of cellular protein metabolic
process
cell cycle process
threonine protease
Proteasome, subunit alpha/beta
threonine-type peptidase activity
threonine-type endopeptidase activity
proteasome core complex
protein catabolic process
proteolysis involved in cellular protein
catabolic process
cellular protein catabolic process
modification-dependent macromolecule
catabolic process
modification-dependent protein catabolic
process
cell cycle
macromolecule catabolic process
positive regulation of catalytic activity
cellular macromolecule catabolic process
negative regulation of macromolecule
metabolic process
positive regulation of molecular function
proteolysis
positive regulation of macromolecule
metabolic process
Average
Annotation Cluster
2
(Ednoplasmic
Reticulum B)
Enrichment Score:
11.87

Annotation Cluster
6

Sub-category

28

1.20E-15

11

37

3.30E-15

14

40
11
11
11
11
11
38
37

4.70E-15
2.20E-14
2.70E-14
6.10E-14
6.10E-14
5.00E-13
2.40E-12
3.90E-12

16
4
4
4
4
4
15
14

37
36

4.50E-12
5.10E-12

14
14

36

5.10E-12

14

41
41
33
39
39

2.50E-11
3.00E-11
3.70E-11
5.20E-11
7.50E-11

16
16
13
15
15

33
45
33

7.80E-10
1.90E-09
4.80E-06

13
17
13

30

12

Count

P Value

Percent

endoplasmic reticulum

50

8.30E-22

19

endoplasmic reticulum

55

3.20E-14

21

endoplasmic reticulum part
nuclear envelope-endoplasmic reticulum
network
endoplasmic reticulum membrane

28
23

1.70E-10
1.00E-08

11
9

21

9.60E-08

8

Average

35

Sub-category

Count
311

14
P Value

Percent

(Nuclear Import A)

Armadillo-like helical

25

3.40E-20

10

Enrichment Score:
9.36

protein import into nucleus, docking

12

1.40E-16

5

domain:Importin N-terminal
Importin-beta, N-terminal
cellular protein complex assembly
protein transport
pore complex
nuclear pore
nuclear envelope
cellular macromolecular complex assembly
transport
protein import into nucleus
nuclear import
protein import
cellular macromolecular complex subunit
organization
protein localization in nucleus
nucleocytoplasmic transport
protein localization
nuclear transport
protein transporter activity
cellular protein localization
cellular macromolecule localization
protein localization in organelle
protein transport
intracellular transport
establishment of protein localization
intracellular protein transport
protein targeting
protein complex biogenesis
protein complex assembly
macromolecular complex assembly
macromolecular complex subunit
organization
Average

11
11
22
31
17
15
22
25
55
14
14
16
25

1.40E-16
9.30E-16
1.00E-13
2.20E-12
1.30E-11
1.20E-10
1.40E-10
2.20E-10
4.90E-10
8.50E-10
1.10E-09
2.30E-09
2.30E-09

4
4
9
12
7
6
9
10
21
5
5
6
10

14
17
40
17
13
26
26
16
36
33
36
24
17
24
24
27
27

2.60E-09
3.30E-09
3.90E-09
4.00E-09
4.90E-09
7.90E-09
9.10E-09
1.00E-08
1.10E-08
1.30E-08
1.40E-08
2.70E-08
3.10E-07
5.20E-06
5.20E-06
1.90E-05
5.60E-05

5
7
16
7
5
10
10
6
14
13
14
9
7
9
9
10
10

Annotation Cluster
7
(Protease)

Sub-category

Enrichment Score:
8.44

23

9

Count

P Value

Percent

threonine protease

11

2.20E-14

4

Proteasome, subunit alpha/beta

11

2.70E-14

4

threonine-type peptidase activity

11

6.10E-14

4

312

threonine-type endopeptidase activity
proteinase
proteasome core complex
Proteasome, alpha and beta subunits
Proteasome, alpha-subunit, conserved site
Proteasome, beta-type subunit, conserved
site
peptidase activity
peptidase activity, acting on L-amino acid
peptides
Protease
endopeptidase activity
hydrolase

11
10
11
8
6
6

6.10E-14
2.30E-13
5.00E-13
3.80E-10
3.30E-08
4.40E-07

4
4
4
3
2
2

22
21

1.10E-04
1.70E-04

9
8

18
16
31

2.60E-04
4.30E-04
2.30E-02

7
6
12

Average

14

5

Annotation Cluster
8
(Heat Repeat)

Sub-category

Count

P Value

Percent

repeat:HEAT 6

13

1.60E-15

5

Enrichment Score:
8.09

repeat:HEAT 5

13

1.50E-14

5

repeat:HEAT 2
repeat:HEAT 1
repeat:HEAT 4
repeat:HEAT 8
repeat:HEAT 3
repeat:HEAT 7
repeat:HEAT 10
repeat:HEAT 9
HEAT
repeat:HEAT 15
repeat:HEAT 14
repeat:HEAT 13
repeat:HEAT 12
repeat:HEAT 11
repeat:HEAT 24
repeat:HEAT 20
repeat:HEAT 21
repeat:HEAT 22
repeat:HEAT 23
repeat:HEAT 17
repeat:HEAT 18
repeat:HEAT 19
repeat:HEAT 16

15
15
13
10
13
10
8
8
11
6
6
6
6
6
4
4
4
4
4
4
4
4
4

2.30E-14
2.30E-14
2.50E-13
9.20E-13
1.80E-12
1.20E-11
4.00E-10
4.00E-10
5.50E-09
8.20E-09
4.80E-08
9.50E-08
9.50E-08
1.70E-07
9.20E-06
9.20E-06
9.20E-06
9.20E-06
9.20E-06
9.20E-06
9.20E-06
9.20E-06
9.20E-06

6
6
5
4
5
4
3
3
4
2
2
2
2
2
2
2
2
2
2
2
2
2
2
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repeat:HEAT 25
repeat:HEAT 26

3
3

Average

7

Annotation Cluster
9
(Mitochondria)

Sub-category

Enrichment Score:
6.78

5.20E-04
5.20E-04

1
1
3

Count

P Value

Percent

organelle envelope

48

2.30E-17

19

envelope

48

2.60E-17

19

mitochondrion inner membrane
mitochondrion
organelle inner membrane
mitochondrial inner membrane
mitochondrion
mitochondrial part
mitochondrial envelope
mitochondrial membrane
oxidoreductase
oxidation reduction
transit peptide:Mitochondrion
transit peptide
mitochondrial membrane part
generation of precursor metabolites and
energy
Parkinson's disease
Huntington's disease

18
34
24
23
47
32
26
25
23
26
19
19
10
14

8.10E-10
1.70E-08
3.20E-08
3.90E-08
4.20E-08
1.10E-07
1.70E-07
2.10E-07
6.00E-06
2.70E-05
5.70E-05
6.70E-05
4.50E-04
1.50E-03

7
13
9
9
18
12
10
10
9
10
7
7
4
5

10
11

2.00E-03
6.30E-03

4
4

Average

25

Annotation Cluster
10
(Nuclear Import B)

Sub-category

Enrichment Score:
5.28

10

Count

P Value

Percent

domain:Importin N-terminal

11

1.40E-16

4

Importin-beta, N-terminal

11

9.30E-16

4

Ran GTPase binding
Ras GTPase binding
small GTPase binding
GTPase binding
enzyme binding

4
4
4
4
11

6.30E-04
1.50E-01
1.90E-01
2.20E-01
2.40E-01

2
2
2
2
4

Average

7

Annotation Cluster
11
(GOLD Domain)

Sub-category

Enrichment Score:

3

Count

P Value

Percent

emp24/gp25L/p24

5

5.10E-06

2

domain:GOLD

5

6.30E-05

2

314

4.48
GOLD

5

Average

5

Annotation Cluster
12
(Proteasome B)

Sub-category

Enrichment Score:
4.35

1.10E-04

2
2

Count

P Value

Percent

PINT

5

9.90E-06

2

Proteasome component region PCI

5

8.80E-05

2

domain:PCI

5

1.00E-04

2

Average

5

2

ANDV_NOT_LCMV
Annotation Cluster
13
(Protein
Translation)
Enrichment Score:
28.79

Annotation Cluster
14
(Ribosome
Biogenesis)

Sub-category

Count

P Value

Percent

ribosome

25

2.30E-40

30

translational elongation

28

7.60E-40

34

Ribosome
translation
protein biosynthesis
ribosome
ribosomal protein
ribosomal subunit
structural constituent of ribosome
cytosolic ribosome
ribonucleoprotein
ribonucleoprotein complex
large ribosomal subunit
cytosolic part
cytosolic large ribosomal subunit
RNA binding
structural molecule activity
intracellular non-membrane-bounded
organelle
non-membrane-bounded organelle
cytosol

28
36
29
31
28
27
28
23
29
37
19
23
15
33
29
49

1.80E-37
4.30E-37
1.80E-36
6.60E-35
1.10E-34
1.30E-34
8.30E-33
2.70E-32
1.80E-31
2.00E-31
2.50E-26
1.00E-25
7.30E-23
2.70E-21
2.30E-18
1.50E-17

34
43
35
37
34
33
34
28
35
45
23
28
18
40
35
59

49
37

1.50E-17
2.50E-17

59
45

Average

30

Sub-category
ribosome biogenesis

315

36

Count

P Value

Percent

16

9.90E-17

19

Enrichment Score:
11.65

ribosomal large subunit biogenesis

8

1.30E-14

10

ribonucleoprotein complex biogenesis
ncRNA metabolic process
rRNA processing
rRNA metabolic process
ncRNA processing
RNA processing

16
16
12
12
12
16

3.70E-14
1.40E-12
2.30E-12
3.70E-12
5.10E-09
2.10E-07

19
19
14
14
14
19

Average

14

Cluster

1. Endoplasmic Reticulum (A)
2. Endoplasmic Reticulum (B)
2. Endoplasmic Reticulum (B)
3. Protein Folding
4. Vesicles
5. Proteasome (A)
6. Nuclear Import (A)
7. Protease
8. HEAT Repeat
9. Mitochondria
10. Nuclear Import (B)
11. GOLD Domain
12. Proteasome (B)
13. Protein Translation
14. Ribosome Biogenesis

316

Average Sample
Percent
of Total
41
Intersect
33
Intersect
14
LCMV
Only
19
Intersect
17
Intersect
12
LCMV
Only
9
LCMV
Only
5
LCMV
Only
3
LCMV
Only
10
LCMV
Only
3
LCMV
Only
2
LCMV
Only
2
LCMV
Only
36
ANDV
Only
16
ANDV
Only

16

317

